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ABSTRACT 
Angiogenesis, although a natural process, when deregulated can be associated with 
many human pathologies, including cancer. The endothelial cells play a crucial role 
in the growth and remodelling of the vasculature. A novel unique endothelial 
marker, endothelial cell specific chemotaxis regulator (ECSCR), has been identified 
and the aim of this project was to characterise its expression patterns and 
mechanism of action. 
In HUVECs the interaction with filamin A was confirmed and immunoprecipitation 
has pulled down several cytoskeletal proteins involved in cell movement, including 
moesin, that binds to ECSCR. ECSCR loss causes cytoskeleton to be disorganised 
and overexpression induces filopodia in HEK 293T cells, but not M2 cells, that do 
not contain filamin A. 
In zebrafish ECSCR is restricted to the major trunk and head vasculature, whereas 
in mouse it appears to be present also in the intersegmental vessels. Morpholino 
mediated knockdown of zebrafish Escr caused disruption of intersegmental vessel 
sprouting from the trunk vessels. The original phenotype was successfully rescued. 
A null Ecscr knockout mouse has been produced and preliminary data show that 
the deletion is not lethal and ECSCR is present in some small vessels, but not all 
vasculature. Loss of ECSCR may result in respiratory complications. 
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1.1  The role of endothelial cells in angiogenesis 
The endothelium is a single layer of simple squamous epithelial cells that line the interior 
surface of blood vessels of the entire human vascular system. The development of new blood 
vessels from existing vasculature is known as angiogenesis or neovascularisation (Risau, 
1997). This complex and organised process comprises vascular initiation, formation, 
maturation, remodelling and regression (Gilbert, 2006). The endothelial cells forming new 
vessels are stimulated with angiogenic factors which make them more permeable. Then, they 
start secreting proteolytic enzymes that breakdown the basement membrane to create space for 
the new vessel (Mignatti and Rifkin, 1996). Some cells from the vessel wall start migrating 
towards the gradient of angiogenic factors and form a tube, that merges with another vessel 
and a lumen is formed. This vessel will then mature and be stabilised by the recruitment of 
pericytes (Carmeliet, 2003; Jain, 2003; Adams and Alitalo, 2007).  
1.2 Developmental and pathological angiogenesis 
Angiogenesis is fundamental for normal development and healing (inflammation, wound 
healing), but it also occurs in over 70 different disease states, due to loss of regulation of normal 
processes.  Diabetic retinopathy, rheumatoid arthritis, psoriasis and cancer are some examples 
of these pathologies (Pandya et al., 2006).  
For over 30 years researchers have been studying developmental and pathology-associated 
vascularisation in quest for angiogenesis-stimulating factors that could be used as targets for 
anti-angiogenic therapies (Folkman, 1971; Denekamp, 1982; Folkman and Klagsbrun, 1987; 
Kidd and Weinstein, 2003). However, these two kinds of vessel development differ from each 
other. 
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Although the heart is the first functional organ of the body, it only begins to beat after the 
embryonic first circulatory loops are formed. A primitive vascular plexus is originated by a 
process called vasculogenesis when the embryo is still being nourished by diffusion. Therefore, 
the embryonic vasculature is different from the adult one, since it must adapt to the changes 
occurring in the embryo. This plexus is connected to the heart tube and when this organ starts 
to pump, this initial network is irrigated and the first circulation is established. The link between 
vasculogenesis and angiogenesis is made by the expression of VEGF receptors by pluripotent 
precursors in response to FGF. This is how the pluripotent precursors become hemangioblastic 
precursors. After vasculogenesis, the primary capillary networks are remodelled and veins and 
arteries are formed, by angiogenesis (Gilbert, 2006; Flamme et al, 1997). 
The initial formation of a tumour is not dependent of blood vessels. Only when it reaches a 
volume of 2 mm3 neovascularisation occurs in response to the tumour oxygen and nutrient 
demands. This vascularisation is called tumour angiogenesis, since it differs from 
developmental and normal angiogenesis (Sacewicz et al., 2009). Due to these differences, 
tumour vasculature can be described as immature vasculature. The walls are poorly developed, 
with few vascular smooth muscle cells and pericytes, which results in higher permeability and 
the networks are chaotic and lack a hierarchy (Tozer et al., 2005; Neri and Bicknell, 2005). 
Apart from recruiting neighbouring blood vessels and vascular endothelial cells to support their 
own nourishment, tumours also have the ability to produce angiogenic factors to mobilise bone 
marrow-derived endothelial precursor cells into the developing vasculature (Rafii et al., 2002). 
1.3 Targeting angiogenesis 
The quest for factors that promote tumour angiogenesis as therapeutic targets for cancer has 
begun many decades ago, with the study of vascular endothelial growth factor (VEGF) 
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(Ferrara, 2002). Although VEGF plays a pivotal role in vascular development, it has become 
clear that it has a function in other non-vascular processes such as organogenesis and patterning 
and therefore new targets are needed without this kind of side effects (Coultas et al., 2005; 
Greenberg and Jin, 2005). Additionally, although showing some therapeutic efficacy in mouse 
models and some human cancers, relapse and tumour progression follow the transitory positive 
effects of anti-VEGF therapies (Bergers and Hanahan, 2008). Free radicals, such as reactive 
oxygen species, are created by hypoxic conditions in tumours. These, in combination with 
hypoxia- reoxygenation cycling  and immune cell infiltration after chemotherapy affect 
hypoxia- inducible factor 1 (HIF1) activity, which is implicated in endothelial and tumour cell 
survival (Dewhirst et al., 2008). Hypoxic and necrotic regions found in tumours offer the 
opportunity for cancer-selective therapy (Brown and Wilson, 2004). Nitric oxide is also a 
highly reactive free radical that regulates several physiological functions, such as angiogenesis, 
blood flow, vascular permeability, leukocyte-endothelial interaction, platelet aggregation, 
microlymphatic flow, as well as neurological and cytotoxic functions (Fukumura et al., 2006). 
This molecule is produced by endothelial nitric oxide synthase (eNOS) which is present, 
together with other signalling proteins, at the endothelial cell surface in microdomains called 
caveolae. Caveolin 1 seems to have the capacity to inactivate eNOS and act as a tumour 
suppressor in vitro although in vivo, at later stages, it appears to play a role in cancer 
chemoresistance, survival and metastasis (Carver and Schnitzer, 2003). Tumour blood vessels 
express markers not present in normal vasculature, but shared by angiogenic vessels in non-
malignant conditions. Thus, a better understanding of tumour cells is needed, as well as caution 
regarding normal angiogenesis, when designing anti-angiogenic therapies (Rouslahti, 2002). 
Since vascular endothelium is not a homogeneous tissue, Kuzu et al. (1992) reported the 
diagnostic usefulness of using a panel of antibodies against vWF, CD31 and CD34 to identify 
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tumours of vascular origin, as they gave reliable immunostaining even for formalin fixed, 
paraffin wax embedded sections. Other known endothelial markers are the transcription factor 
Fli-1, several receptors including the VEGF receptors (FLT1, KDR) and the angiopoetin 
receptors TIE1 and TIE2/TEK (Verissimo et al., 2009). 
The advent of modern sequencing and expression analysis combined with advances in 
bioinformatics datamining has led to the recent discovery of several novel endothelial genes. 
Our group has used a bioinformatics datamining strategy that combined expressed sequence 
tags (EST) cluster expression analysis in the human Unigene index and SAGEmap xProfiler to 
identify novel endothelial-specific genes. Four novel genes were identified: endothelial cell-
specific molecules (ECSM) 1-3 and magic roundabout (similar to the axon guidance protein 
roundabout Robo1). We have also identified endothelial protein-disulfide isomerase 
(EndoPDI), highly expressed in endothelial cells. mRNA and protein levels of EndoPDI are 
induced by hypoxic conditions and it was shown to have a protective role only in cells exposed 
to hypoxia, in contrast to PDI which displayed no differences between cell protection under 
hypoxic or normoxic conditions. Furthermore, we showed by in situ hybridization that 
EndoPDI expression is very rare in normal tissues, being expressed preferentially in tumour 
endothelium and other hypoxia-associated lesions. These data indicate that EndoPDI is a 
potential target for tumour endothelial therapies (Verissimo et al., 2009). 
On the other hand, pro-angiogenic therapies are also useful in treating diseases such as 
ischaemic disorders and some therapies have already been approved for use in several countries 
(Ferrara and Kerbel, 2005). 
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1.4 The identification and characterization of endothelial cell 
specific chemotaxis regulator (ECSCR) 
Expressed sequence tags (EST) of endothelial cell specific chemotaxis regulator (ECSCR – 
formerly ECSM2) were found to be enriched in endothelium by bioinformatics datamining 
(Huminiecki and Bicknell, 2000). It was described as an endothelial marker for the first time 
in a study by Pelosi et al. (2002), where they showed that ECSCR was present in a postnatal 
population of CD34+KDR+ cells comprising hemangioblasts and endothelial progenitors. The 
endothelial specificity of ECSCR has also been confirmed by quantitative polymerase chain 
reaction using a range of endothelial and non-endothelial cell lines (Herbert et al., 2008; 
Armstrong et al., 2008), as well as in situ hybridization on a variety of human tissues 
(Armstrong et al., 2008). By applying a novel method of differential gene expression analysis 
using multiple cDNA libraries, Herbert et al. (2008) have identified ECSCR within the top nine 
predicted tumour endothelial markers. More recently, this protein has been found to be 
upregulated in another type of disease, colitis, where increased pathological angiogenic activity 
plays a role (Fang et al., 2011). ECSCR is a glycosylated type I transmembrane protein, present 
especially in spike-like cell protrusions termed filopodia. Reduced chemotaxis and impaired 
tube formation on MatrigelTM were observed when ECSCR was knocked down by siRNA. 
Filamin A was identified in a yeast-two-hybrid screen as an interacting protein for its 
intracellular domain. This was confirmed by GST (glutathione-s-transferase) pull down. Taken 
together, these data implicate a role for ECSCR in angiogenesis through modulation of the 
actin cytoskeleton. Mouse and zebrafish orthologs were identified (Figure 1.1) (Armstrong et 
al., 2008). The predicted structure for these three proteins using SMART software indicates 
the presence of a signal peptide, and extracellular, transmembrane and intracellular domains, 
as shown on figure 1.2. 
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The chromosomal location of the human, mouse and zebrafish genes is 5q31.2, 18 B2 and 
chromosome 21, respectively. The NCBI accession numbers for cDNA and proteins for Homo 
sapiens, Mus musculus and Danio rerio are NM_001077693/NP_001071161.1, 
NM_001033141.1/NP_001028313.1 and XM_002666009.1/XP_002666055.1, respectively. 
Other names for the protein are ECSM2/ARIA (human), Ecsm2/Riken1110006O17 (mouse) 
and hypothetical LOC100006714 (zebrafish). 
The data produced by Armstrong et al. (2008) were rapidly independently confirmed by Ma et 
al. (2009). They observed that in HEK293 cells transfected with ECSCR-GFP overall tyrosine 
phosphorylation signalling was reduced compared to the controls.  ECSCR may have a role in 
attenuating the epidermal growth factor (EGF)-induced cell migration by cross talking with its 
receptor (EGFR), possibly by inhibiting the Shc-Ras-ERK (MAPKinase) pathway. In these 
transfected cells actin stress fibres formed by filament bundling were destroyed and the 
formation of filopodia was induced. In addition to its location to the plasma membrane and 
enrichment in filopodia in isolated cells, the same group has shown that ECSCR is also present 
in cell-cell junctions in confluent cells (Shi et al., 2011).  ECSCR promotes cell aggregation 
and seems to inhibit basic fibroblast growth factor (bFGF)-mediated cell migration via the 
FGFR-ERK-FAK pathway (Shi et al., 2011). 
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Figure 1.1 – Alignment of ECSCR orthologs.  
To search for ECSCR orthologs, the human gene was aligned with genomes of different species 
using the Ensembl website (www.ensembl.org/). The correspondent proteins were then aligned 
using the online multiple sequence alignment tool Clustalw2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Conserved regions are highlighted in grey. The 
transmembrane and intracellular domains show greater conservation than the extracellular 
domain (adapted from Armstrong et al., 2008). 
 
 
 
 
peptide 
Extracellular Transmembrane Intracellular 
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Figure 1.2 – Predicted structure for human, zebrafish and mouse ECSCR using 
SMART. 
The predicted sequences of the human, zebrafish and mouse ECSCR proteins were obtained 
from NCBI (http://www.ncbi.nlm.nih.gov/) and analysed using SMART (Simple Modular 
Architecture Research Tool) (http://smart.embl-heidelberg.de/) to search for architectural 
features. It was predicted that these proteins contained a signal peptide (SP) (except the murine 
version), an extracellular domain (ECD), a single transmembrane domain (TM) and an 
intracellular domain (ICD). 
aa – amino acids. 
  
Human 
Zebrafish 
Mouse 
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In a second study published in 2009 the authors did not acknowledge the existence of ECSCR 
and submitted their work on a “novel” endothelial protein called ARIA (apoptosis regulator 
through modulating IAP expression) (Ikeda et al., 2009). They described that ARIA (ECSCR) 
interacted with proapoptotic proteins cIAP-1 and cIAP-2, modulating their degradation by the 
proteasome and thus regulating endothelial cell survival. They found that ARIA is expressed 
in mouse embryonic vasculature and also in endothelial cells in vivo and in vitro. ARIA siRNA 
knockdown in HUVECs resulted in significant reduction of apoptosis. More recently, the same 
group has produced an ARIA knockout mouse and described that this molecule regulates the 
PTEN/PI3K/Akt/eNOS pathway. The mice display non-lethal bleeding during embryogenesis 
and increased small vessel density, as well as altered expression of vascular growth factors, 
such as angiopoetins and VEGF receptors. Post-natal neovascularisation was enhanced using 
the critical limb ischemia model and more bone marrow-derived endothelial cells were found 
in ischemic muscle. ARIA was found to be enriched in endothelial progenitor cells (Koide et 
al., 2011). 
Ecscr knockdown in zebrafish developing embryos slows down angioblast migration towards 
the midline (posterior lateral plate mesoderm) (Verma et al., 2010). In HUVECs ECSCR 
partially co-localises with KDR and its knockdown results in lower VEGF-induced 
phosphorylation of KDR (lower sensitivity to VEGF). 
A summary of the current knowledge of ECSCR proposed signalling is depicted on figure 1.3. 
So far, even though there is discrepancy in some results, ECSCR seems to be an interesting 
and promising target for angiogenesis therapies, due to its endothelial specificity and role in 
cell motility, adhesion and apoptosis. 
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Figure 1.3 – Proposed models describing the current knowledge of ECSCR signalling in 
endothelial cells  
Although the literature on ECSCR is still limited, different studies suggest distinct roles for the 
protein in endothelial cells: apoptosis, via direct interaction with cIAP, angiogenesis through 
PTEN, cell motility by directly interacting with Filamin A or contributing to phosphorylation 
of EGFR or KDR and cell-cell adhesion through interaction with a possible ligand or the 
ECSCR molecule itself. KDR - Kinase insert domain receptor; EGFR – epidermal growth 
factor receptor; L – ligand; P – phosphorylation; FAK – focal adhesion kinase; PTEN – 
phosphatase and tensin homolog; cIAP – cellular inhibitor of apoptosis protein; PMSA-7 – 
proteasome subunit α7. (adapted from Verissimo et al., 2009). 
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1.5 Cell migration: the fine orchestration between protrusion, 
retraction and adhesion 
Cell migration is essential for both physiological and pathological processes. During 
embryonic development intensive migration occurs so that different lineages of cells can reach 
a proper location (Kurosaka and Kashina, 2008). Throughout life, certain cell types continue 
to migrate in order to be able to perform their roles, such as those from the immune system 
(Madri and Graesser, 2000). In pathological conditions, such as cancer, metastatic cells are 
highly motile (Seol et al., 2012). Migration is a multi-step, dynamic, cyclic process, that 
comprises the extension of protrusions at the leading edge, substrate adhesion and rear 
retraction. All these are achieved by rapid modulation and coordination of complexes of 
cytoskeletal proteins. 
1.5.1 Filopodia and lamellipodia at the leading edge of migrating cells 
In response to external signals cells polarise, acquiring a conspicuous morphology, 
characterised by flat membrane protrusions, termed lamellipodia, and spike-like protrusions 
called filopodia at the leading edge (figure 1.4). The formation of two distinct protrusive actin 
structures with different architectures and dynamics in close spatial proximity is due to the 
activation of two separate nucleation pathways, Arp2/3 and formins (Gomez et al., 2007). 
Actin filaments polymerise at the leading edge and depolymerise at the rear of lamellipodia, in 
a process named treadmilling (Wang, 1985). The fast-moving and short-lived lamellipodial 
actin speckes are preceded by slow-moving, long-lived speckles that form the lamella. Actin is 
arranged in branched filaments in lamellipodia, whereas in the lamella it is presented as loose, 
unbranched filaments containing tropomyosin and myosin II  (figures 1.4 A and 1.4 D)  
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Figure 1.4 - Processes involving the actin cytoskeleton during cell migration 
In lamellipodia, branched actin filaments are formed at the plasma membrane by WASP-
Arp2/3 and regulated by a set of regulatory proteins (ADF, capping proteins, profilin) (A). 
When migrating, cells extend finger-like protrusions called filopodia beyond the protruding 
lamellipodia to sense the environment. At the tip, formins like mDia2 catalyze the processive 
assembly of profilin-actin. The resulting non-branched actin filaments are tightly bundled by 
several proteins including fascin and the Irsp53-Eps8 complex (B). Slow moving cells form 
focal adhesions, that connect the extracellular matrix to contractile bundles made of actin 
filaments, myosin II, and bundling proteins including alpha-actinin (C). The lamella contains 
tropomyosin and myosin II. The nucleating and anchoring at the plasma membrane 
mechanisms are unknown (D). Lp - lamellipodium; Fp - filopodium; Lm - lamella; SF - stress 
fiber; FA - focal adhesion; FC - focal complex (adapted from Le Clainche and Carlier, 2008)  
Leading edge 
Trailing edge 
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(Le Clainche and Carlier, 2008).  Surprisingly, injection of tropomyosin resulted in loss of 
lamellipodia but increased leading edge protrusions and accelerated migration. This suggests 
that lamellipodia may be more important in other processes, such as pathfinding (Gupton et al., 
2005). At low concentrations, cofilin promotes actin depolymerisation by cleavage and at high 
concentrations it nucleates actin filaments, (Adrianantoadro and Pollard, 2006), whereas 
profilin binds monomeric actin (Yarmola and Bubb, 2006). Treadmilling is a dynamic process 
that involves and depends on the balance of many proteins that contribute to actin filaments 
progression and regression, such as severing, nucleating and capping proteins (Le Clainche and 
Carlier, 2008). 
As cells migrate, actin filaments need to be continuously polymerised at one end and 
disassembled at the other. In the lamellipodium the Wiskott–Aldrich Syndrome Proteins 
(WASP) activate the actin related proteins (Arp)2/3 complex, which works in coordination 
with cofilin, profilin and capping proteins to achieve branched nucleation. The Arp2/3 
complex, located at the leading edge, determines the direction of the protrusion (Goley and 
Welch, 2006). Actin assembly by Arp2/3 through WASP activation occurs downstream from 
Rac1 and Cdc42 (responsible for the formation of ruffles and filopodia, respectively) (Nobes 
and Hall, 1995). 
Contrasting with the branched architecture of lamellipodia, filopodia are formed of 15-20 
parallel filaments tightly packed (figure 1.4 B). They locate exteriorly to lamellipodia, at the 
leading edge of protrusions (Lewis and Bridgman, 1992). Actin assembly and retrograde flow 
control extension and retraction in these structures, respectively. Although Cdc42 controls 
filopodia formation, some authors argue that the Arp2/3 complex does not contribute to actin 
nucleation in this context, supported by the fact that N-WASP null fibroblasts possess normal 
filopodia and the Arp2/3 complex promotes branched rather than linear actin nucleation (La 
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Clainche and Carlier, 2008). In the same year our group has described a role for the Arp2/3 
complex in filopodia formation (Sheldon et al., 2008). In order to investigate the role of 
roundabout proteins in endothelial cell biology, Robo1 and Robo4 siRNA knockdown was 
performed in HUVECs and it was found that both resulted in impaired cell migration and tube 
formation. Yeast-two-hybrid analysis, confirmed by glutathione-s-transferase pull down, has 
identified WASP and Arp2/3 as interacting partners for Robo4 intracellular domain, as well as 
Mena, which signals downstream from Cdc42 and IRSp3 (insulin receptor substrate fo 53 kDa) 
to initiate filopodia. The heterodimer Robo1-Robo4 is essential for the formation of filopodia. 
It was hypothesised that Slit 2 binds to Robo1 when in a complex with Robo4 thus eliciting the 
formation of filopodia. Furthermore, in zebrafish endothelial cells, Robo4 activates and 
controls the levels of Cdc42 and Rac1. Angioblasts isolated from zebrafish embryos where 
Robo4 was knocked down search actively for direction, which suggests a role for Robo4-Rho 
GTPases in attractive vascular guidance (Verissimo et al., 2009). 
Formins are another group of actin-nucleating proteins downstream of Rho GTPases that are 
present at the tip of filopodia and induce their formation (diaphanous-related formin, mDia2). 
In Dyctiostelium dDia2 is required for filopodial extension (Schirenbeck et al., 2005). In a 
study in Drosophila, Homem and Peifer (2009) have shown that activated Dia mobilises 
enabled (Ena) to the deading edge. Although each of these proteins is sufficient to induce 
filopodia, jointly they induce lamellipodia. Taken together, these observations suggest that the 
ratio between Dia and Ena regulate the balance between these protrusive structures. Clearly, 
cytoskeletal rearrangements are complex and multifactorial, contemplating fine equilibria and 
perhaps some redundancy, as well as cell type-specificity. 
Phosphorylated ERM (ezrin, radixin, moesin) actin-binding proteins also locate at filopodia 
(Bretscher et al., 2002). 
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1.5.2 The role of cell-matrix adhesions in cell migration 
Cell migration starts with the emission of cytoplasmatic protrusions and also includes the 
traction of the cell body and tail retraction. Adhesion to the matrix is key in controlling the 
dynamics between protrusion (achieved by actin assembly at the leading edge) and the traction 
of the cell body and retraction of the tail (achieved by actomyosin contractile force) (La 
Clanche and Carlier, 2009). There are three types of adhesion structures: focal complexes, focal 
adhesions and fibrillar adhesions (figure 1.5) (La Clanche and Carlier, 2009). Focal complexes 
are dot-like, Rac1 activated, nascent adhesions that disassemble and reassemble at the leading 
edge during protrusion and contain a loose actin network (Rottner et al., 1999). Proteins such 
as PAK-interacting exchange factor PIX and G-protein-coupled receptor kinase (GRK)-
interacting target 1 (GIT1) participate in focal complex disassembly (Zhao et al., 2000). In 
response to RhoA these structures stabilise, mature and give origin to focal adhesions. These 
are associated with the end of stress fibres and contain vinculin, talin, paxillin, alpha-actinin, 
focal adhesion kinase (FAK) and integrin αvβ3 (Zaidel-Bar et al., 2003). In turn, fibrillar 
adhesions arise from focal adhesions, although much less complex, and contain tensin and 
integrin α5β1, taking the shape of thin actin cords (Zamir et al., 2000). 
Vinculin is present in focal adhesions and is able to bind actin and talin. Its regulation seems 
to be important for angiogenesis, as low levels are required for in vitro tube formation (as well 
as integrin α2, talin, α-actinin and actin, although these proteins don’t decrease as much) 
(Deroanne et al., 1996). Integrins are a large family of transmembrane receptors formed of 
alpha and beta chains that play a major role in mediating interactions between the intracellular 
compartment and the extracellular matrix. Eighteen α subunits and eight β subunits can 
combine to form 24 functional heterodimers. Thus, they are involved in a variety of 
physiological processes, such as cell migration, embryogenesis and haemostasis. Ligand 
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binding leads to clustering and recruitment of actin filaments through the interaction with 
cytoskeletal proteins, such as talin, vinculin, α-actinin and filamin (Hemler, 1999). Integrins 
have the ability to signal bidirectionally, allowing a dynamic exchange between the 
intracellular and extracellular compartments (Legate et al., 2009). Signalling involving 
integrins is very complex as there are, to date, 156 proteins known to be part of the integrin 
adhesome (Moser and Legate, 2009). Focal adhesion kinase plays a crucial role in focal 
adhesions (and therefore in regulating cell motility), by switching between Rho GAPs and 
GEFs. RhoA activation leads to increased cell contractility and trailing edge retraction, whereas 
RhoA inactivation results in decreased cell contractility and lamellipodia formation (Tomar 
and Schlaepfer, 2009). 
Stress fibres are essential to achieve retraction of the rear of the cell, by applying contractile 
force on focal adhesions (Small and Resch, 2005). These structures are formed of actin and 
myosin and are found both in association with focal adhesions and independent from focal 
adhesions. Stress fibre formation associated with focal adhesions is activated by RhoA (Small 
et al., 1998). 
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Figure 1.5 - Adhesion structures. 
Depending on their composition, size, shape, dynamics and location, adhesion structures are 
classified as focal complexes (A), focal adhesions (B) or fibrillar adhesion (C). Rac1 signaling 
elicits the formation of focal complexes, that contain integrin beta-3, talin (Ta), and Paxillin 
(Pa). Focal complexes mature into focal adhesions in response to RhoA signalling, which 
activates ROCK, resulting in stress fibre contractility. Fibrillar adhesions contain high levels 
of tensin (adapted from Le Clainche and Carlier, 2009) 
Focal complex 
Focal adhesion 
Fibrillar adhesion 
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1.6 Cell-cell adhesion 
Endothelial integrity is maintained by intercellular adherence, that regulates transendothelial 
migration of blood cells, as well as permeability. This is achieved through tight and adherens 
junctions. The first are maintained by claudin 5, junctional adhesion molecule and endothelial 
cell adhesion molecule (Schnittler, 1998). The latter are particularly important in this process 
and are essentially composed of vascular endothelial cadherin (VE-cadherin). It forms dimers 
via the extracellular domain and recruits proteins, such as catenins, to the membrane, through 
the cytoplasmic tail (Lampugnani et al., 1992). Catenins serve as a link between VE-cadherin 
and the cytoskeleton (Bogatcheva et al., 2008). Initial contacts between two cells are thought 
to be made through the extension of filopodia and subsequent cell migration. Almagro et al. 
(2010) have shown that VE-cadherin is also present in the tip and body of filopodia in non-
confluent cells. The motor protein myosin X co-localises with and transports VE-cadherin 
along actin filaments towards the membrane, thus contributing to cell-cell junction formation.  
Non-muscle myosin II participates in cytoskeletal rearrangements implicated in cell adhesion, 
migration and division. As well as participating in cell-matrix adhesion, this protein also 
promotes the formation and stabilization of cell-cell junctions, as it is required for cadherin 
clustering. Active RhoA drives contraction and compactation and activates non-muscle myosin 
IIa. At a later stage, myosin II stabilises the junctions by pulling inwards in both cells involved 
in the junction (Ivanov et al., 2007). 
1.7 Filamins and cytoskeleton 
Filamins are a family of large actin-binding proteins that stabilise filamentous (F)-actin 
networks, link actin to the intracellular domain of transmembrane proteins and serve as a 
scaffold for many cytosolic proteins. Thus, they participate in many processes, such as signal 
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transduction, gene transcription and receptor translocation. There are three isoforms, A, B and 
C, and many splice variants have been described, that influence their crosslinking pattern, as 
well as the proteins that bind to them. Filamins A and B are ubiquitous, whereas filamin C has 
a more restricted distribution to skeletal and cardiac muscle cells (Zhou et al., 2009). Filamins 
are formed of 24 repeats of approximately 96 amino acid each that fold into anti-parallel beta-
sheets that overlap to generate rods. They form homo or heterodimers via immunoglobulin-
like (Ig) domain 24 and bind to actin through the N-terminal actin binding domain (ABD). 
There are two hinge regions, between repeats 15 and 16 and also between repeats 23 and 24.  
These sites are susceptible to calpain and caspase cleavage (Stossel et al., 2001) (figure 1.6). 
Many proteins have been found to interact with Filamin A that are involved in diverse 
processes, such as transcription factors (androgen receptor), cell motility (migfilin, FILIP), cell 
adhesion (integrins β1, β2, β7), cell signalling (caveolin-1, Rho-associated protein kinase), 
lymphocyte function (CD28, calcineurin), proteolysis (caspase-3, epithin), metabolic function 
(insulin receptor) and vascular function (calmodulin, calcitonin receptor, ECSCR) (figure 1.7) 
(Popowicz et al., 2006; Zhou et al., 2007; Zhou et al., 2009). This multitude of functions 
highlights the importance of filamin A (and filamins in general, as the other members have 
been found to also interact with a variety of partners, although less studied) in cellular processes 
and implicates its malfunction in many diseases. For example, humans with mutations in 
filamin A develop central nervous system and skeletal disorders, as well as cardiovascular 
malformations. Filamin A knockout mice die at E14 and display disrupted epithelial and 
endothelial organization, altered adherens junctions in many tissues, as well as cardiovascular 
abnormalities and haemorrhage (Feng et al., 2006). 
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Figure 1.6 - Interaction of filamin A with filamentous actin.  
Filamin dimerisation promotes orthogonal bundling of the actin filaments. The Ig repeats 9-
15 of rod domain 1 are very avid for actin, whereas rod domain 2 is responsible for binding 
of most partners, as can be seen in more detail on figure 1.7 (adapted from Zhou et al., 2009) 
 
 
 
Filamin A 
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Figure 1.7 - Structure of filamin A and mapping of binding of some interacting proteins. 
Filamin A encompasses 24 repeats that fold into antiparallel β-sheets and function as interfaces 
for protein–protein interactions. At the N terminus there is an actin-binding domain that 
contains two calponin-homology domains (CH1 and CH2). Most of binding partners interact 
with FLNA at the C-terminus, as depicted. These partners are divided into groups of 
transcription factors, GTPase-related proteins, other filamins and filamentous actin, and cell 
adhesion and migration proteins (adapted from Zhou et al., 2009) 
CH – calponin homology domains (actin binding domain); 1-14 – Ig repeats; H1 and H2 – 
hinge regions, susceptible to calpain cleavage. AR – androgen receptor; ECSM – ECSCR 
  
ECSCR 
ECSCR 
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Filamin C knockout causes perinatal lethality, but does not seem to cause cardiovascular 
malformations (Dalkilic et al., 2006). Filamin B, that has recently been implicated in VEGF-
induced endothelial cell migration via Rac-1 and Vav-2, seems to indeed have a role in the 
formation of the vascular system, as knockout mice for this protein have impaired 
microvascular development (as well as in other larger vessels, such as the middle cerebral 
artery). The embryos die at stage E11 (Valle-Perez et al., 2010; Zhou et al. a, 2007). 
To perform so many distinct functions, not only does filamin A have several splice variants, 
but it also can be cleaved into different fragments, that allow migration into different cell 
compartments and further interactions. The full-length 280 kDa protein can be cleaved to 170 
kDa (actin-binding domain plus Ig repeats 1-15) and 110 kDa (Ig repeats 16-24). The latter can 
be further cleaved to a 90 kDa fragment (loses Ig repeat 24) that has the ability to translocate 
into the nucleus and interact with the androgen receptor, which results in repression of its 
transcriptional activity (Gorlin et al., 1990; van der Flier and Sonnenberg, 2001; Loy et al., 
2003). 
Filamin A is essential for cell migration, as cells deficient in this protein fail to undergo 
locomotion in response to migration-stimulating factors. These cells are able to protrude and 
retract multiple spherical processes termed blebs, as a result of the inability of enduring internal 
hydrostatic pressure. Bleb protrusions start with monomeric actin, and some weak 
polymerization and crosslinking occurs, but the lack of filamin A and proper crosslinking limits 
the growth of these protrusions and they eventually retract (Cunningham, 1995).  Transfection 
of filamin A re-establishes migratory capacity (Cunningham et al., 2002). 
Filamin A localizes to filopodia, lamellipodia, stress fibers and focal adhesions (Campbell, 
2008). During spreading this protein is enriched near the cell membrane and adhesion sites 
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(Kim et al., 2008). It regulates intracellular traffic of β1 integrins, thus controlling cell 
adhesion. Cells that lack filamin A show reduced expression of cell-surface β1 integrins during 
the initial period of adhesion to matrix, that is rescued by the re-introduction of filamin A 
(Meyer et al., 1998; Kim et al., 2010). In turn, blocking β1 integrin function reduces cell 
spreading and the localization of filamin A to cell extensions (Meyer et al., 1998). The fine 
regulation of the integrin-filamin interaction results in two different phenotypes: some binding 
is required to stabilise cell-matrix adhesions, whereas excessive binding prevents proper actin 
remodelling and cell motility (Kim et al., 2008). In order to achieve signalling and movement, 
filamin A must be replaced by talin in the β-chain of integrins. Cell adhesion and spreading 
depend on the integrity of actin filaments, intermediate filaments and microtubules and the 
stability of these three complexes depends on each other. Although the precise mechanism 
underlying this interdependence is not yet fully understood, filamin A seems to act as a bridge 
between these systems, as it is present in all of them (Kim and McCulloch, 2010).  More 
evidence for the importance of filamin A in adhesion comes from the fact that siRNA-mediated 
knockdown of filamin A results in reduction of vinculin and paxilin recruitment to focal 
adhesion sites (Kim et al, 2010). 
Filamin A is present in the extremities of spreading and migrating cells, in lamellipodia during 
early stages of cell spreading and is enriched in filopodia upon cell migration stimulation. Cells 
that do not possess filamin A fail to respond to these stimuli and are unable to form filopodia 
(Ohta et al., 1999). Filamins control the nature of cell protrusions and retractions because they 
are located both at the leading edge as well as the rear of polarised cells (figure 1.8). Filamin 
A interacts with small GTPases of the Rho family, which are activated upon integrin binding 
to the extracellular matrix. These signalling cascades lead to the formation of filopodia and 
lamellipodia through actin porlymerization (Zhou et al., 2009). Filamin A is necessary for 
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RalA-mediated filopodial protrusion (Ohta et al., 1999). Another process, membrane ruffling, 
is mediated by p21-activated kinase-1 (PAK1), that is activated by binding to and 
phosphorylation of filamin A. PAK1 is a downstream effector of Rac1 and Cdc42. In addition, 
filamin A is capable of associating with the Rho downstream effector ROCK in areas or 
membrane protrusions, as well as sphingosine kinase 1, which further stimulates PAK1, 
through the production of sphingosine-1-phosphate (Zhou et al., 2009). For a tighter regulation 
of Rho signalling, filamin A is also able to bind guanine nucleotide-exchange factors (GEFs), 
such as Trio, and GTPase-activating proteins (GAPs), such as FilGAP. 
Accumulation of p190RhoGAP in the cell membrane leads to Rho inactivation and Lbc 
stimulates ROCK activity which inactivates Rac through phosphorylation and stimulation of 
FilGAP. This causes protrusions at the leading edge to be suppressed and cell retraction is 
promoted. Furthermore, ROCK phosphorylates and activates myosin II, which is responsible 
for contractile activity (Tseng et al., 2004). 
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Figure 1.8 - Interaction of filamin A with filamentous actin. 
During cell migration FLNA acts as a scaffold for small GTPases. The lamellar membrane at 
the leading edge of motile cells participates in a series of complex movements that involve the 
assembly and reorganization of actin bundles and networks, both formed by FLNA. FLNA 
crosslinks actin filaments and engages transmembrane proteins (β-integrins), as well as small 
GTPases (Cdc42, Rho, Rac, RalA) and their upstream (Trio, Lbc, FilGAP, RhoGAP) and 
downstream (ROCK, PAK1) factors (adapted from Zhou et al., 2009)  
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1.8 Angiogenesis assays and models 
 In vitro assays allow the study of endothelial cell proliferation, migration, tube formation, fluid 
shear stress and flow, intracellular signalling and cell interactions (single or co-culture studies) 
(Auerbach et al., 2003; Staton et al., 2006; Martin and Murray, 2009). The endothelial cell tube 
formation assay on basement membrane is very easy to perform and allows the study of 
angiogenic and antiangiogenic factors, to define mechanisms and pathways involved in 
angiogenesis and to define endothelial populations. Basically, upon seeding on an appropriate 
matrix, endothelial cells undergo a series of differentiation processes that lead to the 
establishment of vessel-like structures (Arnaoutova et al., 2009). A step closer to a more 
complete strategy is the quantitative-three dimensional ex vivo mouse aortic ring angiogenesis 
assay, as the vessel contains other cell types that interact with the endothelium in vivo (Baker 
et al., 2012). After dissection, aortic rings are serum-starved and embedded in a matrix of 
choice, according to the objectives of the study. Then, the rings are fed and allowed to develop 
sprouts for about 5-9 days. Before embedding, the rings can be treated with siRNA and during 
regular media changes throughout the assay drugs, growth factors, etc. can be added. 
Subsequently, the rings can be analysed for a variety of parameters, such as sprout number and 
length, pericyte coverage, as well as used for immunofluorescent staining and confocal 
imaging. Although this assay can be informative, one of its limitations is the fact that it may 
not be physiologically relevant, as normal aorta does not really sprout. Retina has also proved 
to be a good and widely used model in angiogenesis research to investigate neurovascular 
relationships and developmental and pathological angiogenesis (Gariano and Gardner, 2005). 
Although very informative, cell cultures and ex vivo models don’t account for the whole 
picture, and need to be complemented with in vivo assays. 
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In vivo comparative studies of normal and pathological conditions, such as subcutaneous 
implantation of matrigel plugs or sponge and subsequent  analysis of vascularisation, as well 
as the use of transgenic mice and zebrafish help to better understand the mechanisms of 
angiogenesis and to develop and predict the effect of antiangiogenic drugs (Staton et al., 2006; 
Martin and Murray, 2009). 
The mouse (Mus musculus) has been used as a mammalian model for a very long time. More 
recently, the zebrafish (Danio rerio) has proven to be a suitable model to human angiogenesis 
and its use over the last years has increased. Zebrafish embryos have an external development 
and are transparent, being suitable for very simple microscopy analysis with much detail 
(Lessman, 2011). Being a vertebrate, the vasculature is similar to the mammalian one (Gore et 
al., 2012). The molecular mechanisms regulating vasculogenesis and haematopoiesis are 
conserved throughout vertebrate evolution as demonstrated, for example, by studies using the 
cloche and spadetail mutants. In brief, both mutants display defects in haematopoiesis, but only 
the cloche mutants have altered vascular gene expression. In these fish no vasculature at all 
develops (Thompson et al., 1998). Transgenic lines are already available and they can be used 
to directly assess the effect of morpholino knock down of genes of interest. The fact that the 
genome is sequenced is another advantage (Weinstein, 2000). 
The zebrafish model has contributed to finding novel endothelial-specific genes, uncover gene 
function, understand developmental processes, as well as disease pathogenesis, progression 
and regression. Sumanas et al. (2005) have identified several endothelial specific genes using 
the zebrafish cloche mutant. They analysed over 15,000 zebrafish genes or ESTs in mutants 
affected at a very early step of haematopoiesis and vasculogenesis. These fish lack almost all 
blood cells, head and trunk endothelial cells and the endocardium, as well as markers for both 
lineages, such as scl, gata1, flt1 and flt4. Dual specificity phosphatase 5, cadherin 5 (VE-
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cadherin), aquaporin 8 and ETS1-like protein (etsrp) were found to be significantly down-
regulated in these mutants and their expression pattern has shown their endothelial specificity. 
The same authors have then characterised etsrp and demonstrated that it is necessary and 
sufficient for the initiation of vasculogenesis (Sumanas and Lin, 2006). Etsrp morpholino 
knockdown in vivo resulted in the impairment of angioblast migration, differentiation and 
functional blood vessel formation. Vascular endothelial markers were highly reduced in these 
morphants and overexpression of etsrp restored their expression in the cloche mutants. More 
vascular-specific genes were identified in the zebrafish by microarray analysis of etsrp 
overexpressing zebrafish embryos, such as angiotensin II type 2 receptor, endothelial cell 
specific adhesion molecule and stabilin 2 (Wong et al., 2009). 
Zebrafish have been found to develop almost any tumour type known in humans, with 
comparable morphology and acting through similar signalling pathways (Feitsma and Cuppen, 
2008). Given all the manipulation and imaging advantages of zebrafish, a model for hypoxia-
induced pathological angiogenesis that mediates tumour cell dissemination, invasion and 
metastasis has been created (Lee et al., 2009). Under hypoxia implanted murine fibrosarcoma 
cells were disseminated from primary sites, invaded neighbouring tissues and metastasised to 
distal parts of the body, whereas under normoxic conditions this did not happen. 
Over the years many mouse models have been developed to study angiogenesis (both normal 
and pathological), as well as cancer and many other conditions. These models can be wild type 
mice that are surgically or otherwise physically modified or transgenic mice, which are 
genetically altered. For example, the acute murine hind limb ischemia and reperfusion model 
entails simultaneous occlusion of several branches of the femoral and iliac arteries to achieve 
limb ischemia, followed by loosening of the pressure source to allow reperfusion (Crawford et 
al., 2006). Knockout mouse models for endothelial genes have provided many insights into 
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vascular cell biology. The models available can be more or less complex, ranging from null 
knockouts of the gene of interest obtained by gene targeting to conditional or inducible 
knockouts, where the disruption of the occurs only in certain tissue types or upon stimulation. 
An example of the former is the creation of the Tie2Cre deleter strain, that allows the study of 
gene deletions specifically in the endothelium (Kisanuki et al., 2001). Another type of 
transgenic mice include the expression of specific proteins fused to GFP, to allow visual 
analysis, as well as cell isolation (Hillen et al., 2008). A new transgenic line can also be created 
by crossing and combining pre-existing ones. 
With the development of new laboratorial techniques and tools, software and equipment, the 
available amount of data for mouse tumour models is enormous. In order to facilitate the 
integration, location and visualisation these data, the Mouse Tumour Biology database has been 
created (Kupke et al., 2008).  
1.9  Hypothesis 
With evidence showing that ECSCR is specifically expressed in endothelium and is involved 
in cytoskeletal processes, the hypothesis being tested is that ECSCR promotes specific 
endothelial cells events and its absence leads to defective vasculature formation. 
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1.10 Aim of the study 
Our group has shown that ECSCR is specific to the endothelium, binds to filamin A and its 
absence in HUVECs causes impairment of chemotactic migration and tube formation. It locates 
to the plasma membrane and is enriched in filopodia. This suggested a role for ECSCR in 
modulating cell migration through the modulation of the actin cytoskeleton (Herbert et al., 
2008; Armstrong et al., 2008). However, to the date of the start of this project nothing else was 
known about this interesting molecule. 
For this study, three models were used to establish molecular mechanisms by which ECSCR 
regulates endothelial cell chemotaxis and angiogenesis, one in vitro: primary human umbilical 
vein endothelial cells (HUVECs), and two in vivo: zebrafish and mice. The main objectives 
were: 
 
1– To identify ECSCR binding partners and reveal downstream signalling. The 
elucidation of ECSCR-filamin A interaction was pursued and other binding partners were 
investigated and uncovered. The effect of ECSCR loss on the distribution of these proteins was 
assessed. 
 
2– To determine the role of Ecscr during zebrafish vascular development.  
The endothelial specificity of Ecscr in zebrafish was confirmed by in situ hybridization (it 
seems to be located only in the zebrafish head and major trunk vasculature) and RT-PCR has 
shown that Ecscr expression increases at the onset of vasculogenesis (around 15 hpf). When 
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Ecscr is knocked down with morpholino antisense oligonucleotides, the sprouting of 
intersegmental vessels is disrupted. 
3– To develop and characterise an Ecscr knockout mouse model  
In order to further characterise the role of Ecscr during mammal development and, potentially, 
during adult life in healthy and pathological andgiogenesis conditions, an Ecscr null knockout 
mouse was generated. Preliminary data from LacZ staining show endothelial specificity. 
Interestingly, Ecscr seems to be present only in some vessels and not all vasculature. 
4 – To investigate if the function of ECSCR is conserved across species 
Evidence from qPCR and in situ hybridization shows that endothelial specificity of ECSCR is 
conserved in human, mouse and zebrafish. Taking data together from this work and published 
literature, ECSCR seems to have a role in the development of vessels of smaller calibre (mouse 
and zebrafish).  
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2 MATERIALS AND METHODS 
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2.1 Reagents and equipment 
All chemicals used were of analytical or molecular biology grade and purchased from Sigma-
Aldrich (Gillingham, UK), unless otherwise specified. 
Different centrifuges were used, according to the volumes, temperatures and centrifugation 
speeds required: 
- Biofuge Pico Heraeus (Kendro Laboratory Products GmbH, Langenselbold, Germany) for 
1.5 ml tubes and up to 16060 x g; 
- Hettich Mikro 22R (refrigerated) (Andreas Hettich GmbH, Tuttlingen, Germany) for 1.5 ml 
tubes and up to 21910 x g; 
- Biofuge Primo Heraeus (Thermo Electron Corporation, Waltham, USA) for 15 or 50 ml tubes 
and up to 2576 x g; 
- AvantiTM J-20XP (refrigerated) (Beckman Coulter, Brea, CA, USA) for up to 500 ml bottles 
and up to 26000 x g. Depending on the tube/bottle size, JLA-10.5 or JA-25.5 rotors were used. 
All other equipment used is listed throughout this chapter, within the respective sections. 
2.1.1 Buffers and solutions 
 The general use buffers and solutions utilised are listed and described below, on table 2.1.1. 
Any other specific or commercial solutions are referred in the respective sections. 
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Table 2.1 - Buffers and solutions 
Solution name Contents 
NP40 lysis buffer 0.02% (w/v) NaN3, 2% (v/v) NP40, 20mM Tris-HCl pH7.5, 
300mM NaCl, 2mM EDTA, 1x Protease inhibitor mix 
E. coli lysis buffer 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 2  mM EGTA, 
2mM EDTA, 1 mM DTT, 1 mM PMSF, 1x protease inhibitor 
mix 
E. coli washing buffer 20 mM Tris-HCl, pH 7.4, 0.2 M NaCl, 1 mM EDTA, 10 mM 
b-mercaptoethanol 
Elution buffer 20 mM Tris-HCl, pH 7.4, 0.2 M NaCl, 1 mM EDTA, 10 mM 
b-mercaptoethanol, 10 mM maltose 
TBST (Tris-buffered saline 
Tween) 
20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % (v/v) Tween-
20 
6x DNA sample loading 
buffer 
30 % (v/v) glycerol, 0.25 % (w/v) bromophenol blue, 0.25 % 
(w/v) xylene cyanol FF 
2x SDS-PAGE  sample 
loading buffer 
100 mM Tris-Cl, pH 6.8, 20% (v/v) β-mercaptoethanol, 4% 
(w/v) SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) 
glycerol 
TAE buffer 40 mM Tris-base, 18 mM glacial acetic acid, 1 mM EDTA 
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Solution name Contents 
SDS-PAGE running buffer 
(1x) 
25 mM Tris-base, 0.25 M glycine, 0.1 % (w/v) SDS 
Western blotting transfer 
buffer (1x) 
6 mM Tris-base, 47.6 mM glycine, 20 % (v/v) methanol, pH 
8.3 
Stripping buffer 1M Tris pH7.5, 10% (v/v) SDS 
Coomassie staining buffer 40 % (v/v) methanol, 10 % (v/v) acetic acid, 0.2 g Coomassie 
Briliant Blue dye 
Coomassie destaining buffer 10 % (v/v) acetic acid, 12.5 % (v/v) isopropanol  
PBS 0.14 M NaCl, 2.68 mM KCl, 10 mM Na2HPO4, 1.76 mM 
KH2PO4, pH 7.4 
Hybridization buffer 50% (v/v) formamide, 5x SSC, 0.5 mg/ml tRNA, 0.05 mg/ml 
heparin, 9.2 mM citric acid, 1% (v/v) Tween 20 
MABT 0.1M maleic acid, 0.15M NaCl, pH7.5, 0.1% (v/v) Tween 20 
BCL buffer III 0.1M Tris-HCl, 0.1M NaCl, 0.05M MgCl2, 1% (v/v) Tween 
20 
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2.1.2 Antibodies 
The antibodies used are listed and described on tables 2.2 and 2.3. Unless another species is 
stated, the antibodies were raised against human antigens. 
Table 2.2 – Primary antibodies 
Antibody 
 
Optimisation 
range 
Working 
concentration 
Source 
Rabbit anti-ECSCR icd pAb 
1:200 – 1:10000 
5 – 30 µl 
1:5000 (WB) 
10 µl (IP) 
CRUK 
Rabbit anti-ECSCR  pAb 1:200 – 1:10000 1:1000 (WB) Harlan, UK 
Rabbit serum pre-bleed 
(IgG control) 
 
- 
Same as test 
antibody 
CRUK/Harlan, UK 
Rabbit anti-zebrafish Ecscr 
icd pAb 
1:200 – 1:10000 
1:500 (WB) CRUK 
Goat anti-moesin pAb 
1:500 – 1:5000 
1:100 – 1:500 
1:2500 (WB) 
1:200 (IF) 
Abcam, Cambridge, UK 
Mouse anti-talin1 mAb 2-8 µg/ml 4 µg/ml (WB) Abcam, Cambridge, UK 
Mouse anti-vinculin mAb 1-5 µg/ml 2 µg/ml (WB) Abcam, Cambridge, UK 
Rabbit anti-T-plastin pAb 1:500 – 1:5000 1:1000 (WB) Abcam, Cambridge, UK 
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Antibody 
Optimisation 
range 
Working 
concentration 
Source 
Mouse anti-filamin A mAb 
1:250 – 1:1000 
1:50 – 1:200 
1:500 (WB) 
1:100 (IF) 
Millipore 
Mouse anti-tubulin mAb 1:10000* 1:10000 Sigma, Poole, UK 
Anti-digoxigenin 1:5000* 1:5000 Roche 
 
Abbreviations: pAb – polyclonal antibody; mAb – monoclonal antibody; WB – western blot; 
IP – immunoprecipitation; IF – immunofluorescence. 
The antibody concentrations marked with an asterisk on tables 2.2 and 2.3 had previously 
been optimised and validated by other people in the lab. 
 
Table 2.3 - Secondary antibodies 
Abbreviations: WB – western blot; IP – immunoprecipitation; IF – immunofluorescence; HRP 
– horseradish peroxidase. 
Antibody Working concentration Source 
Donkey anti rabbit-HRP 
conjugated  
1:5000 (WB)* GE Healthcare, Chalfont St 
Giles, UK  
Goat anti mouse-HRP 
conjugated  
1:5000 (WB)* Dako, Ely, UK 
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Table 2.3 (cont.) – Secondary antibodies 
Antibody Working concentration Source 
Mouse anti-rabbit light chain 
specific-HRP conjugated 
1:1000 (WB)* Millipore 
Donkey anti-rabbit-Alexa 488 
conjugated 
4 µg/ml (IF)* Invitrogen 
Goat anti-rabbit-Alexa 546 
conjugated 
4 µg/ml (IF)* Invitrogen 
Goat anti-mouse-Alexa 488 
conjugated 
4 µg/ml (IF)* Invitrogen 
Goat anti-mouse-Alexa 546 
conjugated 
4 µg/ml (IF)* Invitrogen 
 
 
 
2.1.3  Cloning vectors 
The plasmids used to insert various complete or partial open reading frames are listed and 
described on table 2.4.  
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Table 2.4 - Cloning vectors 
Plasmid Source Use 
Pmal New England Biosciences MBP-fusion proteins 
Pgex Amersham Biosciences GST-fusion proteins 
PCR Topo blunt Invitrogen General blunt end cloning 
pCS2 DL Turner, Michigan In situ probes synthesis 
pACT2 Clontech Yeast-two-hybrid assay 
pGBT9 Clontech Yeast-two-hybrid assay 
Zipper-hGLuc[1]93 
Gift from Remy and 
Michnick, 2006 
Luciferase 
complementation assay 
Zipper-hGLuc[2]93 Remy and Michnick, 2006 
Luciferase 
complementation assay 
pRGFP-N1 Clontech C-terminus GFP fusions 
 
2.1.4 Oligonucleotides 
All the primers, as well as the siRNA duplexes were purchased from Eurogentec (Southampton, 
UK). Probes for qPCR were purchased from Roche Applied Science, UK and RNA antisense 
morpholinos were obtained from Gene Tools, USA. 
 
Table 2.5 - Oligonucleotides used for sequencing, cloning, colony PCR screen and site-
directed mutagenesis (SDM) 
Primer Oligonucleotide sequence (5’-3’) Application 
SP6 CATACGATTTAGGTGACACTATAG Sequencing 
T7 TAATACGACTCACTATAGGG Sequencing 
EGFP-N 
CGTCGCCGTCCAGCTCGACCAG 
Sequencing 
pGEXF CACGTTTGGTGGTGGCGACC Sequencing 
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Primer 
Oligonucleotide sequence (5’-3’) 
Application 
PGEXR 
CCGGGAGCTGCATGTGTCAGAGG  
Sequencing 
pGBT9F 
GAGTAGTAACAAAGGTCAAAGACA  
Sequencing 
pGBT9R 
GAGTCACTTTAAAATTTGTATACAC 
Sequencing 
pACT2F 
AATACCACTACAATGGATGATGTA 
Sequencing 
pACT2R 
GTTTTTCAGTATCTACGATTC 
Sequencing 
pGEX/pMALzECSCRF TAGTAGGGATCCGGACGCTGTTGTAGAAACAC Ecscr icd PCR 
pGEX/pMALzECSCRR CTACTAGTCGACTCATGAACCCAGTGAAATCA Ecscr icd PCR 
mECSCR-insitu-F AAGTCTTCTCAGGTCTCCTTGGTAT In situ probe PCR 
mECSCR-insitu-R TGGACAATCTACCTCATTATTTCCTTA In situ probe PCR 
zECSCRatg CATTTGGACTTAGCCATGGAGAAACTGCTC Ecscr PCR 
zECSCRtag TCATGAACCCAGTGAAATCAGCTGGTCTCT Ecscr PCR 
InsituF AAGTCTTCTCAGGTCTCCTTGGTAT Genotyping 
WTintron3R CCATTTCCCTCCTCCATCTGTTCTTT Genotyping 
UNeoF GCAGCCTCTGTTCCACATACACTTCA Genotyping 
InsituR TGGACAATCTACCTCATTATTTCCTTA Genotyping 
ECSCREcoRIF  GAATTCAGCCTGAGGTTCAAGTGTCGG ECSCR icd PCR 
ECSCRSalIF GTCGACTTAAAGAACCTTCTCTGCTGAG ECSCR icd PCR 
ECSCRicdBamHIR CTACTAGGATCCTAAGAACCTTCTCTGCTGAG ECSCR icd PCR 
BamHIFLNA1F TAGGGATCCAGATTGGGGAGGAGACGGTGATCACTG Filamin A 1 PCR 
EcoRIFLNA1R GAATTCTTAGCTTCCTGGGATGTGCATGTT Filamin A 1 PCR 
BamHIFLNA2F TAGGGATCCAGCGGACGTGCAGGGTCACCTACTGCC Filamin A 2PCR 
EcoRIIFLNA2R GAATTCTTAGTCGGGAATGTGTTCCTCGTT Filamin A 2PCR 
MoesinSacIR CTACTAGAGCTCTTACATAGACTCAAATTCGTC Moesin PCR 
EzrinXhoIR CTACTACTCGAGTTACAGGGCCTCGAACTCGTC Ezrin PCR 
ECSCRicd1BamH1R CTACTAGGATCCTTAGGCTGTGGAGCAGCTTTCAGAC ECSCR icd 1 PCR 
ECSCRicd2EcoRIF TAGTAGGAATTCAATGGAGAGAAAGACAGCATCAC ECSCR icd 2 PCR 
ECSCRicd2BamH1R CTACTAGGATCCTTAAAGAACCTTCTCTGCTGAG ECSCR icd 2 PCR 
42 
 
Primer Oligonucleotide sequence (5’-3’) Application 
MoesinNotIF 
TAGTAGGCGGCCGCACCATGCCCAAAACGATCAGTGTGC
GTGTG 
Moesin PCR 
MoesinClaIR CTACTAATCGATCATAGACTCAAATTCGTCATTGCGC Moesin PCR 
ECSCRNotIF 
TAGTAGGCGGCCGCACCATGGGCACCGCAGGAGCCATGC
AGCTG 
ECSCR PCR 
ECSCRClaIR CTACTAATCGATAAGAACCTTCTCTGCTGAGAGACTTTG ECSCR PCR 
Beta-actinF GCACCCAGCACAATGAAGA (Probe 63) qPCR 
Beta-actinR CGATCCACACGGAGTACTTG (Probe 63) qPCR 
ECSCRF AGCTGTGCTGGGTGATCCT (Probe 69) qPCR 
ECSCRR ATTGTGGGCTGGGAGTTGT (Probe 69) qPCR 
 
 
 
 
 
 
Table 2.6 - siRNA duplexes for in vitro knock-down 
siRNA Duplex Gene knock-down Duplex sense strand (5’-3’) 
D1 Human ECSCR ACAAUGACCCAGACCUCUA99 
NCD No interaction Eurogentec keep this sequence private 
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Table 2.7 - RNA antisense morpholinos for in vivo translation or splice interference 
Morpholino Gene affected Antisense sequence (5’-3’) 
5’UTR Zebrafish Ecscr GCGTAAGTCCAAATGACGTTCAATC 
5’UTR mismatch None GGCAAACTCGAAATCACCTTCAATC 
Splice Zebrafish Ecscr CATCAGTAGAAAACCTACCAAAGGC 
Splice mismatch None CATGACTACAAAACCTACGAAACGC 
 
2.2 Mammalian cell culture and related techniques 
2.2.1 Mammalian cells 
Human umbilical vein endothelial primary cells (HUVECs) were isolated from cords obtained 
through Birmingham Women’s Health Care NHS Trust, donated with informed consent. They 
were prepared according to Jaffe et al., (1973). These cells were cultured in M199 complete 
medium. 
Human embryonic kidney 293T (HEK 293T) cells were obtained from Cancer Research UK 
Central Services (Clare Hall, Hertfordshire). These cells were cultured in complete DMEM 
medium. 
2.2.2 Cell culture 
All cell culture techniques were performed using sterile plastic culture dishes or plates (Falcon, 
Becton Dickinson Labware, Franklin Lakes, USA) and the cells were incubated in a humidified 
atmosphere with 5 % CO2 supply at 37 °C (Sanyo CO2 incubator, Sanyo Electric CO, Japan). 
The media and gelatine were filtered through sterile 0.22 μm pore filters (Millipore) prior to 
use and PBS was sterilised by autoclaving. 
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HEK 293T cells don’t require surface coating. Before seeding HUVECs, the Petri dishes, 
coverslips or wells were coated with 0.1% (w/v) gelatine from porcine skin (Fluka, 
BioChemika, Seelze, Germany) in PBS and incubated at 37ºC for 30 minutes. After that time 
the gelatine was removed and the cells were plated, covered with warm complete M199 
medium and incubated at 37ºC. 
To culture HUVECs M199 medium (CRUK Central Services or Sigma-Aldrich) was 
supplemented with 10% (v/v) foetal calf serum (FCS) (PAA Cell Culture Company), 0.3% 
(v/v) bovine brain extract (prepared according to Maciag et al., 1979), 90 μg/ml of heparin, 4 
mM of L-glutamine and penicillin/streptomycin (Invitrogen), if required. Complete DMEM 
was made by adding 10% (v/v) FCS, 4 mM of L-glutamine and penicillin/streptomycin 
(Invitrogen), if required, to Dulbecco’s Modified Eagle’s Medium. 
HUVEC primary cells should be used within five passages, split once a week at a 1:3 ratio. In 
order to split them, the medium was removed, the cells were washed with PBS and 1.5 ml of 
trypsin (20 mg/ml) were added to a 10 cm dish. After 5 minutes the reaction was stopped by 
adding 4.5 ml of warm medium. The suspension was then centrifuged at 195 x g, the 
supernatant containing trypsin was discarded and the cells were ressuspended in warm medium 
and seeded. HEK 293T cells were split in the same fashion, 1:10, twice a week. 
Cell counting, when necessary, was performed after exposing the cells to trypsin and quenching 
the reaction with complete medium, by mixing 10 μl of the cell suspension and 10 μl of Trypan 
blue (Stratagene). 10 μl of this mixture were loaded into a haemocytometer counting chamber 
(Neubauer, Paul Marienfeld GmbH & CO, Germany) and counted according to the 
manufacturer’s instructions, on an inverted Leica DM IL microscope (Leica Microsystems, 
Houston, USA). 
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2.2.3 siRNA knock down of ECSCR in HUVECs 
The siRNA duplexes were designed according to the rules described by Reynolds et al. (2004). 
One million HUVECs were seeded on gelatine coated 10 cm plates and incubated for 24 hours 
at 37oC. The next day transfections were performed with Mock (sterile water), ECSCR duplex 
1 (D1) and negative control duplex (NCD) siRNA at 10 nM with 0.3% (v/v) lipofectamineTM 
RNAiMAX (Invitrogen). Two mixes were setup, the first containing 2 μl of 20 μM duplex / 
water (Mock) in 678 μl of OptiMEM (Gibco BRL, UK) and the second containing 12 μl of 
RNAiMAX lipofectamineTM and 108 μl of OptiMEM medium. Both mixtures were 
homogenised and incubated separately for 10 min at room temperature and then combined, 
gently mixed and incubated for another 10 min at room temperature. Meanwhile, the cells were 
washed twice with PBS. The transfection mixtures were added to 3200 μl of OptiMEM 
medium, mixed and the cells were covered with this solution. The plates were incubated for 
four hours at 37ºC. After that time, the transfection mix was replaced with normal complete 
M199 medium (without antibiotics). Two days after transfection the cells were used for various 
assays. 
2.2.4 Polyethylenimine (PEI) transfection of HEK 293T cells 
Conventional transfection protocols rely on the calcium phosphate precipitation technique. 
However, large variability in transfection efficiency is observed ans it is difficult to scale-up 
the precipitation reactions (Naldini et al., 2006). Polyethylenimine is a hydrophilic polymer 
that condenses DNA into positively charged particles, which bind to anionic cell surface 
residues and are imported into the cell via endocytosis. Once inside, protonation of the amines 
results in an influx of counter-ions and a lowering of the osmotic potential. Osmotic swelling 
causes the vesicles to burst and release the polymer-DNA complex (polyplex) into the 
cytoplasm. When the polyplex unpacks the DNA diffuses to the nucleus (Rudolph et al., 2000; 
46 
 
Akinc et al., 2004). Toledo et al. (2009) have shown that HEK293T transfections with PEI 
after 24h display an efficiency of 94.3% (±3.2), compared to 66.2 (±5.6) to those made with 
calcium phospate. Another advantage is that PEI transfections, unlike those that use calcium 
phosphate, do not require a medium change 16-20h after transfection. This protocol was 
described for transfection of lentiviral vectors and optimised for smaller plasmids by Dr. Mike 
Tomlinson (University of Birmingham, UK). 
Three million HEK 293T cells were seeded on 10 cm plates, covered with complete DMEM 
medium and incubated at 37ºC for 24 hours. On the next day the medium (without antibiotics) 
was replaced 2 hours before the transfection. For the transfection 9 μg of DNA plasmid were 
mixed with 1 ml of OptiMEM medium and 36 μl of PEI (1 mg/ml).  The tubes were briefly 
vortexed and left to rest for 10 min, to allow the PEI/DNA complexes to form. This solution 
was then added to the medium and gently mixed in. The cells were incubated at 37ºC for 48h 
and used for different assays. 
2.2.5 Scratch wound assay 
The scratch wound assay allows the observation of cell migration in vitro after a scratch is 
made on a confluent monolayer. It is a quick, easy and inexpensive method (Liang et al., 2007). 
For that purpose, HUVECs were plated and transfected with siRNA as described in section 
2.2.3. After 36 h the cells were treated with trypsin and seeded at a 7.5 x 104 cells/well density 
on glass coverslips (13 mm diameter, VWR International), pre-coated with 0.1% gelatine (in 
24-well cell culture plates, covered with 1 ml of complete M199 medium). At 48 h two 
scratches were made across each monolayer and the cells were allowed to migrate for eight 
hours. After that time, the cells were fixed and immunostained for various proteins, as 
described on section 2.2.6. In the classical scratch wound assay the cells are allowed to migrate 
for 24h, with images being taken at 4, 6, 8, 12 and 24h to monitor the speed of wound closure. 
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In this case, the cells were allowed to migrate for only 8h because the aim was to stain cells 
that were confluent as well as cells that were in the process of migration. 
2.2.6 Immunofluorescent staining 
The cells were seeded and treated as described on section 2.2.5. The medium was removed 
from the wells and the cells were washed with PBS. Then, they were fixed with 4% PFA (w/v) 
in PBS for 15 min at room temperature and permeabilised with 0.1% (v/v) Triton X100 in PBS 
for 4 min. One more PBS wash was performed and the cells were incubated with 100 µl of 
blocking buffer (10% (v/v) FCS, 3% (w/v) BSA in PBST – PBS with 0.1% (v/v) Tween 20) 
for 1 h at room temperature. All the subsequent incubations were done at this temperature. The 
primary antibodies were added in the concentrations described on table 2.1.2, in blocking 
buffer and incubated for 1 h. After that time, the cells were washed 3 times with PBST for 5 
min each and incubated for one more hour with secondary antibody with an appropriate 
fluorescent tag diluted in blocking buffer (4 µg/ml). This solution was washed out with PBST 
for 5 min, 3 times. The coverslips were then mounted on glass slides (Menzel-Glaser GmbH, 
Braunschweig, Germany) using 5 μl of ProLong Gold Antifade reagent with DAPI (Invitrogen) 
per coverslip. The stained cells were observed and images were acquired using an Axiovert 
100M confocal microscope and LSM 510 software (Zeiss). LSM Image Browser software 
(Zeiss) was used to open, edit and export the images. 
2.3 Protein analyses and assays 
2.3.1 Cell lysis and protein extraction 
10 cm confluent plates of cells were washed with 1x PBS, exposed to trypsin, quenched with 
medium and centrifuged at 195 x g. The pellet was ressuspended and lysed in 100μl of NP40 
buffer by pipetting up and down (on ice). Alternatively, after the PBS wash, the cells were 
treated with 150 μl of lysis buffer and scraped and collected into tubes on ice. The samples 
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were centrifuged at 10000 rpm for 5 min and the supernatant was transferred into a new tube 
containing 1 V of 2x SDS-PAGE sample loading buffer. This mixture was boiled for 5 min at 
100ºC and loaded on an SDS-PAGE gel or stored at -80ºC. 
2.3.2 Immunoprecipitation using an anti-ECSCR intracellular (icd) domain antibody 
To precipitate possible binding partners for ECSCR, 1050 μl of HUVECs lysate from seven 10 
cm plates for each assay were incubated for 2 hours at 4ºC on a wheel with 10 μl of antibodies  
(either the polyclonal antibody against the icd of ECSCR or rabbit IgG as a control) and 30 μl 
of packed G-protein beads (Sigma). After that period the supernatant was removed and the 
beads were washed with 1ml of NP40 buffer 3 times. SDS-PAGE loading buffer was added 
1:1 and the samples were boiled at 100oC for 5 min and loaded on a polyacrylamide gel, ran, 
and stained with brilliant blue coomassie. 
2.3.3 SDS-PAGE 
Protein samples were boiled for 5 min at 100ºC, spun down for 10 s and loaded on 6-10% 
polyacrylamide gels (Protogel, National Diagnostics, Hessle Hull, UK), according to the size 
of the proteins of interest. These gels were prepared according to Sambrook and Russel (2001). 
All the electrophoresis equipment used was from Invitrogen (Carlsbad, USA). Electrophoresis 
was performed in 1x running buffer at 80 V until the samples reached the resolving buffer and 
then the voltage was increased to 120 V. After the electrophoresis the gels were Coomassie 
stained or used for western blotting. 
2.3.4 Gel staining of proteins with Coomassie Brilliant Blue  
For protein staining, polyacrylamide gels were placed in coomassie brilliant blue staining 
buffer and rocked for at least 1 hour at room temperature (or overnight). The gel was then de-
stained at room temperature using Coomassie Brilliant Blue de-staining buffer. For the 
preparation of samples for mass spectrometry analysis, gels were stained with Protoblue Safe 
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(National Diagnostics) colloidal stain (1 part of ethanol plus 9 parts of the colloidal solution) 
and de-stained with distilled water. 
2.3.5 In-gel digestion of proteins separated on SDS-PAGE gel for mass spectrometry 
analysis 
All tubes, boxes, ruler and glass plate were rinsed with 0.1% formic acid (Fluka)/50% 
acetonitrile. The stained gel was placed the glass plate and the bands were excised with a sterile 
scalpel blade (about 5 mm each) and placed in individual 1.5 ml tubes. The gel pieces were 
washed 2x with 100 µl of 50% acetonitrile/50 mM ammonium bicarbonate for 45 minutes at 
37oC with agitation and then dried down in the speedvac. 50 µl of 50 mM DTT (made up in 
10% acetonitrile/50 mM ammonium bicarbonate) were added and an incubation at 56oC for 1h 
followed. The supernatant was discarded and 50 µl of 100 mM iodoacetamide (made up in 
10% acetonitrile/50 mM ammonium bicarbonate) were added. The tubes were covered in foil 
and incubated at room temperature for 30 minutes. The supernatant was removed and the bands 
were washed 3x with 10% acetonitrile in 40 mM ammonium bicarbonate for 15 minutes at 
room temperature with agitation. The pellets were dried down in the speedvac and rehydrated 
in 20 µl or 1.5x the gel volume (if greater than 20 µl) of 12.5 µg/ml Promega seq. Grade 
modified trypsin in 10% acetonitrile/40 mM ammonium bicarbonate for 1h at room 
temperature. 20 µl of 10% acetonitrile/40 mM ammonium bicarbonate were added and the 
bands were incubated at 37oC overnight. 
On the following day the supernatant was collected and saved and 30 µl of 3% formic acid in 
water were added to the pellet and incubated at 37oC for 1h. This supernatant was added to the 
one previously collected. This step was repeated for 30 min and the three supernatants 
containing the digested peptides were combined. The samples were stored at -20oC and ran by 
Dr. Douglas Ward from Cancer Sciences, University of Birmingham. 
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2.3.6 Expressing zebrafish Ecscr intracellular domain (icd) fused to MBP 
Zebrafish Ecscr icd was amplified by PCR from cDNA and cloned into pMAL. This plasmid 
was used to transform chemically competent BL21(DE3) pLys S E. coli. One colony was 
inoculated in LB-broth (Ampicillin, Chloramphenicol), incubated over night at 37 ºC and then 
diluted 100-fold into LB-broth (Ampicillin, Chloramphenicol). The bacteria were cultured at 
37 ºC until OD600nm = 0.4-0.6, when they were induced with 1 mM IPTG for 3 hours. To 
minimise protein degradation, 0.5 mM PMSF was added. After the induction, the bacteria were 
centrifuged (10 min, 6000 rpm), washed with E. coli washing buffer and centrifuged again. 
Pellets were stored in -80 ºC. After that, the bacteria were thawed on ice, lysed with ice-cold 
E. coli lysis buffer (2 ml per 100 ml of bacterial culture) and ultra-sonicated for 3 min 
(Ultrasonicator Vibra CellTM, Sonics & Materials, Newtown, USA). Triton X100 to 1% was 
added and the samples were incubated on ice for 30 min. The lysates were centrifuged (10 min, 
14000 rpm, 4 ºC), the supernatant was collected and mixed with glycerol to give a final 
concentration of glycerol 50% (v/v) and stored at -20 ºC. 
To purify the zebrafish Ecscr-MBP protein, bacterial lysate was incubated with packed amylose 
beads on a rotating wheel for 2 hours at 4 °C. After that time beads were washed with E. coli 
washing buffer and eluted with elution buffer and de-salted through a PD10 column. To 
roughly assess the efficacy of purification and the amount of protein that was bound to 
amylose-agarose beads, 10 μl of each sample was run on a polyacrylamide gel alongside with 
the BSA samples as mass standards. The purified samples were sent to CRUK to immunise 
two rabbits and produce a polyclonal antibody (1x 1200 µl of 50-100 µg and 5x 1200 µl of 
200-400µg). 
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2.3.7 GST pull down 
Human ECSCR icd was amplified by PCR from cDNA and cloned into pGEX, to make a GST 
fusion protein, that was expressed and purified in the same way as described in 2.3.6, but using 
glutathione beads instead of amylose ones. As a control, GST alone was also expressed (pGEX 
vector alone). The pulldown was performed using 300 µl of bacterial lysates and 1050 µl of 
HUVECs lysates, as described on section 2.3.2 for immunoprecipitation, but using glutathione 
beads instead of protein G ones. After the final wash, 2x SDS-PAGE sample buffer was added 
1:1 and the samples were boiled, ran on an SDS-PAGE gel and analysed by western blot. 
2.3.8 Western Blot 
After the SDS-PAGE, the gels, blotting paper and blotting pads were soaked in transfer buffer 
for 10 min prior to assembling the transfer apparatus in the X cell II™ Mini cell, X cell II™ 
Blot Module and X cell sure lock™ (Invitrogen, Carlsbad, USA). PVDF membrane 
(Immobilon-P, 0.45 μm, Millipore, Billerica, USA) was activated by pre-wetting in methanol 
(Fisher Scientific) for 30 s and then placed also in 1x transfer buffer. Wet transfer was 
performed at 30 V for 2 hours at 4 ºC. The membranes were stained with Ponceau S dye 
(Sigma) to check the transfer and then blocked with 5 % dried milk (prepared in TBST buffer) 
for 1 hour at room temperature or overnight at 4ºC. The membranes were briefly washed in 
TBST and placed in appropriate primary antibody solution probing at room temperature for 1h 
on a rotator. After this incubation, the membranes were washed for 30 min in TBST with 4 
buffer changes and incubated with appropriate secondary antibodies conjugated with 
horseradish peroxidase (HRP). After 1 hour of incubation at room temperature, the membranes 
were washed for 30 min as above and developed with ECL Western Blotting 
Detection Reagents (GE Healthcare, Little Chalfont, UK) for 1 minute. The blots were 
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visualized by autoradiography on Hyperfilm ECL (GE Healthcare) which was exposed to the 
membrane for different times, in the dark. 
When reprobing with another antibody was required, the membranes were stripped. For that 
purpose, the membranes were incubated for 30 min at 65ºC in 50 ml of stripping buffer 
supplemented with 350 μl of beta-mercaptoethanol (Sigma), washed with TBST for 30 min 
changing the buffer every 10 min, blocked and probed as described above. 
2.3.9 Yeast-two-hybrid assay 
In order to assess direct interactions between ECSCR and candidate binding partners identified 
by mass spectrometry, yeast-two-hybrid assays were performed. 
2.3.9.1 Yeast strain and media 
The yeast strain used for this assay was PJ69-4A (genotype: MATa, trp1-901, leu2-3,112, ura3-
52, his3-200, gal4Δ, gal80Δ, GAL2-ADE2, LYS2::GAL1-HIS3, met2::GAL7-lacZ). 
PJ69-4A yeast was grown on yeast-peptone-dextrose (YPD) full medium (1 % (w/v) bacto-
yeast extract, 2 % (w/v) bacto-peptone, 2 % (w/v) dextrose, 0.01 % (w/v) tryptophan (Trp) and 
2 % (w/v) bacto-agar (when solid medium was required). 
For the assay, selective media were used. Special synthetic complete dextrose (SCD) medium 
contained 0.67 % (w/v) yeast nitrogen base without amino acids, 2 % (w/v) dextrose and 0.14 
% (w/v) yeast synthetic drop-out media supplement lacking histidine (His), leucine (Leu), 
uracil (Ura) and Trp and 2 % (w/v) bacto-agar (for solid medium). Before the final screening, 
as described below, SCD medium was supplemented with 100 mg/L Trp, 50 mg/L Leu, 40 
mg/L His or 20 mg/L Ura. Except for Trp and Ura, that were sterilised by filtering through 0.22 
μm-pore filters (Millipore), all the stock solutions were autoclaved. 
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2.3.9.2 Yeast-two-hybrid method 
The entire method was carried out using aseptic technique. 
ECSCR icd was cloned into pGBT9 (to be fused to the binding domain of Gal4p) and the 
interacting candidates were cloned into pACT2 (to be fused to the activation domain of Gal4p). 
These constructs were transformed into the yeasts sequentially and the positive clones were 
selected by SCD medium lacking Trp (for clones containing pGBT9), Leu (for clones 
containing pACT2) or both (for double transformants). This yeast strain contains a Gal4 
promoter-His3 reporter gene. Once the double transformants were obtained, they were grown 
on SCD-Leu--Trp- at 30oC and diluted to an OD600 of 0.5. Then, five ten-fold serial dilutions 
were made and 10 µl of each were carefully placed on agar plates of SCD-Leu--Trp- and SCD-
Leu--Trp-His-(3AT) and allowed to grow for 3-7 days at 30oC. All spots should grow on the 
former plates and in the latter only the ones where an interaction occurs should survive. 
For the transformations yeasts were grown overnight at 30oC with agitation from a single 
colony in 3 ml of YPD or SCD lacking the appropriate ingredients. The lithium acetate / single 
stranded carrier DNA / polyethylene glycol method by Gietz and Woods (2002) was used. 
Briefly, on the following morning the cultures were diluted to an OD600 of 0.25 and allowed to 
grow for two more generations up to OD600 of 0.5-1. An OD600 of 1 is approximately 2 x 10
7 
yeast/ml. For this protocol, 2 x 108 yeasts were used per transformation. These were centrifuged 
for 2 min at 5000 x g and the pellets washed with 1 ml of sterile water and transferred into 1.5 
ml tubes. Another centrifugation as before followed and the water was removed. In this order, 
240 μl of 50 % (w/v) polyethylene glycol (PEG, molecular weight of 3350 g), 36 μl of 1 M 
lithium acetate, 10 μl of 10 mg/ml single-stranded-carried DNA from salmon sperm 
(Invitrogen) (previously boiled for 5 min and chilled on ice), and 34 μl of plasmid DNA diluted 
in water (0.1 to 1 μg of DNA) were added to the yeast pellet, that was then ressuspended in this 
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mixture. The yeasts were agitated at 30oC for 30 min and then a 15 min heat-shock at 42oC was 
performed. The yeasts were centrifuged as previously and the pellets were washed with 1 ml 
of water. In the end, they were plated in the appropriate media, after ressuspending in 150-200 
µl of water. 
2.3.10 Luciferase complementation assay 
When the yeast-two-hybrid method was unable to provide a more specific answer, protein-
protein interaction was studied using the luciferase complementation assay, where ECSCR was 
cloned into Zipper-hGLuc[1]93 (to replace the zipper protein and make a fusion to the first half 
of Gaussia luciferase) and the interacting candidates were cloned into Zipper-hGLuc[2]93 (to 
replace the zipper protein and make a fusion to the second half of Gaussia luciferase) (Remy 
and Michnick, 2006). When an interaction occurs, the two halves of luciferase come together 
to form an active enzyme, and this activity can be measured using a luminometer upon supply 
of an appropriate substrate (the Renilla luciferase assay system, from Promega was used). 
The complementing plasmids were transfected into HEK 293T cells, following the PEI 
protocol on section 2.2.4. As a transfection efficiency control, a third plasmid expressing beta-
galactosidase was co-transfected (1/10th of the concentration of the other plasmids, as advised 
by Dr. Michael Tomlinson). After 48 h the medium was removed and the cells were washed 
with PBS. For a 6-well plate 500 µl of 1x lysis buffer (Promega) were added to each well and 
the plates were placed on a rocker and incubated at room temperature for 15 min. 
The lysates were collected into 1.5 ml tubes. For the luciferase assay, it is not necessary to 
remove the cell debris, but for other applications the lysates were spun down at 16,000 x g and 
the clear supernatant was collected. 100 µl of 1x Renilla luciferase substrate in Renilla 
luciferase assay buffer (Promega) were aliquoted into each well of an opaque, white, shiny, 
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clean 96-well plate and 20 µl of cell lysate were added and mixed thoroughly. This was done 
in triplicates. Untransfected cells, as well as water and lysis buffer only were used as controls. 
The plates were placed in the luminometer and the bioluminescence was read. Luminescence 
was integrated over 10’’ with a 2’’ delay. 
To normalise the luminescence data, a beta-galactosidase assay was also performed. For that, 
900 µl of phosphate buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4) 
were added to 200 µl of ONPG (4 mg/ml dissolved in phosphate buffer 0.1 M, pH 7) and 40 
µl of cell lysate. This mixture was incubated 37oC for about 1h, until yellow. The reaction was 
stopped by adding 200 µl the Na2CO3 1M and the tubes were spun down for 10 minutes at 
13000 rpm. The OD was measured at 420 nm. The normalised activity was calculated as 
follows: normalised activity = luciferase activity/β-gal activity. 
2.4 Molecular biology methods 
All molecular biology methods were performed according to either the manufacturer’s 
insctructions when kits were used or according to protocols existing in the laboratory that have 
been optimised over time by various scientists, based on Sambrook and Russell (2001). 
2.4.1 Bacterial strains and media 
For transformation with various plasmids, fusion protein expression and site-directed 
mutagenesis, chemically competent Escherichia coli strains DH5α, BL21(DE3) pLys S or 
XL1-Blue Supercompetent Cells (Stratagene, La Jolla, USA) were used. All bacteria were 
cultured in liquid Luria Bertani (LB) broth or plated on LB agar (both from Cancer Research 
UK Central Services, Clare Hall, Hertfordshire or Sigma). According to the antibiotics 
resistance carried by the different plasmids, 0.1 of mg/ml ampicillin (Amp, Sigma, Poole, UK), 
56 
 
0.02 mg/ml chloramphenicol (Sigma) and/or 0.03 mg/ml kanamycin (Sigma) were added to 
the media. 
2.4.2 DNA amplification by PCR 
DNA fragments were amplified by polymerase chain reaction (PCR) using a high fidelity 
polymerase. 25 μl of reaction contained 5.8 μl of water, 4 μl of 5x Phusion HF Buffer (New 
Engalnd Biolabs (NEB), Herts, UK), 2 μl of dNTP (2 mM, Bioline, London, UK), 2 μl of each 
primer (10 μM) and 0.2 μl of PhusionTM High-Fidelity DNA Polymerase (NEB). In the end 
500 ng of template were added to the mixture. For the negative control, the template was 
replaced by water. The PCR reaction conditions were as follows: initial denaturation (98ºC, 30 
s), 30 cycles of denaturation (98ºC, 10 s), annealing (appropriate temperature for each pair of 
primers, 30 s) and elongation (72 ºC, for the time necessary for the fragment to be amplified – 
ca. 1000 bp/min). A final elongation step at 72ºC for 5 min was included. 
2.4.3 DNA digestion using restriction enzymes 
Restriction enzyme digestion was used either to confirm the presence of inserts in plasmids or 
to digest inserts and vectors for ligation (sticky ends). Purified PCR product or plasmid were 
incubated in 50 μl of digestion mixture, containing 5 μl of suitable 10x NEBuffer, 5 μl of 10x 
BSA (if necessary, NEB), 3-5 units of each restriction enzyme (NEB) per microgram of DNA 
and water. Digestion was carried out for 2 hours at the appropriate temperature for each 
enzyme. 
2.4.4 Nucleic acids electrophoresis in agarose gel 
DNA/RNA gel electrophoresis was performed in 0.8 – 1.5% agarose (VWR International, 
Lutterworth, UK) gels made up with TAE buffer and containing 1:10000 DNA Sybr Safe 
(Invitrogen). The separation was carried out in TAE buffer, at 90 V. Gels were visualised and 
imaged using Gene Genius Bio Imaging System (Syngene, Cambridge, UK). 
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2.4.5 Plasmid ligation and bacterial transformation 
Inserts obtained directly by PCR or restriction digestion were ligated into the appropriate 
digested plasmids using T4 Ligase (400000 U/ml, NEB). To 16 μl of insert/vector ratio of 3:1, 
2 μl of enzyme and 2 μl of T4 Ligase Buffer (NEB) were added. Ligations were performed at 
room temperature for 1 hour or overnight for greater efficiency.  Chemically competent E. coli 
(25 μl) were mixed with 5 µl of ligation mix or 50-500 ng of plasmid (for protein expression) 
and incubated on ice for 30 min. Subsequently, the bacteria were heat shocked at 42ºC for 1.5 
min and incubated on ice for further 2 min. 250 µl of room temperature SOC medium (or LB) 
were added to the bacteria and they were incubated at 37ºC for 1 hour, with 200 rpm shaking 
(Sanyo/Gallenkamp, Loughborough, UK). Bacteria were plated on LB-agar plates (containing 
appropriate antibiotics) and incubated overnight at 37 ºC. 
 Positive colonies were screened by PCR or digestion with the appropriate restriction enzymes. 
For further confirmation of ligation and sequence integrity, the plasmids were sent out to 
Functional Genomics and Proteomics (School of Biosciences, University of Birmingham) for 
sequencing. 
Glycerol stocks of bacteria containing all constructs were produced by mixing saturated 
bacterial cultures with an equal volume of 30 % (v/v) glycerol and stored at -80 ºC. 
2.4.6 Plasmid preparation and purification 
Large scale preparation of plasmids was performed from 200 ml cultures grown overnight 
using the GenEluteTM Plasmid Maxiprep Kit (Sigma, Poole, UK) according to the 
manufacturer’s instructions. For small-scale plasmid preparations DNA was isolated from 5 ml 
cultures according to the GeneJETTM Plasmid Miniprep Kit (Fermentas, UK). DNA 
concentration was measured using the NanoDrop ND-1000 Spectrophotometer (Labtech, 
Ringmer, UK). 
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2.4.7 Cell lysis and RNA extraction 
The medium was removed from the cells growing in 10 cm dishes and 1 ml of Tri Reagent 
(Ambion) was added. The cells were lysed by pipetting up and down, the lysate was collected 
in 1.5 ml tubes and frozen at -20ºC.  To extract the RNA the samples were thawed, incubated 
at 30ºC for 10 min and vortexed. After that, the solutions were centrifuged at 12000 rpm for 5 
min, 200 μl of chloroform (per 1 ml of Tri Reagent) were added and the tubes were agitated. 
Following a 10 min incubation at room temperature, the samples were centrifuged at 12000 
rpm for 10min and the supernatant was transferred into a new tube containing 0.7 V of ice cold 
isopropanol. This mixture was incubated at -20ºC for 30 min, centrifuged at 12000 rpm for 10 
min, the pellet was washed with 70% ethanol and the final pellet was suspended in nuclease-
free water and quantified using NanoDrop ND-1000 Spectrophotometer (Labtech, Ringmer, 
UK). 
2.4.8 cDNA synthesis 
cDNA synthesis was performed using the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems) for qPCR or the Superscript III for RT-PCR kit for cloning. For the first 
one, per reaction, 2 μl of 10x RT buffer, 0.8 μl of 25x dNTP mix, 2 μl of 10x random primer, 
1 μl of multiscribe RT, 4.2 μl of RNase free water and 10 μl of RNA sample were added in a 
tube. The reaction was carried out at 25ºC for 10 min followed by 2 hours at 37ºC. For the 
latter, 1 μl of 0.5 μg/μl oligo(dT)12-18 primers, 1 μl of 10 mM dNTP mix, 5 μg of RNA and 
water up to 13 μl were added to a nuclease-free tube. The mixture was heated at 65ºC for 5 min 
and incubated on ice for 1 min. Then, 4 μl fo 5x first strand buffer, 1 μl of 0.1 M DTT, 1 μl of 
RNase out (40 U/μl) and 1 μl of Superscript III RT (200 U/μl) were added and after 
homogeneising, the reaction was incubated at 50ºC for 1 hour. Finally, the reaction was 
inactivated by heating at 70ºC for 15 min. 
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2.4.9 Quantitative RT-PCR (qPCR) 
To quantify relative gene expression, 12.5 μl of sensi mix (Abgene, Epsom, UK), 1 μl of each 
primer (10 μM), 0.25 μl of each probe (Exiqon, Vedbaek, Denmark) and 0.25 μl of nuclease-
free water were mixed in a hood. On the lab bench, 10 μl of each sample dilution (1:10, 1:100) 
were added to the previous mixture (in triplicates). The qPCR reaction was performed on 
Rotor-Gene RG-3000 qPCR machine (Corbett Research Ltd, Australia). 
2.4.10 Microarray 
Unless otherwise stated, the reagents used to perform the microarray were purchased from 
Agilent Technologies. 
For the microarray three 10 cm plates of ECSCR siRNA transfected and three plates of negative 
control duplex transfected HUVECs were used (after 48h of transfection). Total RNA was 
extracted and purified. Cy3 dye was used for knock down samples and Cy5 dye for the controls. 
To generate the microarray the Agilent Two Colour Microarray-Based Gene Expression 
Analysis (Quick Amp Labelling) kit was used, following the manufacturer’s instructions. The 
protocol comprises the following steps: cDNA synthesis, cRNA synthesis and labelling, 
purification and quantification of the labelled/amplified cRNA, hybridization, washing, 
reading, extracting data and data analysis. 
In brief, a total of 1μg of each RNA sample was mixed with the T7 promoter primer, spike mix 
(A for Cy3 or B for Cy5) and nuclease-free water. The samples were denatured and first strand 
buffer, DTT, dNTP mix, MMLV-RT, RNase out and water were added for the cDNA synthesis 
reaction. cRNA was synthesized and labelled by adding nuclease-free water, transcription 
buffer, DTT, NTP mix, PEG, RNase out, inorganic pyrophosphatase, T7 RNA polymerase and 
Cy3 or Cy5 to the previous reaction. Labelled and amplified cRNA was purified and washed 
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using RNeasy mini spin columns (Quiagen) and quantified on Nanodrop ND-1000 UV-VIS 
Spectrophotometer version 3.2.1. 
The microarray data were analysed using two different programs: SAM (statistical analysis of 
microarrays) contained in a program called MeV (multiexperiment viewer) from Tigr – the 
institute for genomics research (http://www.tm4.org/mev/) and R, a free statistical program 
from Bioconductor (http://www.bioconductor.org). The workflow for both programmes is 
equivalent and includes quality control, normalisation and differential expression analysis. The 
final list of genes was obtained for a fold change above 2 and a p value below 0.01. 
In order to put the results into context, the lists of up and downregulated genes were analysed 
using Ingenuity Pathway Analysis (Quiagen) (www.ingenuity.com).  
2.5 Methods employed for in vivo analyses 
2.5.1 Species and strains 
To study the function of ECSCR in vivo, two model species were used, Danio rerio (zebrafish, 
vertebrate fish model) and Mus musculus (common mouse, mammalian model). The animals 
were reared and bred at the Biomedical Services Unit, University of Birmingham. 
Two strains of zebrafish were used, wild type AB* and transgenic tg[fli1:EGFP]. The mouse 
strain used as background was black C57Bl/6JOlaHsd, the white strain used to obtain 
blastocysts and do germline transmission testing was albino C57Bl/6 and the strain used 
implant blastocysts injected with ES cells was CD-1. 
2.5.2 Zebrafish and mouse whole mount in situ hybridization (WISH) 
The in situ hybridization technique allows the detection of sites of expression of a certain gene. 
For that purpose, a digoxigenin-labelled anti-sense RNA probe (complementary to the mRNA 
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to be detected) is synthesized and hybridized against paraffin sections or, in this case, whole 
embryos to detect expression of the target gene (Thisse and Thisse, 2008). 
For the WISH E9.5 C57Bl/6JOlaHsd mouse embryos and 24 hours post-fertilization (hpf) AB* 
zebrafish embryos were used. The protocol was done according to Thisse and Thisse (2008). 
2.5.2.1 Mouse RNA probe synthesis 
SEND cells were cultured and RNA was extracted. cDNA was synthesized using the high 
capacity cDNA reverse transcription kit. An 857 bp fragment was amplified by PCR and cloned 
into PCR TOPO blunt (using 0.5 µl of salt solution, 0.5 µl of TOPO vector, 2 µl of DNA and 
0 µl of nuclease-free water). The purified plasmid was linearised with NotI (for antisense RNA) 
and BamH1 (for sense RNA). For the transcription of the sense and antisense RNA probes, by 
this order, 1 µg of linear plasmid (10 µl), 2 µl of 10x transcription buffer (Roche), 2µl of 10x 
digoxigenin label mix (Roche), 2 µl of 10x SP6 (for antisense probe) or T7 (for sense probe) 
RNA polymerase, 1 µl of ribolock RNase inhibitor (Fermentas) and 3 µl of nuclease-free water, 
to a total of 20 µl were added. The solutions were mixed and incubated at 37C for 2.5 hours. 1 
µl of DNaseI was added and the tubes were incubated at 37ºC for 15 min. The probes were 
then purified using the Mini Quick spin columns (Roche Applied Science), according to the 
manufacturer’s instructions. The probes were quantified and 10 µl aliquots were stored at -
80oC. The probes were visualised on a 2% (w/v) agarose gel. 
2.5.2.2 Whole-mount in situ hybridization  
On the first day the embryos were rehydrated through a methanol series of 75%, 50% and 25% 
(in DEPC-treated PBS), for 5min each and rinsed twice (5 min) in PBST (0.1% v/v of Tween 
20 in DEPC-treated PBS). The embryos were then incubated with freshly made proteinase k 
10 µg/ml (Sigma) for 30 min and the reaction was stopped with 2 mg/ml of glycine (Sigma) in 
PBST for 5 min. After that the embryos were washed twice with PBST for 5 min, post-fixed 
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in 4% (w/v) PFA (in DEPC-treated PBS) and washed again with PBST. Subsequently, they 
were incubated with 50% PBST/50% hybridization buffer for 3 min at room temperature and 
with 100% hybridization buffer at 70ºC for 4 hours, with a change after 2 hours. The probes 
were denatured at 95ºC for 5 min and diluted in the hybridization buffer to 500 ng/ml. The 
embryos were incubated with this solution overnight at 70ºC. 
On the following day the hybridization buffer was removed and the embryos were washed 
through a series of hybridization buffer: 2xSSC (100:0, 75:25, 50:50, 25:75 and 0:100), 10 min 
each. They were then washed with 0.2% SSC and another series of 0.2% SSC: MABT (75:25, 
50:50, 25:75 and 0:100) for 5 min each. The embryos were blocked in 2% Boehringer blocking 
agent, 5% goat serum (in MABT) at room temperature for 1 hour. After that time, another 2 
hour incubation as described before took place, with fresh solution. The embryos were then 
incubated overnight with gentle shaking at 4ºC with 1:5000 anti-digoxigenin antibody in the 
same solution. 
On the last day of the protocol the tubes containing the embryos were transferred to room 
temperature for 1 hour. The antibody mix was removed and the embryos were were washed 8x 
with MABT, 15 min each. After one quick wash with BCL buffer III, two 15 min washes 
followed. Finally, colour was developed by using 400 µl of BM purple at room temperature 
(the tubes were wrapped in foil). After two hours the embryos were checked for development 
of colour. The reaction was stopped by washing with 20mM EDTA in PBST, the embryos were 
post-fixed with 4% PFA and stored at 4ºC. 
2.5.3 Injection of antisense zebrafish Ecscr morpholino oligonucleotides 
Antisense morpholino zebrafish Ecscr oligonucleotides were microinjected into the yolk of 1-
cell transgenic tg[fli1:EGFP] zebrafish embryos. As controls, uninjected embryos and embryos 
injected with mismatched morpholinos were used. The concentrations tested were 0.2, 0.4 and 
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0.8 ng of morpholino per embryo (1 nl of 0.25, 0.5 and 1 mM). The transgenic embryos were 
observed, photographed and counted at 28 hpf. They were divided into three categories, 
according to the severity of the effects caused by the morpholino injections, compared to the 
controls: no abnormal phenotype, mild and severe. The percentages of embryos in each 
category were calculated. This experiment was done three times and at least 100 embryos were 
counted each time, for each condition. 
2.5.3.1 Zebrafish Ecscr morpholino phenotype rescue assay 
In order to assess the specificity of the morpholinos, a rescue assay was performed, by co-
injecting zebrafish Ecscr mRNA. 
Zebrafish Ecscr was amplified by PCR from cDNA and cloned into the pCS2 vector, that 
contains an RNA polymerase promoter, SP6. The plasmid was linearised with Not I (New 
England Biosciences) and mRNA was synthesized with SP6 RNA polymerase using the 
MmessageMmachine kit (Ambion). This mRNA was microinjected into one cell zebrafish 
embryos alone (to optimise the right concentration to be used) or in combination with the 
zebrafish Ecscr translation or splicing blocking morpholinos. 
All animal work was carried out under approved Home Office projects and personal licenses. 
The PhD student’s personal license number for both zebrafish and mice was PIL 40/9557 and 
the two project licenses held by Prof. Roy Bicknell were PPL 40/3131 (“An analysis of tissue 
development in zebrafish”) and PPL 80/2217 (“Validation of novel endothelial genes as 
vascular targets”). 
2.6 Statistical analyses 
Unless otherwise stated, all experiments were repeated at least three times with similar results. 
Data were plotted with error bars representing the standard deviation. A Shapiro-Wilk 
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normality test was performed on data sets to confirm a normal distribution. For this test, data 
are normally distributed when p ≥ 0.05. P values were determined using GraphPad Prism 5 to 
test for significant differences in data. Unpaired, two-tailed Student’s t-test was used to 
determine the significance of experiments. When the calculated p value was less than 0.05, the 
hypothesis that the means of the two compared groups differed significantly was accepted. On 
chapter 4 (figures 4.7 and 4.8) a chi-squared test was performed, as the data sets are lists of 
counts. Differences between conditions were also considered significant when p ≤ 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
3 IDENTIFICATION OF 
PROTEINS INTERACTING 
WITH ECSCR 
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3.1 Introduction 
Endothelial cell specific molecule 2 (ECSM2) was first identified in 2000 (Huminiecki and 
Bicknell, 2000) but until 2008 there were no other publications concerning ECSCR. Armstrong 
et al. (2008) used siRNA knockdown and implicated a role for ECSM2 in cell migration and 
tube formation and identified a molecular interaction with filamin A. In the light of these 
findings, ESCM2 was renamed by the Human Genome Organization (HUGO) Gene 
Nomenclature Committee (HGNC) endothelial cell specific chemotaxis regulator (ECSCR). In 
2009, two further independent studies were published. The first showed that ECSCR can 
attenuate the epidermal growth factor receptor (EGFR)‐induced cell migration, possibly by 
inhibition of the Shc‐Ras‐ERK (MAPKinase) pathway (Ma et al., 2009). The second identified 
the role of ECSCR in cell survival by interaction with the cIAP-1 and cIAP-2 pro-apoptotic 
proteins and modulation of their degradation by the proteasome (Ikeda et al., 2009). More 
recently, a zebrafish developmental study by Verma et al. (2010) has proposed that ECSCR 
enhances endothelial VEGF receptor 2 sensitivity to VEGF, thus in turn promoting migration 
of zebrafish angioblasts. 
The endothelial specificity of ECSCR and its effect on cell migration suggests a role in 
endothelial cell biology. Although some possible interactions between ECSCR and other 
molecules are starting to emerge, the exact mechanism of action and signalling pathways are 
yet to be clarified. 
3.2 Identification of binding partners for ECSCR 
To capture and identify ECSCR interacting proteins/complexes a co-immunoprecipitation (co-
IP) analysis was performed. This used anti-ECSCRicd antiserum (rabbit serum was used as an 
IgG control). Co-IPs were run on a gradient gel (4-12%), stained and processed for mass 
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spectrometry (MS) analysis. The results were analysed, proteins were ranked by number of 
hits/differences between the ECSCR and negative control IPs and grouped by function, using 
the DAVID software. Principal functional groups were cytoskeletal processes, trafficking, 
protein folding, apoptosis and metabolism (figure 3.1 A). As ECSCR had been previously 
implicated in cytoskeletal modulation, this cluster was analysed in more detail. (figure 3.1 B). 
The analysis of the MS data has also revealed a good peptide diversity for each hit, i.e., each 
protein was identified by several different peptides, which adds confidence to the results. 
Identification of filamin A (with 34 peptides for the specific IP versus 5 for the control), 
confirmed earlier work by Armstrong et al. (2008). Putative interacting proteins were chosen 
for confirmation of the MS data by GST pull down (ECSCRicd-GST and GST alone, as a 
control) and subsequent western blot – talin 1, vinculin, filamin A, moesin, myosin 9 (myosin 
II) and plastin 3. Briefly, there are no apparent differences in myosin II, talin and vinculin, and 
there seems to be more filamin A (as shown by the Armstrong et al., 2008), moesin and plastin 
3 in the pull down with ECSCRicd-GST than with GST alone (figure 3.2). 
Filamin A, moesin and plastin 3 were chosen for further studies, as the two latter ones are 
present in filopodia, which is where ECSCR is enriched. Filamin A and moesin were analysed 
for direct interactions with ECSCRicd by yeast-two-hybrid. Bioinformatics analysis of the 
ECSCR protein primary structure using the tools available at www.expasy.com, such as 
SMART, revealed no conserved domains or structural features similar to other proteins 
contained in public databases. However, ECSCRicd contains a cluster of basic amino acids 
RK(S)K, immediately after the transmembrane domain, which has been shown to interact with 
ezrin-radixin-moesin (ERM) family of proteins in other proteins (Yonemura et al., 1998). As 
for filamin A, the interaction with ECSCRicd had already been found by others 
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Figure 3.1 - Proteins that co-immunoprecipitate with ECSCR from HUVECs lysate. 
The list of proteins that co-IP with ECSRicd was submitted to DAVID, to obtain functional 
clusters (A). The cytoskeletal fraction was chosen for study in further detail (B). IP – number 
of peptides obtained for each protein upon immunoprecipitation using an antibody against 
ECSCR icd; IgG – number of peptides obtained for each protein upon immunoprecipitation 
using rabbit serum. The lines in green show proteins present in filopodia. 
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 (Armstrong et al., 2008), so the aim was to confirm these results and try to map the interaction 
to the ECSCRicd. 
The ultimate goal, after finding direct interactions with specific regions, would be to mutate 
them and to show that the proteins no longer interacted, as well as using those mutants in 
functional assays (like the Boyden chamber, for example, since it was demonstrated by 
Armstrong et al. (2008) that the lack of ECSCR significantly reduces HUVECs migration 
through a pore). 
For the yeast-two-hybrid assay, the complete intracellular domain of ECSCR was amplified by 
PCR and inserted into the pGBT9 plasmid using EcoRI and BamHI restriction enzymes. The 
candidate interactors, full length moesin and two fragments of filamin A corresponding to Ig 
repeats 15-16 and 19-21 (Armstrong et al., 2008) were inserted into pACT2, using BamHI and 
EcoRI restriction enzymes. Ezrin full length was also cloned in the same way and was used as 
a negative control, as it is very closely related to moesin (both part of the ERM family) but did 
not appear in the MS results. Combinations of ECSCRicd and the potential interactors were 
transfected into yeast (as well as combinations of ECSCRicd and empty pACT2 as a control). 
The two plasmids encode for an activating domain and a binding domain of Gal4p which, upon 
binding of the fused interacting proteins, come together to activate a reporter gene (HIS3). For 
more details see section 2.3.9. 
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Figure 3.2 - Assessment of the results of mass spectrometry by GST pull down and 
western blot analysis 
GST pull down was control for ECSCRicd-GST. There were proteins that showed no 
difference between the test and the control (A) and others that were specifically pulled down 
with ECSCRicd-GST (B). This experiment was performed 3 times with similar findings. GST 
– glutathione-S-transferase; ECSCRicd-GST – ECSCR intracellular domain fused to GST. 
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After seeding the double transformants in the appropriate selective media, all contained both 
plasmids (as they grew on SCD Trp- Leu-) (Figure 3.3). However, only the colonies containing 
ECSCRicd and either fragment of filamin A grew on the medium that selected for interactions 
(SCD His- (3AT) Trp- Leu-) (figure 3.3). This confirmed that Filamin A and ECSCRicd directly 
interact. To look further into this result, yeast containing ECSCRicd and moesin, ezrin (and 
pACT2 as a control) were grown and total protein was extracted and analysed by western blot. 
This revealed that neither moesin nor ezrin were expressed by the yeast. Therefore, other 
methods were employed to test for this interaction, as described below. 
After confirmation of binding between ECSCRicd and filamin A, an attempt was made to map 
the region of ECSCRicd responsible for it. Since there are no conserved domains, two halves 
of ECSCR (the first 30 amino acids and the second 30 amino acids) were amplified by PCR 
and inserted into pGBT9 using EcoRI and BamHI restriction enzymes. These constructs were 
then co-transfected into yeast with the pACT2 plasmids containing either fragment of filamin 
A.  The yeast-two-hybrid assay revealed that neither of the two halves of ECSCRicd was able 
to bind either of the filamin A fragments (figure 3.4). This study was abandoned because this 
technique didn’t seem to be the most appropriate to determine the region of filamin A where 
ECSCR binds. Making a construct where ECSCR becomes much smaller than the protein it is 
fused to may result in occlusion of the amino acids that bind to filamin A, leading to a false 
result. On the other hand, since neither half of ECSCR seems to bind to Filamin A, the next 
step would be to test a region in the junction between the two. This could also lead to false 
results, as often proteins need to be in a certain conformation to be able to interact with other 
molecules. Therefore, it cannot be ruled out that instead of the middle region, actually both 
halves of ECSCR are important for binding to filamin A, as they may interact with each other 
via distant amino acids to confer a certain secondary structure necessary for interaction. An 
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alternative but time consuming method would be to mutate individual amino acids and evaluate 
the effect upon binding. The fact that ECSCR bares no homology to any other protein makes 
this study more difficult, as there is no obvious candidate region to start with. 
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Figure 3.3 - Yeast-two-hybrid assay to assess protein interactions between ECSCRicd 
and filamin A 
A yeast-two-hybrid assay was performed using ECSCR intracellular domain to look for 
interactions with filamin A fragments corresponding to repeats 15-16 (FLNA 1) and 19-21 
(FLNA 2), as well as moesin and ezrin. The assay confirmed direct interaction between 
ECSCRicd and filamin A, but not moesin or ezrin. SCD – synthetic complete dextrose;  Trp- - 
lacks tryptophan; Leu- - lacks leucine; His- - lacks histidine; 3AT – 3-amino-1,2,4-triazole. 
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Figure 3.4 - Yeast-two-hybrid assay to assess protein interactions between the two 
halves of ECSCRicd and filamin A 
To further investigate the interaction between ECSCR and filamin A, a yeast-two-hybrid assay 
was performed using either the first 30 amino acids (ECSCRicd1) or the last 30 amino acids 
(ECSCRicd2) of ECSCR intracellular domain to look for interactions with filamin A fragments 
corresponding to repeats 15-16 (FLNA 1) and 19-21 (FLNA 2). The assay showed that either 
half of ECSCRicd is insufficient to bind to either fragments of filamin A. SCD – synthetic 
complete dextrose;  Trp- - lacks tryptophan; Leu- - lacks leucine; His- - lacks histidine; 3AT – 
3-amino-1,2,4-triazole. 
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To obtain a more conclusive answer about the ECSCRicd-moesin interaction, a luciferase 
complementation assay was performed. This assay is similar to the yeast-two-hybrid, in the 
sense that the two potential interactors are fused to two halves of a protein that becomes 
functional upon binding. In this case, luciferase is an enzyme that is able to degrade a substrate 
and the interaction is measured by a luminometer, as the degradation product is bioluminescent. 
The method was developed by Remy and Michnick (2006), who kindly provided the Zipper-
hGLuc[1]93 and Zipper-hGLuc[2]93 plasmids, which were used as a positive control. Moesin 
and ECSCRicd were amplified by PCR and inserted into these plasmids using the NotI and 
ClaI restriction enzymes, which resulted in the replacement of the zipper protein by these two. 
Instead of yeast, for this method mammalian cells (HEK 293T) were tansfected with the 
appropriate combinations of plasmids (and also each one plus either Zipper-hGLuc[1]93 or 
Zipper-hGLuc[2]93 to assess specificity). In addition, all cells were transfected with a third 
plasmid, encoding beta-galactosidase, to normalise the trasnfection efficiency. 
The results indicate a positive interaction between ECSCRicd and moesin (p < 0.05) (figure 
3.5). However, marginal significance was obtained only after five repeats, as there is a big 
variation between replicates and the negative controls containing moesin fused to the first half 
of luciferase co-transfected with the second half of luciferase fused to a zipper protein (which 
should not interact with either ECSCR or moesin) produce high levels of background, having 
luminescence reads close to those of the ECSCR-moesin interaction. The same result was 
observed for the other negative control, where ECSCR intracellular domain is fused to the 
second half of luciferase co-transfected with the first half of luciferase fused to a zipper protein.  
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Figure 3.5 - Luciferase complementation assay to assess the interaction between ECSCR 
and moesin in HEK 293T cells 
To assess the interaction between ECSCR and moesin, full length moesin and the intracellular 
domain of ECSCR were inserted into two complementary plasmids that contain half of the 
luciferase enzyme sequence each. Two zipper proteins known to interact with each other were 
used as a positive control. Water, lysis buffer and untransfected cells were used as negative 
controls, as well as combinations of each test plasmid (MoeG1, ECSCRG2) with the respective 
complementary half of luciferase fused to a non-specific interactor. The experiment was 
repeated 5 times. This assay demonstrates that the interaction between ECSCRicd and moesin 
is specific, as it is significantly higher than the interaction of either with a zipper protein (p < 
0.05, two tailed unpaired t-test). The error bars represent the standard deviation from the mean. 
ZG1 – Zipper-hGLuc[1]93; ZG2 – Zipper-hGLuc[2]93; MoeG1 – moesin fused to first half of 
luciferase; ECSCRG2 – ECSCR fused to the second half of luciferase.  
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3.3 The effect of ECSCR on the cytoskeletal arrangement 
It has been shown that the knockdown of ECSCR by siRNA in HUVECs causes impaired tube 
formation and migration in a Boyden chamber assay and that ECSCR probably modulates the 
cytoskeleton organization via filamin A (Armstrong et al., 2008). 
In the present study the interaction with filamin A has been confirmed and other cytoskeletal 
proteins involved in filopodia formation have been co-immunoprecipitated with endogenous 
full length ECSCR, as well as pulled down by its intracellular domain. 
To further investigate the role of ECSCR at a cellular level, siRNA knockdown was performed 
in HUVECs and cytoskeletal proteins such as plastin 3, talin1,  VE-cadherin, F-actin 
(phalloidin), moesin, filamin A and non-muscle myosin II were visualised using 
immunofluorescence (figure 3.6). These proteins were chosen because they have been 
specifically co-immunoprecipitated with ECSCR (figure 3.1). Additionally, VE-cadherin was 
stained because ECSCR also localises to cell-cell junctions (Shi et al., 2011). The aim was to 
evaluate if the lack of this protein would somehow disrupt cell-cell adhesion. Phalloidin was 
used to stain stress fibres (F-actin) because Ma et al. (2009) have reported that in HEK 293T 
cells transfected with ECSCR-GFP stress fibres were largely destructed compared to the GFP 
control. Phalloidin was used in cells treated with ECSCR siRNA (and negative control duplex 
control) to assess if ECSCR knockdown would result in an increase of stress fibres.   
Plastin 3 locates to cell protrusions and seems to be less evident in cells where ECSCR is 
depleted. Talin 1 locates near the cell edges in adhesion points, which seem to be lost when 
ECSCR is absent. VE-cadherin locates to cell-cell junctions and ECSCR knockdown does not 
seem to have an effect on this protein. When ECSCR is knocked down, stress fibres seem to 
be less organised (F-actin). Moesin is located at cell protrusions and seems to have a more 
diffused distribution when ECSCR is knocked down. Both filamin A and myosin II are 
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arranged in fibre-like structures along the cells, which seem disorganised in the absence of 
ECSCR. In general, the lack of ECSCR seems to result in a less organised cytoskeleton in terms 
of protrusions and fibre-like structures, that seem to be disconnected from the membrane. This 
is consistent with a role for ECSCR in anchoring the cytoskeleton to the membrane. Although 
the immunofluorescence protocol was optimised for each antibody and the experiment was 
done 3 times, some antibodies still did not produce a very good staining. Some further 
optimisation could be attempted or different antibodies could be purchased to generate results 
that are clearer. 
On the other hand, the opposite experiment was performed, where ECSCR-GFP was 
overexpressed in cells that do and do not contain filamin A. ECSCR is located at the plasma 
membrane and filopodia in HEK 293T cells. The construct was able to induce the formation of 
filopodia in HEK 293T cells (that contain filamin A), but not in and M2 cells (that do not 
express filamin A) (figure 3.7). The experiment was done 3 times for HEK 293T cells and only 
once for M2 cells. In the latter ECSCR also seems to locate at the plasma membrane. However, 
these cells seem to be blebbing (even the GFP control). The experiment should be repeated to 
obtain reproducible results. 
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Figure 3.6 (part 1) – Immunofluorescent staining of cytoskeletal proteins upon ECSCR 
siRNA knockdown 
siRNA knockdown was performed in HUVECs and cytoskeletal proteins such as plastin 3, talin1,  VE-
cadherin and F-actin (phalloidin) were visualised using immunofluorescence (green). DAPI was used 
to stain the nuclei (blue). Plastin 3 locates to cell protrusions and seems to be less evident in cells where 
ECSCR is depleted. Talin 1 locates near the cell edges in adhesion points, which seem to be lost when 
ECSCR is absent. VE-cadherin locates to cell-cell junctions and ECSCR knockdown does not seem to 
have an effect on this protein. When ECSCR is knocked down, stress fibres seem to be less organised 
(F-actin). 
Negative control duplex ECSCR duplex 1 
Plastin 3 
Talin 1 
VE-cadherin 
Phalloidin 
(F-actin) 
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Figure 3.6 (part 2) – Immunofluorescent staining of cytoskeletal proteins upon ECSCR 
siRNA knockdown 
siRNA knockdown was performed in HUVECs and cytoskeletal proteins such as moesin, 
filamin A and myosin II were visualised using immunofluorescence (green). DAPI was used 
to stain the nuclei (blue). Moesin is located at cell protrusions and seems to have a more 
diffused distribution when ECSCR is knocked down. Both filamin A and myosin II are 
organised in fibre-like structures along the cells, which seem disorganised in the absence of 
ECSCR.  
Negative control duplex ECSCR duplex 1 
Moesin 
Filamin A 
Myosin II 
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Figure 3.7 – ECSCR overexpression in HEK 293T and M2 cells 
ECSCR-GFP was transfected into HEK 293T and M2 cells (B, C, E, F). GFP was used as a 
control (A, D). C and F are magnifications of B and E, respectively. The white arrows point at 
the location of ECSCR. ECSCR is able to induce filopodia in HEK 293T cells, but not in M2 
cells. The experiment was repeated 3 times with similar results for HEK 293T cells and once 
for M2 cells. Total magnification: 400x. 
  
A B C 
D E F 
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3.4 siRNA duplex titration and transfection stability assessment 
In order to study the role of ECSCR, siRNA-mediated knock down can be performed to 
evaluate the loss of function of this molecule in various assays. 
The siRNA duplex 1 (D1) had already been used by Armstrong et al. (2008), at a concentration 
of 50 nM, but no titration had been done to assess the minimum concentration that could be 
used. For that purpose, HUVECs were transfected with 1, 10, 30 and 50 nM of D1 (mock 
transfection was used as a control) and the ECSCR mRNA and protein were quantified by 
qPCR and western blot, respectively (figures 3.8 and 3.9). ECSCR has a molecular weight of 
55 kDa. From the two figures it is possible to verify that all the concentrations of D1 tested had 
a significant effect on knocking down ECSCR. 
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Figure 3.8 - Relative ECSCR expression of siRNA transfected HUVECs assessed by 
qPCR. 
In order to assess the minimum concentration of siRNA duplex (D1) that could be used to 
knock ECSCR down, HUVECs were treated with 1, 10, 30 and 50 nM of D1. Mock-treated 
cells were used as a control. RNA was collected, converted to cDNA and amplified by qPCR. 
ECSCR expression was normalised to that of actin for each sample and ECSCR relative 
expression in the treated cells is presented relative to that of the mock control. The experiment 
was done 3 times and qPCR for each sample was performed in triplicate. All concentrations 
tested were able to produce an ECSCR knock down. A two-tailed unpaired t-test was performed 
between each treated sample and the control and all p-values were <0.005. 
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Figure 3.9 - Relative ECSCR expression of siRNA tranfected HUVECs assessed by 
western blot 
In order to assess the minimum concentration of siRNA duplex (D1) that could be used to 
knock ECSCR down, HUVECs were treated with 1, 10, 30 and 50 nM of D1. Mock-treated 
cells were used as a control. Total protein was collected, ran on a 12% acrylamide gel, 
transferred onto a PVDF membrane and blotted for ECSCR and tubulin, as a control. The 
experiment was done 3 times. As for the mRNA levels, all D1 concentrations have successfully 
knocked down the ECSCR protein. 
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3.5 Microarray 
In addition to finding molecules that interact directly with ECSCR, in order to have an insight 
on its role on endothelial cell biology, a microarray was performed using cells transfected with 
ECSCR siRNA and cells transfected with an unspecific duplex. The RNA quality was analysed 
using Bioanalyser (Agilent Technologies) and all the samples had a RIN (RNA Integrity 
Number) above 9.4. The maximum value on this scale is 10 and the closer to this number the 
RIN of a sample is the better. Samples with RIN values below 6 or 7 should not be considered. 
After labelling, the specific activity was above 13 in all samples. This value should be between 
10 and 14. 
The slides were scanned and the data were extracted. The microarray data were analysed using 
two different programs: SAM (statistical analysis of microarrays) contained within the MeV 
(multiexperiment viewer) from Tigr (the institute for genomics research) and R, a free 
statistical program from Bioconductor. The lists of up and downregulated genes obtained from 
both programs were very similar, and the one produced by R had the advantage of containing 
information about the fold change. All the genes considered had a fold change equal to or 
greater than 2. 342 genes were found to be upregulated and 354 downregulated. The most 
upregulated gene was CCL20 (a chemokine involved in attracting lymphocytes and dendritic 
cells towards endothelial cells) and the most downregulated gene was CYP26B1 (a member of 
the cytochrome P450 family of metabolism enzymes, responsible for inactivating all-trans 
retinoic acid to hydroxylated forms). The full lists of up and downregulated genes can be found 
on appendix 1. 
From these lists, 15 random genes (8 upregulated and 7 downregulated) were chosen to validate 
the microarray by qPCR. The six original samples (RNA from three controls and three ECSCR 
knocked down HUVECs) plus six new ones (also RNA from D1 and negative control duplex-
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treated HUVECs) were analysed by qPCR (in triplicate). Gene expression was normalised to 
that of actin for each sample and a fold change between the samples treated with ECSCR-
targeting duplex and negative control duplex was calculated using the delta delta CT method 
(Livak and Schmittgen, 2001). Although the fold change value is different from that obtained 
from the microarray analysis, all genes show the same trend as they do in the microarray results 
(figure 3.10). CD 36 was not detected in any samples by qPCR. 
The two lists of genes were analysed separately in a program that creates clusters of genes 
according to their common structural features or role in a certain pathway or process. This 
program is called DAVID (Database for Annotation, Visualization and Integrated Discovery) 
(Dennis et al., 2003). 123 upregulated and 90 downregulated clusters were identified. Most of 
the genes, both up- and downregulated, fell into the categories of adhesion molecules, 
glycoproteins, cytoskeleton-related, chemotaxis and apoptosis (figure 3.11). Figure 3.11 does 
not show the category “glycoproteins” because this is a structural feature common to many 
unrelated proteins, rather than a more specific grouping according to function. 
Within each general cluster several others could be found. For example, upregulated genes 
involved in adhesion are specifically involved in cell-cell adhesion, whereas downregulated 
gens in this category are involved in both cell-cell adhesion and cadherin-mediated adhesion 
(figure 3.11). Upregulated cytoskeletal genes are involved in actin processes and cell 
projection, whereas downregulated genes interact with actin mostly via a kelch domain (β-
propeller tertiary structure) or are associated with microtubules. Regarding chemotaxis, the 
absence of ECSCR seems to increase inflammation and decrease locomotive behaviour. 
Negative regulators of apoptosis are upregulated, whereas positive modulators of apoptosis 
seem to be both up and downregulated, in cells treated with ECSCR-targeting siRNA duplex 
compared to cells expressing normal levels of this protein.  
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Figure 3.10 – Gene expression validation by qPCR of 15 random genes differentially 
expressed in the microarray 
To validate the results obtained from the microarray analysis, the same 3 samples and 3 new 
ones of RNA from HUVECs treated with ECSCR-targeting siRNA duplex or a negative control 
duplex were analysed by qPCR. Fold change between gene expression in controls and ECSCR 
knocked down cells was calculated using the delta delta CT method. The results largely validate 
the microarray, as all show the same trend. CD36 was not detected in any sample. The error 
bars represent the standard deviation from the mean. A two-tailed unpaired t-test was 
performed to assess significant differences between gene expression of HUVECs treated with 
D1 and negative control duplex. * - p < 0.05 two tailed unpaired t-test. 
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Figure 3.11 – Main functional clusters of up and downregulated genes when ECSCR is 
knocked down 
The lists of up- and downregulated genes found using R were submitted to DAVID so that 
genes could be grouped by function. The main clusters were adhesion, cytoskeleton, 
chemotaxis and apoptosis. Purple arrows pointing up refer to clusters containing upregulated 
genes; green arrows pointing down refer to clusters containing downregulated genes. Examples 
of genes contained in each cluster were included in brackets. 
 
89 
 
To have an idea of what pathways may be altered when ECSCR is depleted, the results from R 
(gene accession number, log ratio, fold change and p-value) were also analysed on the 
Ingenuity Pathway Analysis program (Quiagen). A cut off of 2 fold (either up or 
downregulated) and p < 0.01 were selected. This software clusters genes according to how they 
relate to each other in specific interaction networks. Figure 3.12 illustrates the initial outputs 
once the data are analysed. The different pathways are represented by blue bars, identified on 
the x axis and are ordered by the proportion of genes in a certain pathway that were contained 
in the supplied results list (from R) compared to the total number of genes in that pathway 
(figure 3.12 A). The whole data sets can be viewed in different formats, such as a network 
connecting the different pathways (figure 3.12B). 
By clicking on each blue bar, the up and donwregulated genes from the list obtained from R 
that are on a specific pathway can be seen. Furthermore, the pathway itself can also be 
visualised. Figures 3.13 and 3.14 illustrate two of those pathways: granulocyte adhesion and 
diapedesis and atherosclerosis. Genes represented in grey are part of the pathway, but were not 
on the list of significantly differentially expressed genes between HEVECs treated with 
negative control duplex and ECSCR-targeting siRNA duplex. Green represents 
downregulation and red represents upregulation. Stronger or weaker shades of these colours 
represent higher or lower fold change, respectively. 
Although very informative, the actual interpretation of the pathways provided is difficult, as 
some molecules in the same pathway are downregulated and others that are affected by those 
are upregulated. Also, many of the molecules are expressed (or more described) in other cell 
types. However, only HUVECs were used for this experiment, so not much can be concluded 
about other cells.  
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Figure 3.12 – Examples of Ingenuity Pathway Analysis initial outputs   
The lists of up and downregulated genes found using R were submitted to Ingenuity Pathway 
Analysis to look for altered pathways when ECSCR is depleted. The initial outputs once the 
data are analysed are illustrated. The different pathways are represented by blue bars, identified 
on the x axis and are ordered by the proportion of genes in a certain pathway that were 
contained in the supplied results list compared to the total number of genes in that pathway 
(A). The whole data sets can be viewed in different formats, such as a network connecting the 
different pathways (B). 
 
B 
A 
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Figure 3.13 – Granulocyte adhesion and diapedesis pathway (this page and previous 
page) 
Granulocyte adhesion and diapedesis was the pathway with the highest proportion of submitted genes 
compared to the total amount of genes in the pathway. Genes represented in grey are part of the pathway, 
but were not on the list of significantly differentially expressed genes between HEVECs treated with 
negative control duplex and ECSCR-targeting siRNA duplex. Green represents downregulation and red 
represents upregulation. Stronger or weaker shades of these colours represent higher or lower fold 
change, respectively. 
A 
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Figure 3.14– Atherosclerosis signalling (next page) 
This pathway was chosen as another example because endothelial cells are known to play a 
role in atherosclerosis and also to illustrate the different information the program can provide. 
In this figure, not only the pathways are shown, including molecules and different types of 
cells/compartments, but also a diagram with a series of events that lead to atherosclerosis is 
provided. Part of the pathway is cut out from the figure, so that it can be legible, as the aim of 
this image was to show what types of analyses the program can perform. Genes represented in 
grey are part of the pathway, but were not on the list of significantly differentially expressed 
genes between HEVECs treated with negative control duplex and ECSCR-targeting siRNA 
duplex. Green represents downregulation and red represents upregulation. Stronger or weaker 
shades of these colours represent higher or lower fold change, respectively. 
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Additionally to this work, a monoclonal antibody produced against ECSCR by Phusion 
Antibodies (Belfast) was used to detect ECSCR in normal and cancer human tissues and in 
angiogenesis assays. The results are presented as appendix 2, as only in the end it was 
discovered that the antibody does not recognise ECSCR after all and this work cannot be 
published. However, it represented many months of work towards this thesis. The antibody has 
blocks endothelial cell migration on a scratch wound assay and tube formation on matrigel. In 
situ hybridization on human paraffin-embedded normal and cancer specimens done by Bicknell 
and Nagy (University of Birmingham, UK) seemed to show that ECSCR was upregulated in 
some cancers. Based on this, the antibody was used to stain tissue arrays containing human 
normal and cancer samples. This antibody recognises the naked protein, but not endogenous 
endothelial glycosylated ECSCR on a western blot. The final proof was provided by FACS 
analysis, where the antibody induced a shift in the population compared to that not treated with 
antibody, but there was no difference between HUVECS expressing ECSCR and not 
expressing ECSCR (knocked down by siRNA). In conclusion, this antibody recognises 
endothelium specifically and has biological effects on angiogenesis assays. However, its target 
is unknown. 
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3.6 Discussion 
3.6.1 Finding binding partners for ECSCR 
Previously to the present study, Laura Armstrong (2005), a PhD student in the same laboratory, 
had isolated, cloned and characterised full length ECSCR cDNA, as the only available 
sequence at the time was derived from alignment of EST sequences. Then, she verified the 
endothelial specificity by detecting the transcript in several cell lines by qPCR, as well as 
human tissue paraffin sections, by in situ hybridization. A range of endothelial cell stimuli were 
tested, alone or in combination, to identify which ones regulated ECSCR expression. Hypoxia 
(0.1% oxygen), oxidative stress (1 mM H2O2), confluence (250,000 cells seeded on each plate 
and harvested at different times), VEGF (10 ng/ml), FGF (10 ng/ml), VEGF + FGF (10 ng/ml 
each), IFN-gamma (100 units/ml), TNF-alpha (100 ng/ml), IFN-gamma + TNF-alpha (100 
units/ml and100 ng/ml, respectively) and IL1-beta (10 ng/ml). The conditions were tested at 4, 
8, 16 and 24h. None has had a significant effect on ECSCR expression. Much effort was also 
dedicated to producing an antibody that would recognise ECSCR, which was largely 
unsuccessful. Filamin A was identified as a binding partner for the intracellular domain of 
ECSCR using yeast-two-hybrid on an endothelial cell library. 
Ikeda et al. (2009) reported that cIAP-1 and cIAP-2 also interacted with this domain. So far, 
no other interacting molecules for the intracellular domain have been described and no attempt 
made to find interacting partners or even a ligand for the extracellular domain. That is a crucial 
step to understand the mechanism by which ECSCR signals. 
Protein co-immunoprecipitation using a polyclonal antibody against ECSCR and subsequent 
analysis of the samples by mass spectrometry (MS) showed that ECSCR potentially interacted 
with proteins involved in cytoskeletal processes (actin bundling and anchorage of cytoskeletal 
proteins to the plasma membrane), trafficking (endosomes), protein folding, apoptosis 
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(ubiquitin and ubiquitin-related proteins) and metabolism (glycolytic proteins) (figure 3.1). The 
protein with most specific hits in the co-immunoprecipitation with ECSCR versus IgG control 
was Filamin A, which is in line with the work by Armstrong et al. (2008). Curiously, filamin 
A is ubiquitous whereas filamin B expression is more restricted to endothelial cells. Filamin B, 
but not filamin A knockdown by siRNA has impaired VEGF-induced cell migration of 
HUVECs through the increase of the number of focal adhesions. This seemed to be achieved 
by changes in activity and location of Rac-1, a small GTP-binding protein, with consequences 
on downstream signalling. This indicated a possible pathway involving filamin B, Rac-1 and 
Vav-2 (an activating guanine nucleotide exchange factor for Cdc42/Rac-activated kinase 
kinase (PAK)-4/5/6) (Valle-Perez et al., 2010). The fact that filamin B is somehow more 
specific to endothelium than filamin A and this isoform but not filamin A is involved in VEGF-
induced cell migration, indicates they have different roles and participate in distinct signalling 
pathways. This is reinforced by the current data, where filamin A strongly associates with 
ECSCR and, although very structurally similar, no filamin B was co-immunoprecipitated. 
The co-immunoprecipitation results were subsequently confirmed by GST-pull down, where 
moesin, filamin A and plastin 3 were pulled specifically with ECSCR, whereas talin-1, vinculin 
and myosin II were not (figure 3.2). The GST pull down is considered to be a more stringent 
method than immunoprecipitation. The latter can yield entire complexes of proteins that bind 
to the target of the antibody, whereas the former relies on more specific affinity, as the fusion 
protein is competing with the endogenous one for potential interacting partners. This explains 
why there were more proteins associated with ECSCR using co-immunoprecipitation 
compared to GST-pull down. These two techniques are complementary, as 
immunoprecipitation can give a broader insight into signalling complexes, as it is able to 
capture them to the beads, conserving true endogenous interactions. GST-pull down is then a 
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refinement, capturing proteins that interact with ECSCR more directly. By combining these 
two techniques it is possible to start building networks, where Filamin A, moesin and plastin 3 
are more directly associated with ECSCR (not necessarily in the same pathway) and other 
molecules, such as talin-1 or myosin II may still be part of the same pathways, but are separated 
by several other proteins. 
The current study differs from that performed by Armstrong (2005) in the number of candidate 
interactors found. This is because distinct methods were applied. In this study, co-
immunoprecipitation was followed by GST-pull down and yeast-two-hybrid, which first give 
a general view of what proteins may be involved (directly and indirectly) with ECSCR 
signalling and then direct interactions can be confirmed to establish the role and position of 
ECSCR within the network.  Laura has used BD matchmaker two hybrid system (Clontech, 
UK) to look for ECSCR interacting proteins. The 58 amino acids of ECSCR intracellular 
domain were expressed as bait, in pGBKT7 and a placental cDNA library was inserted into 
pGADT7. Placental polyA+ RNA was used to make cDNA. Colonies that contained several 
inserts were excluded, as well as unlikely partners for the intracellular domain, such as secreted 
proteins. Colonies containing only one insert were selected to re-confirm interactions that were 
consistently reproducible and most expressed filamin A. PIAS1 (protein inhibitor of activated 
STAT1), a nuclear protein, was also identified. There is a possibility that ECSCR is cleaved 
and translocated into the nucleus in a similar manner to Notch, a membrane-bound transcription 
factor (Kopan, 2002) or PIAS1 can translocate into the cytoplasm. However, this protein was 
not further analysed. In the present study this protein was not found in ECSCR 
immunoprecipitation. Although a library holds potential to find interactors for Ecscr, Laura has 
encountered various technical difficulties related to several constructs being present in the same 
colony, false positives and low reproducibility. As discussed below, yeast may not be able to 
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express some human proteins at all or with the correct post-translation modifications that are 
essential for signalling or binding. Also, it is a more artificial system than using actual 
endothelial cells and trying to capture endogenous interactions using an antibody. The latter 
method captures endothelial molecules produced in endothelial cells, bound to each other in a 
way that is closest to what may be physiological than any other method using yeast or non-
endothelial cells. 
ECSCR shows no structure homology to any known protein. However, its intracellular domain 
contains a cluster of basic amino acids, that was shown to be critical for the binding of other 
proteins to moesin (Martin-Villar et al., 2010). In the light of these findings and given that 
ECSCR selectively pulled down moesin, this protein was chosen to proceed to more 
specifically test a possible direct interaction. As yeast-two-hybrid failed to answer this question 
(the yeast did not express moesin), a luciferase complementation assay was performed (figures 
3.3 and 3.5). The two methods are similar in the sense that the two candidates for interaction 
are each fused to one half of a reporter protein that is only expressed if an interaction occurs. 
However, yeast-two-hybrid uses yeast, whereas the luciferase complementation assay uses 
mammalian cells. Yeast are not able to reproduce many post-translational modifications 
present in mammalian cells, which may be important for interactions (Luo et al., 1997). Also, 
due to toxicity or other species incompatibilities, yeast may not be able to produce the protein 
of interest at all, which was the case for moesin. The luciferase complementation assay has 
successfully demonstrated an interaction between ECSCR intracellular domain and moesin. 
However, minimal significance (p < 0.05) was only obtained after 5 replicates. Negative 
controls were included where either moesin or ECSCR were co-expressed with a zipper protein 
fused to the complementary luciferase half for each case. No interaction between the zipper 
protein and moesin or ECSCR was expected to happen. However, the luminescence values for 
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these controls, although lower than those for the specific interaction between moesin and 
ECSCR, were quite high. HEK 293T cells are a popular cell line to use for protein expression, 
as they can produce most post-translational mammalian modifications and yield high amounts 
of protein expression (Thomas and Smart, 2005). In the case of the luciferase complementation 
assay, however, this may not be an advantage. Too much protein being overexpressed may 
mean that non-specific interactions start to occur due to excessive amounts of protein, rather 
than real interactions. To obtain cleaner results, perhaps HeLa cells could be used instead of 
HEK 293T. 
The interaction between ECSCR and filamin A found by Armstrong (2005) was also confirmed 
in this study using yeast-two-hybrid (figure 3.3). The two regions from filamin A (repeats 15-
16 and 19-21) have been shown to bind many other proteins (Zhou et al., 2009). These are 
involved in a variety of functions, from intracellular signalling to cell cycle, transcription and 
adhesion. Protein kinase C (PKC) also binds to filamin A, this interaction occurs at the plasma 
membrane and is believed to lead to lead to the phosphorylation of filamin A, influencing its 
interaction with  cell surface molecules. As for ECSCR, PKC was shown to bind to filamin A 
at two separate sites in repeats 1-4 and 22-24 (Tigges et al., 2003). ECSCR localises to the 
plasma membrane and filamin A is known to interact with several other membrane bound 
proteins, many of which are involved in cell adhesion and coagulation pathways. For example, 
filamin A can promote and inhibit adhesive functions. When bound to the integrin cytoplasmic 
domain, it restricts integrin-dependent cell migration by inhibiting transient membrane 
protrusion and cell polarisation (Calderwood et al., 2001). The multitude of filamin A 
interactors involved in many different pathways may implicate a diverse role for ECSCR, 
controlling the filamin A availability not only to bind to other molecules but also to be anchored 
to the membrane, thus modulating these pathways. 
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3.6.2 The role of ECSCR in modulating the cytoskeleton 
To further investigate the role of ECSCR in modulating the cytoskeleton siRNA knockdown 
was performed and several cytoskeletal proteins found in the co-immunoprecipitation assay 
were visualised by immunofluorescence (figure 3.6). VE-cadherin, a molecule present in cell-
cell adhesion regions was also stained, as Shi et al. (2001) have reported that ECSCR also 
localizes to cell-cell junctions. Although ECSCR promotes cell aggregation in vitro (Shi et al., 
2001) its loss does not seem to be sufficient to affect cell-cell adhesion, as there seems to be 
no difference between VE-cadherin staining in HUVECs transfected with ECSCR siRNA  or 
negative control duplex. 
Additionally, Armstrong (2005) has demonstrated that ECSCR co-localises with F-actin, which 
also binds filamin A. Co-localisation around the membrane was expected, but clusters of co-
localised proteins were also observed at the base of cell protrusions. This suggests that ECSCR 
has a role in the development of these protrusions through its interaction with filamin A and 
possible coupling to F-actin, in a migratory or adhesive function. F-actin was stained using 
phalloidin. Although subtle, there seems to be a difference in stress fibres of cells transfected 
with ECSCR siRNA compared to those treated with negative control duplex. Loss of Ecscr 
seems to result in more disorganised fibres, that are more distant from the cell edges. Ma et al. 
(2009) have reported that the transfection of ECSCR-GFP into HEK 293T cells had resulted in 
the destruction of stress fibres. In accordance to that observation, loss of ECSCR should result 
in increased stress fibres, however the opposite was observed. This can be due to differences 
between the two cell types, where different binding partners may be available, thus influencing 
distinct pathways. Also, ECSCR produced in HEK 293T cells is slightly smaller than the 
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endothelial one (Armstrong, 2005), which means it may lack important post-translational 
modifications, such as a specific glycosylation pattern of carbohydrate, which affects its role 
in stress fibre formation. 
As for the other proteins studied, the loss of ECSCR results in a similar phenotype: filamin A 
and myosin II are present in fibre-like structures, which become destructed and disorganised 
when ECSCR is lost, in a similar fashion to F-actin. This is consistent with a role for ECSCR 
in anchoring the cytoskeleton to the membrane. Talin-1 and plastin 3 also seem to be lost at 
cell-surface adhesions and cell protrusions, respectively. Actin-bundling proteins not only 
structure the cortical actin cytoskeleton, but also control actin dynamics. Plastin 3 has been 
shown to decrease F-actin disassembly rate and inhibit cofilin-mediated depolymerisation of 
actin filaments in vitro (Giganti et al., 2005). If upon ECSCR loss plastin 3 is dislocated, then 
its role in keeping actin fibres assembled may be impaired. Moesin, rather than lost, seems to 
be more distant from the membrane and to have a more diffused distribution, compared to the 
very well-defined spike-like structures observed in HUVECs treated with negative control 
duplex. The staining protocol for this antibody could still be further optimised, as it has 
produced a clearer staining when used by Martin-Villar et al. (2010). ERM proteins, such as 
moesin, link membrane proteins to the underlying cortical cytoskeleton and control the 
distribution of and signalling from membrane receptors (McClatchey and Fehon, 2009). Since 
many proteins work cooperatively, loss of ECSCR may affect their distribution, regardless of 
interacting directly or indirectly with them. Additionally, ECSCR may have specific roles in 
adhesion, protrusion or migration that are only revealed in a particular context. Armstrong et 
al. (2008) have shown that lack of ECSCR results in slower migration through a membrane 
pore. Myosin II has been demonstrated to have a very specific role in contraction only during 
passage through narrow gaps, where squeezing contraction of the trailing edge propels the rigid 
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nucleus (Lämmermann et al., 2008). To further investigate the interaction of ECSCR with these 
proteins (or its influence in a signalling pathway where they are important), context-specific 
assays could be performed, such as the Boyden chamber assay to assess migration through a 
pore rather than migration on a flat surface, where myosin II has no role. 
To further elucidate any role for ECSCR, the opposite experiment was performed, where 
ECSCR-GFP was overexpressed. The M2 cell line is deficient in filamin A and the cells display 
defects in membrane stability and migration. When filamin A is re-introduced, these functions 
are restored (Cunningham et al., 1992). Other studies in these cells have also revealed that 
filamin A is essential for the maintenance of protrusions or lamellae which enable the cells to 
crawl (Flanagan et al., 2001). In the current study, M2 cells were transfected with ECSCR. The 
cells were still unable to form filopodia, whereas in HEK cells (that contain filamin A), ECSCR 
was able to induce the formation of these structures (figure 3.7). This shows that ECSCR has 
the ability to induce the formation of filopodia and needs filamin A to do so. 
Interestingly, M2 cells contain filamin B, which does not appear to have a redundant function 
to that of filamin A, as demonstrated by these cells’ inability to form cell protrusions 
(Cunningham et al., 1992). ECSCR seems to require specifically filamin A but not filamin B 
for tube formation. This is reinforced by the fact that filamin A was specifically co-
immunoprecipitated with ECSCR (34 hits for ECSCR versus 5 for the IgG control) and filamin 
B, although very similar in structure, was not found to be associated to ECSCR. 
Consistent with its role in cytoskeleton modulation, ECSCR knockdown resulted in less stress 
fibres and displacement of cytoskeletal components and its overexpression has induced the 
formation of filopodia. The overexpression experiments were performed in both cells that 
express filamin A and cells that do not. It had been reported that M2 cells, due to the lack of 
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filamin A, were unable to respond to RalA and Cdc42 to form filopodia. The current study 
shows that ECSCR, which interacts directly with filamin A, is also not able to induce filopodia 
in the absence of filamin A. The M2 experiments, nevertheless, should be repeated to confirm 
these results. The cells were a kind gift from Dr. Jo Morris (University of Birmingham, UK). 
However, they were found to be contaminated with fungus. They were subject to treatment 
with anti-fungal agents and after two weeks seemed to be contamination-free. There were no 
apparent morphological changes under bright field microscopy, but when transfected with 
GFP, even the controls showed very small blebs. ECSCR was still able to locate to the 
membrane, but it is unclear whether blebs were caused by these cells not being healthy, or due 
to ECSCR expression (as they were much more evident in ECSCR-containing cells). For many 
years blebbing has been associated with cell death. However, it also constitutes a mode of 
locomotion that is actin-free and completely dependent on myosin, as demonstrated by Blaser 
et al. (2008) in zebrafish primordial germ cells in vivo. 
 
3.6.3 Microarray to test the effect of ECSCR knockdown 
A microarray was performed to assess the effect of ECSCR knockdown in the gene expression 
of HUVECs. All the genes considered had a fold change equal to or greater than 2. 342 genes 
were found to be upregulated and 354 downregulated. The most upregulated gene was CCL20 
(a chemokine involved in attracting lymphocytes and dendritic cells towards endothelial cells) 
and the most downregulated gene was CYP26B1 (a member of the cytochrome P450 family of 
metabolism enzymes, responsible for inactivating all-trans retinoic acid to hydroxylated 
forms). 15 up and downregulated genes were chosen to confirm the microarray data by qPCR 
(figure 3.10). They have shown the same trend as the microarray. CD36 was not detected by 
qPCR. The reason why CD36 was detected in samples from HUVECS by microarray but not 
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by qPCR may have to do with the sensitivity of each technique. The microarray chip was 
designed for very low-input samples. HUVECs have been reported as being CD36 negative 
(McCormick et al., 2000), as well as CD36 positive (Sölder et al., 2012). The latter authors 
have also found that HUVECs are negative for LYVE-1, whereas the in the current study the 
message for this protein was found elevated (and, therefore, present) in HUVECs with low 
levels of ECSCR, both by microarray and qPCR. 
Most of the genes, both up- and downregulated, fell into the categories of adhesion molecules, 
glycoproteins, cytoskeleton-related, chemotaxis and apoptosis (analysis done using DAVID) 
(figure 3.11). When possible pathways were analysed using ingenuity pathway analysis, the 
more apparent role for ECSCR in these functions seemed to be diluted (figures 3.12-3.14). The 
first method groups proteins by function regardless of a specific pathway, whereas the second 
one groups them by pathway and the result was not as useful as anticipated in interpreting the 
effects of ECSCR loss. Also, most of the figures show other types of cells that are not 
endothelial, as that particular pathway is either specific to them or has been more extensively 
studied in those cell types. 
VEGFA and FGF13, well known angiogenesis stimulators, were found to be upregulated (4.2 
and 8.9 fold, respectively). This cell response to the loss of ECSCR appears to make HUVECs 
more angiogenic. Many chemokynes and their receptors also seemed to be altered, both up and 
donwregulated. It is known that, for example, CXC chemokines have both anti-and pro-
angiogenic effects. Those with an ELR motif promote angiogenesis and those that are inducible 
by interferons and do not contain the ELR motif inhibit angiogenesis (Belperio et al., 2000). 
Members of both groups were up and downregulated. Microarray results should be interpreted 
carefully and together with other experimental evidence. It is suggested that more cell based 
assays are performed, such as Boyden chamber to evaluate any role of ECSCR in myosin II-
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mediated contraction and then, based on a specific context, the tables produced from the 
microarray analysis can be used to suggest what other genes can be measured or visualised. 
3.6.4 siRNA duplexes titration and transfection stability assessment 
The expression of ECSCR was silenced in HUVECs using a regulatory cellular pathway known 
as RNA interference (RNAi). In the eukaryotic cell, long dsRNA are cleaved by Dicer, a 
ribonuclease III–like enzyme, into short RNA duplexes, small interfering RNA (siRNA). 
Synthetic siRNA can be generated and introduced into cells to knockdown the expression of a 
particular gene. After entering into cells by lipofection, the siRNA is assembled into an 
endoribonuclease-containing complex, known as RNA-induced silencing complex (RISC) and 
unwinds to become single stranded. The siRNA strand incorporated into RISC base pairs to its 
complementary mRNA sequence, resulting in its cleavage and degradation. This blocks the 
translation of mRNA into protein thus silencing its expression in the cell (Xia et al., 2002). 
Cells can sometimes display an innate immune interferon response to double stranded siRNA 
duplexes used in RNAi technology, because double stranded RNA is sometimes present in 
virus-infected cells (Anderson et al., 2008). Also, siRNA duplexes can trigger off-target effects 
such that they can knock down unintended mRNAs with high silencing efficacy (Sledz et al., 
2003). In order to minimize both the interferon response and off-target effects, the lowest 
concentration of siRNA required to knockdown ECSCR expression was determined. In 
addition, it had been shown by Armstrong et al. (2008) that ECSCR siRNA with D1 does not 
elicit interferon response (by quantifying the expression of OAS1 and ISG20 by qPCR). 
3.6.5  In silico analysis of conserved ECSCR putative functional motifs 
ECSCR is a unique protein that does not share domain homologies with any known protein 
when analysed in silico. To find those similarities and confirm the functionality of such 
conserved domains usually constitutes the first step when trying to characterize a novel protein. 
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Therefore, to have some insights on possible functions or protein interactions, other in silico 
analyses for the ECSCR primary structure have been done, such as the search for conserved 
predicted functional sites using the human, mouse and zebrafish sequences. 
This was done using Eukaryotic Linear Motif (ELM) resource for predicting functional sites in 
eukaryotic proteins. For the intracellular domain several possible functional sites conserved in 
all three species were found and could be investigated: PKA (protein kinase A) and CK1 
(casein kinase 1) phosphorylation sites and GSK3 (glycogen synthase kinase 3) 
phosphorylation recognition site, class III PDZ domains binding motif (in the C terminus of 
the protein) and a sorting and internalisation signal found in the cytoplasmic juxtamembrane 
region of type I transmembrane proteins (figure 3.15). 
The endosomes play key roles in the cell such as sorting and recycling of membranes and cargo 
and the intracellular delivery of proteins, toxins and viruses by endocytosis. In addition to these 
classical functions, it has become clear over the last few years that endosomes are also involved 
in cell signalling (by internalising receptors or facilitating the recruitment and integration of 
signalling cascades on the surface of endocytic vesicles), cytokinesis, polarity and migration 
(Gould and Lippincott-Schwartz, 2009). So far, ECSCR-GFP seems to localize to the plasma 
membrane and filopodia, rather than organelles. However, in the MS analysis of proteins that 
co-precipitated with ECSCR, some proteins regulating trafficking related to endosomes have 
been identified. 
CK1 is involved in cytoskeleton remodelling by, for example, phosphorylating RhoB and thus 
impeding actin stress fibre organization and epidermal growth factor receptor (EGF) 
stabilization (Tillement et al., 2008). In quiescent cells, β-catenin in association with 
cytoskeletal components (such as E-cadherin), orchestrates actin dynamics and regulates cell 
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adhesion, cell-cell interactions, and intercellular communication. CK1 phosphorylation of β-
catenin primes it for additional phosphorylation by GSK3, which targets it for proteasomal 
destruction (Kim and Kimmel, 2006). PKA activity regulates integrin activation and actin 
cytoskeletal organization. In neutrophils asymmetrical PKA activity is necessary and sufficient 
for actin cytoskeletal polarization and migration during chemotaxis (Jones and Sharief, 2005). 
Furthermore, PKA is needed for syndecan-2 induced filopodia formation via Enabled (Ena) 
and vasodilator-stimulated phosphoprotein (VASP) (Lin et al., 2007).  There is a conserved 
cysteine residue in ECSCR located three amino acids upstream from the putative serine to be 
phosphorylated by PKA (figure 6.1). Palmitoylation of a cysteine near the transmembrane 
region, either up or downstream from the serine residue seems to be fundamental for PKA 
phosphorylation modulatory functions (Moffett et al., 1996; Tian et al., 2008). The interaction 
of ECSCR with these kinases (or proteins phosphorylated by GSK3) could be investigated by 
the use of kinase inhibitors. 
PDZ domains recognize specific motifs that occur at the C-termini of target proteins and act as 
modules for protein-protein interactions. The PDZ motifs are common in the cytoplasmic tails 
of transmembrane receptors and channels (Niethammer et al., 1996), although they can also 
recognize internal sequences (Xu et al., 1998). By recruiting downstream proteins in a 
signaling pathway, PDZ domains mediate assembly of specific multi-protein complexes. PDZ 
domains containing proteins perform functions such as maintaining epithelial cell polarity and 
morphology (Bredt, 1998), organizing the postsynaptic density in neuronal cells, and regulating 
the activity and trafficking of membrane proteins (Harris and Lim, 2001). Since the putative 
class III PDZ domains binding motif is located in the C terminus of ECSCR, being ECSCR a 
type I transmembrane protein, the existence of this binding motif is possible to be true and 
could be investigated.  
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3.6.6 Glycosylation paterns of ECSCR 
Glycosylation is one of the most frequent post-translational modifications of proteins. It is well 
documented that altered glycosylation is a feature of cancer cells and some glycan types can 
even be used as markers of tumour progression (Dall’Olio, 1996; Varki, 2008). The altered 
glycosylation profiles of tumour-associated endothelium, however, are not well characterized. 
Peng et al. (2010) have recently found that beta-1,6-GlcNAc branching modification of 
PECAM-1 leads to cytoskeletal conformational changes that result in cell contraction, which 
facilitates tumour cell extravasation. 
ECSCR is predicted to be heavily glycosylated, due to containing multiple O-glycosylation and 
one consensus N-glycosylation sites and also because on a western blot it is detected at around 
55 kDa and the predicted size is 21.6 kDa (Armstrong et al., 2008). An attempt was made to 
immunoprecipitate ECSCR and then digest it using different combinations of glycosidases. 
Changes in size of the protein would be detected both by western blot (proteins) and using a 
kit containing the Schiff reagent, based on the periodic acid reaction, that recognizes 
carbohydrates. However, all antibodies are glycosylated and the heavy chain has the same size 
as ECSCR. The positive control (fetuin) has been successfully deglycosylated, but the analysis 
of ECSCR was not conclusive. All samples were incubated with five different 
glycosidases(PNGase F, sialidase, beta-glycosidase, glucosaminidase and O-glycosidase) from 
the DeGlycoMx kit (QA-Bio). It was not possible to know if the (incompletely digested) band 
around 50 kDa was ECSCR or the heavy chain of the antibody. As an alternative, a kit 
containing different lectins that will bind to and allow the identification of specific 
carbohydrate groups could be used, rather than trying to remove specific carbohydrate groups. 
Another alternative would be to overexpress ECSCR- GFP in HUVECs using a lentiviral  
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Figure 3.15 –Putative conserved predicted functional sites on ECSCR. 
The transmembrane domain is depicted in blue. The predicted functional sites are highlighted 
in yellow or underlined, when overlapping. The terminal predicted PDZ III domain binding 
motif for zebrafish was manually added, as it locates to the end of the C-terminus, but this 
protein is longer and has a part of the sequence that doesn’t align with the other orthologs. 
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system and subsequent immunoprecipitation and deglycosylation. This would remove ECSCR 
from the 50 kDa range, so that it could be distinguished from the antibody heavy chain. It is 
important to use HUVEC cells, as glycosylation patters in endothelial cells are very specific. 
For example, an antibody against the extracellular domain of ECSCR was raised by a company 
in Belfast (appendix 1). They have used the bacterially expressed naked protein as an 
immunogen and the antibody was able to recognize ECSCR-GFP overexpressed in HEK 293T 
cells. However, this protein was not as glycosylated as it would have been in HUVECs, as it 
runs at a much lower molecular weight on an SDS-PAGE. This was also observed by Shi et 
al., (2011), when an ECSM2-FLAG fusion protein was observed at ~40 kDa, compared to the 
~55 kDa from HUVECs) 
Shi et al., (2011) have immunoprecipitated ECSCR from HUVECs using a monoclonal 
antibody and treated the purified protein with a glycosidase mix. They were able to produce 
some lighter bands, but the full length ECSCR did not disappear, which may indicate that 
ECSCR has a very specific type of carbohydrate or there are other post-translational 
modifications contributing to its molecular weight. 
3.6.7 What regulates ECSCR? 
A quick promoter analysis of the region 2000 bp upstream of ECSCR and intron 1 using a 
program available online, TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html), 
has found some interesting conserved potential transcription factors. These could be narrowed 
down to a small number and all seem to be related to haematopoiesis and endothelial cells 
(table 3.1). In the future it would be interesting to knock some of these transcription factors 
down (the ones more specific to endothelial cell biology) and assess their effect on the 
expression of ECSCR and angiogenesis. 
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Table 3.1 – Conserved transcription factors potentially regulating ECSCR  
Transcription factor Function 
SRY (SOX11) 
Spermatogenesis, developing nervous system, developmental tissue 
remodelling (upregulated 4x in the microarray) 
Gata-1 Erythroid development 
Gata-2 
Activator which regulates endothelin-1 gene expression in endothelial cells 
(EDNRB is 3x downregulated in the microarray) 
Gata-3 T-cell development and plays an important role in endothelial cell biology 
AML-1a (Runx-1) Haematopoiesis (runx1T1 2x downregulated in the microarray) 
Nkx-2.5 Heart formation and development 
c-Ets-1 (ETS1) 
stem cell development, cell senescence and death, and tumorigenesis; turns 
endothelial cells angiogenic by upregulating MMPs and ITGB3 (upregulated 
4x in the microarray, 2 probes) 
CdxA Tumour suppressor (migration, proliferation, apoptosis) 
Evi-1 Haematopoiesis and vascular patterning 
Oct-1 (POU2F1) 
Transcription factor for IL8 (POU2F2 is upregulated 5x in the microarray 
and IL8 19x) 
MZF-1 Induces cancer migration and invasion through Axl 
 
 
 
113 
 
 
 
 
 
4 THE ROLE OF ECSCR IN 
DEVELOPMENTAL 
ANGIOGENESIS OF THE 
ZEBRAFISH (DANIO RERIO) 
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4.1 Introduction 
HUVECs primary cells were used as a human in vitro model to perform signalling and 
interaction studies. As a complement, in vivo studies were also performed, using zebrafish and 
an Ecscr knockout mouse as models. Mouse and zebrafish orthologs for ECSCR have been 
identified by Armstrong et al. (2008). Zebrafish are very easy to use, as they reproduce often 
and quickly and the embryos are transparent and develop rapidly, which allows direct 
observation. In addition, there are several transgenic lines available suitable for angiogenesis 
studies, such as tg[fli1:EGFP] (Lawson and Weinstein, 2002). In this line, friend leukaemia 
integration 1 (fli1) is fused to enhanced green fluorescent protein (EGFP), which allows the 
visualisation, study and manipulation of the vasculature. Fli1 is an E-twenty six (ETS)-domain 
transcription factor that is present in vasculature since the appearance of the haemangioblasts 
(Brown et al. 2000).  
Blood and endothelial cells derive from a mesodermal common precursor, the haemangioblast 
(Keller, 2001). In the developing zebrafish embryo two populations of haemangioblasts arise 
at the lateral plate mesoderm to form the primitive vasculature. The anterior population forms 
the head vasculature and the posterior originates the dorsal aorta and posterior cardinal vein, 
the axial vessels of the tail and trunk (Fouquet et al., 2007). The latter starts migrating into the 
midline at the 14 hours post fertilization (hpf) stage (10 somites) and coalesces to form a tube. 
Soon after, the anterior angioblasts also migrate to locate ventrally to the dorsal aorta and by 
13-15 hpf (7-12 somites) the arterial and venous fates are already determined (Zhong et al., 
2001). Cell fate is controlled by neighbouring tissues. The dorsal aorta is located ventrally to 
the notochord and hypocord and dorsally to the posterior cardinal vein, being laterally flanked 
by the somites (Fouquet et al., 2007; Zhong et al., 2001). The posterior cardinal vein is dorsally 
flanked by the aorta and ventrally by the endoderm. The midline structures secrete hedgehog 
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towards the dorsal aorta, which controls important signalling pathways, including Vegf and 
Notch (Lawson et al., 2002). Hedgehog signalling is required in vascular development at three 
stages: medial migration of dorsal aorta progenitors, arterial-specific gene expression and 
sprouting of intersegmental vessels (Gering and Patient, 2005). By 22 hpf primary 
intersegmental vessels sprout upwards from the dorsal aorta and soon after, by 24 hpf, the 
primitive vascular loop is formed and circulation starts (Isogai et al., 2003). Secondary 
sprouting from the posterior cardinal vein starts at 32 hpf and gives rise to venous 
intersegmental vessels and the lymphatic system. Through remodelling of the trunk 
vasculature, primary arterial sprouts contribute to the formation of both arterial and venous 
intersegmental vessels (Isogai et al., 2003). Arterial sprouting depends on Vegfa, kdr and kdr-
1, whereas venous intersegmental vessels require Vegfc. Delta-like ligand 4 supresses the 
ability of developing intersegmental arteries to respond to Vegfc-driven Flt4 signalling (Hogan 
et al., 2009). 
At 22 hpf, the sprouting of primary intersegmental vessels from the dorsal aorta occurs by 
angiogenesis and has been widely used as a model to study that process. Sprouting starts with 
arterial cells migrating out and overlapping. Then, they form a multicellular tube. After 
undergoing several complex rearrangements, such as division, rearrangement and changes in 
cell-cell contacts, the dorsal-most cell (tip cell) acquires a T-shape and joins with its anterior 
and posterior neighbours to form the dorsal longitudinal anastomotic vessel. The lumen of the 
vessel is formed through the formation and fusion of vacuoles from contiguous cells (Blum et 
al., 2008). 
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4.2 Zebrafish Ecscr expression pattern 
Armstrong et al. (2008) reported that an uncharacterised putative zebrafish protein showed 
similarity to human ECSCR, especially in the intracellular domain. The endothelial specificity 
in zebrafish embryos of this protein is now investigated. RNA whole mount in situ 
hybridization was performed. RNA antisense (and sense, as a control) probes were made by 
extracting total RNA from 24 hours post-fertilization (hpf) zebrafish embryos. RNA was 
converted into cDNA, putative Ecscr was amplified by PCR and inserted into the PCR TOPO 
blunt vector using EcoRI and BamHI restriction enzymes. The orientation of the insert was 
confirmed by sequencing and the plasmid was linearised using NotI (for the sense probe, 
synthesised using the SP6 RNA polymerase promoter) and BamHI (for the antisense probe, 
synthesised using the T7 RNA polymerase promoter) restriction enzymes. The RNA probes 
were synthesised using the mMessagemMachine kit and subsequently purified, so that they 
could be used for detection of the Ecscr transcript by whole mount in situ hybridization. 
Figure 4.1 shows that zebrafish Ecscr is specifically expressed in the vasculature, namely in 
the major head and trunk vessels. No expression in the intersegmental vessels was detected. 
Subsequently, the message levels of Ecscr were detected by reverse-transcription PCR using 
lysates from AB* wild type embryos at different developmental stages, from 1 cell to 72 hpf 
(Figure 4.2). Ecscr is maternally expressed and the levels decrease up to the 12-somite stage. 
By the 16-somite stage, transcription levels increase substantially and remain high at 72 hpf. 
This suggests that Ecscr may play a part in the developing vasculature. A second transcript of 
Ecscr was detected. This transcript seems to have a role between 12 and 30 hpf, as it is not 
detectable on samples from other stages. Elongation factor 1 alpha was used as a housekeeping 
gene and a -RT PCR was performed using the samples not converted into cDNA to assess 
possible contamination with genomic DNA. 
117 
 
Although the gels shown on figure 4.2 allow a more visual assessment and the detection of a 
second transcript, real-time quantitative PCR was also performed on the same samples (figure 
4.3). The Ecscr expression was normalised to that of EF1-alpha. The pattern observed on figure 
4.3 is the same as on figure 4.2.  
To further investigate the presence of two Ecscr bands, full-length Ecscr was amplified by PCR 
from cDNA and the two bands were excised from an agarose gel, purified and sequenced. The 
sequencing results have revealed two alternative transcripts, differing on the presence/absence 
of exon 2 (figure 4.4). 
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Figure 4.1 - Zebrafish Ecscr mRNA expression pattern in 24 hpf zebrafish AB* wild type 
embryos 
The zebrafish Ecscr transcript was detected by whole mount in situ hybridization. At 24 hpf 
Ecscr is expressed in the head and major trunk vessels, as indicated by the black arrows. The 
two inserts below the main image are a magnification of the head and trunk regions where the 
transcript was detected. This staining has been repeated 3 times with similar results, on 10 
embryos each time. 
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Figure 4.2 - Ecscr transcript levels during zebrafish embryonic development using 
reverse transcriptase-PCR 
Wild type zebrafish embryos were collected at different stages, from 1 cell (maternal) to 72 
hpf. PCR reactions for Ecscr, Ef1-alpha and –RT were performed (from cDNA) and repeated 
3 times with similar results. The Ecscr transcript is maternally expressed and levels decrease 
up to the 12-somite stage. By the 16-somite stage, transcription levels increase substantially 
and remain high at 72 hpf. A second transcript was detected. hpf – hours post fertilization; Ef1-
alpha – elongation factor 1 alpha ; -RT – negative control for the reverse transcriptase reaction.  
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Figure 4.3 – Ecscr transcript levels during zebrafish embryonic development using real 
time quantitative PCR. 
Wild type zebrafish embryos were collected at different stages, from 1 cell (maternal) to 72 
hpf. Total RNA was extracted and converted to cDNA. qPCR reactions were performed and 
the expression levels of Ecscr were normalised to those of Ef1-alpha. Each reaction was 
performed in triplicate and repeated 3 times with similar results. As observed for figure 4.2, 
Ecscr transcript is maternally expressed and levels decrease up to the 14 hpf stage. By the 15 
hpf stage, transcription levels increase and remain high at 72 hpf. Statistical variation is shown 
as standard deviation. hpf – hours post fertilization.  
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Figure 4.4 - Alternative splicing of the zebrafish Ecscr transcript 
When analysing the Ecscr expression during embryonic development by reverse-transcriptase 
PCR (figure 4.2), the gel has revealed a second band for the stages between 12 and 30 hpf that 
are not present before or after these points. This was further investigated by excising and 
sequencing the two bands. The results have shown that there are two alternatively spliced Ecscr 
variants in wild type zebrafish, differing in the presence/absence of exon 2 (A and B).  
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Figure 4.5 – Test of antibodies suitable to detect zebrafish Ecscr 
To be able to detect the zebrafish Ecscr protein, the polyclonal antibody against human ECSCR was 
tested on HUVECs (positive control) and 24 hpf zebrafish lysate. This antibody did not detect the fish 
protein (A). Therefore, a new antibody was produced in rabbit, using Ecscricd-MBP. The different test 
bleeds were able to detect the immunogen (B, arrow), as well as the endogenous protein (C). the MBP 
– maltose-binding protein; Ecscricd-MBP – zebrafish Ecscr intracellular domain fused to MBP; PB – 
pre-bleed; TB1 – test bleed 1; TB2 – test bleed 2; BO – bleed out; CoMo – negative control morpholino; 
UTR Mo – morpholino targeting Ecscr 5’ UTR region. 
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4.3 Raising an antibody against the zebrafish Ecscr intracellular 
domain (icd) 
Many antibodies have the ability to detect ortholog proteins from different species, when the 
regions used as immunogens show sufficient conservation. Since a polyclonal antibody against 
the whole human ECSCRicd (conserved across species) was available, total protein from wild 
type zebrafish embryos was extracted and analysed by western blot. Total protein from 
HUVECs was used as a positive control. This antiserum did not recognise the zebrafish protein 
(figure 4.5 A). In order to detect Ecscr on a western blot or to use it for immunoprecipitation 
studies in the future, the production of a suitable antibody was necessary. A zebrafish Ecscricd-
MBP (maltose binding protein) fusion protein was produced and purified. A rabbit was 
immunised and the bleeds were tested against the protein that was sent to CRUK for antisera 
production, as well as against zebrafish embryos lysates (injected with control or UTR 
morpholino, as described on the next section). Prior to being tested, the antiserum was 
incubated with PVDF membrane where containing MBP, so that it could be depleted from 
these antibodies. The antibody successfully recognised both the bacterially produced fusion 
protein and endogenous zebrafish Ecscr (figure 4.5 B and C). This validates not only the 
antibody, but also the morpholino, as the double band (~40-47 kDa) is present in the negative 
control and absent in samples from embryos treated with an Ecscr 5’ UTR-targeting 
morpholino. 
 
4.4 Loss of Ecscr function causes defects in intersegmental vessels 
sprouting 
One of the most commonly used strategies to study the function of a given gene consists of 
removing it from the system, either by knockdown or knockout techniques. To study the loss 
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of Ecscr function antisense morpholino technology was used (Nasevicius and Ekker, 2000). 
Two different morpholinos were designed to target Ecscr: one that binds to the 5’ UTR region 
immediately before the start codon and another one that binds between the end of exon 5 and 
the beginning of intron 5. The first should interfere with and block translation, whereas the 
latter should impair splicing between exons 5 and 6. As controls for specificity, a mismatch 
morpholino was designed for each targeting one, differing in five nucleotides, which causes 
them not to bind to the specific target. Transgenic tg[Fli1:EGFP] one cell embryos were 
injected with 8, 4 and 2 ng of each morpholino, which correspond to 1 nl of 1, 0.5 and 0.25 
mM, respectively. The amount of morpholino that caused a phenotype for the Ecscr-targeting 
sequence and no alterations for the mismatch controls was 4 ng for both pairs. In the light of 
this result, 4 ng per embryo was the amount chosen for further loss of function studies. The 
embryos were observed and counted at 30 hpf. Three independent experiments were performed 
for each morpholino and at least 100 viable embryos were counted and assessed for each 
condition. Figure 4.6 depicts the basic anatomy of a zebrafish embryo and shows what region 
has been used for imaging. The embryos injected with control morpholinos were not affected 
(Figure 4.7). The specifically targeted morphants displayed a range of intersegmental vessel 
effects due to Ecscr loss of function. In general, Ecscr knockdown caused defects in the 
sprouting of intersegmental vessels from the main trunk vasculature. The range of phenotypes 
observed was divided into four categories: no abnormal effects detectable (the embryos look 
like the controls), mild (one or two intersegmental vessels disrupted), intermediate (three or 
four abnormal intersegmental vessels) and severe effects (more than five intersegmental vessels 
disrupted) (Figure 4.7). The embryos were counted for each category and are represented on 
figures 4.8 A and 4.8 B as a percentage of the total. Upon morpholino injection, approximately 
75% of the embryos presented vessel defects in both conditions. 
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The specificity of the targeting morpholinos was also tested by using in vitro transcribed Ecscr 
mRNA, where neither of the morpholinos can bind. The construct used to make the transcript 
contained only the open reading frame (so the 5’UTR morpholino cannot bind) and, since the 
mRNA was already spliced, the splicing-interfering morpholino was also unable to target this 
molecule. The injection of this message alone caused a similar phenotype to the one inflicted 
by the morpholino when used at high concentrations (1, 100 and 1000 ng/µl were tested). The 
concentration chosen for the assay was 100 ng/µl). When co-injected with the morpholino, a 
rescue of the phenotype was achieved, reflected by the significant decrease (p < 0.05) in the 
number of embryos displaying mild and especially severe abnormalities (figures 4.9 A and 4.9 
B). Even in the few cases where significance of decrease was not achieved, those categories 
still showed a decreasing trend. A western blot was also performed for protein samples from 
embryos injected with the various morpholinos and mRNA, to assess changes in Ecscr protein 
expression (figure 4.10). The injection of mRNA alone has produced an increase in Ecscr 
expression, whereas the injection of either morpholino has produced a considerable decrease. 
The injection of either mismatch negative control morpholino has not affected the amount of 
Ecscr compared to the uninjected control. A co-injection of either targeting morpholino and 
Ecscr mRNA has restored the protein levels back to those of the uninjected control. An 
antibody against mouse actin was used as a loading control. This antibody can still recognise 
the fish protein but, probably due to evolutionary distance, the bands are faint and somewhat 
diffused.  
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Figure 4.6 – The zebrafish vasculature at 36 hours post fertilization 
To illustrate the typical vasculature of a 36 hpf zebrafish embryo, a transgenic tg[fli1:EGFP] 
embryo was imaged (A). The white rectangle represents the area of the trunk that was selected 
for further imaging and comparisons. The main zebrafish axial vessels are schematically 
represented in (B). The black rectangle highlights the main trunk axial vessels. DA – dorsal 
aorta; CV – cardinal vein; ISV – intersegmental vessels. 
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Figure 4.7 – Ecscr loss of function in transgenic tg[Fli1:EGFP] 30 hpf zebrafish embryos.  
At 30 hpf zebrafish embryos injected with Ecscr-targeting morpholinos displayed 
intersegmental vessel formation abnormalities, that ranged from no abnormal phenotype (A) 
to more than 5 vessels disrupted (D). This was quantified in at least 100 viable embryos, 3 
times. The red arrows indicate the disrupted vessels and their number in each panel is 
proportional to the severity of the abnormal phenotype. A – No abnormal phenotype; B – mild 
(1-2 disrupted vessels); C – intermediate (3-4 disrupted vessels); D – severe (more than 5 
disrupted vessels). 
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Figure 4.8 - Quantification of the defects in intersegmental vessels sprouting resulting 
from Ecscr loss of function. 
The morpholino-injected embryos for each category represented on figure 4.7 were counted 
and divided by the total number of embryos observed (at least 100, 3 times). 
A – proportions of embryos in each category of the range of effects caused by the splice 
morpholino injection. B – proportions of embryos in each category of the range of effects 
caused by the 5’ UTR morpholino injection.  NAP – no abnormal phenotype. Statistical 
variation is shown as standard deviation. 
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Figure 4.9 - Quantification of the defects in intersegmental vessels sprouting after 
mRNA rescue 
To verify the specificity of the targeting morpholinos, these were co-injected with Ecscr RNA 
and the same counts were performed as for figure 4.8. A chi-square test was done to determine 
significant differences between counts of morpholino-injected embryos and rescued embryos, 
for the same category. A p-value < 0.05 is represented by *. A – proportions of embryos in 
each category of the range of effects caused by the splice morpholino and zebrafish Ecscr 
mRNA co-injection. B – proportions of embryos in each category of the range of effects caused 
by the 5’ UTR morpholino and zebrafish Ecscr mRNA co-injection injection.  NAP – no 
abnormal phenotype. Statistical variation is shown as standard deviation.  
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Figure 4.10 – Ecscr protein assessment by western blot of zebrafish embryos injected with 
morpholinos and mRNA 
A western blot was performed for protein samples from embryos injected with the various morpholinos 
and mRNA, to assess changes in Ecscr protein expression. The injection of mRNA alone has produced 
an increase in Ecscr expression, whereas the injection of either morpholino has produced a considerable 
decrease. The injection of either mismatch negative control morpholino has not affected the amount of 
Ecscr compared to the uninjected control. A co-injection of either targeting morpholino and Ecscr 
mRNA has restored the protein levels back to those of the uninjected control. An antibody against 
mouse actin was used as a loading control. A – Ecscr splice morpholino; B – Ecscr 5’ UTR morpholino. 
CoMo – mismatch control morpholino  
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Figure 4.11 – Effects of ECSCR knockdown at the transcript level. 
After injection of the morpholinos, RNA was purified and cDNA was synthesised. This was 
used to amplify the full length zebrafish Ecscr (A). The 5’UTR morpholino resulted in no 
transcript being made and the splice morpholino resulted in a smaller transcript. The difference 
in sizes is shown by the black arrows. The two transcripts were sequenced and the smaller one 
lacked exon 6 (B). 
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After injection of the morpholinos, RNA was purified and cDNA was synthesised. This was 
used to amplify the full length zebrafish Ecscr. The 5’UTR morpholino resulted in no transcript 
being made and the splice morpholino resulted in a smaller transcript (figure 4.11 A). The two 
transcripts were sequenced and the smaller one lacked exon 6 (figure 4.11 B). 
The intersegmental vessels are known to sprout from both the dorsal aorta and the cardinal vein 
(Isogai et al., 2003). Using specific markers for artery (Ephb2) and vein (Efn4) endothelial 
cells, the major trunk vessels seem to be intact when Ecscr is depleted (figure 4.12). These 
markers do not stain intersegmental vessels. MyoD, a marker for myogenesis, was used to 
assess endoderm integrity, to attest that the intersegmental vessel phenotype was specific and 
other structures deriving from the mesoderm were not affected. The somites, as the blood 
vessels, originate from the mesoderm. There may be a slight ventral expansion of the cardinal 
vein in embryos injected with Ecscr morpholino. However, these are preliminary data that need 
to be repeated, as the experiment was performed only once. 
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Figure 4.12 - RNA staining for vascular markers in zebrafish embryos with depleted 
Ecscr by morpholino injection. 
Zebrafish embryos were injected with 5’ UTR morpholino and the transcripts of blood vessel 
markers were detected by in situ hybridization. The arrows indicate specific staining for the 
dorsal aorta (Ephb2) and cardinal vein (Efn4). MyoD was used to make sure that mesoderm-
derived structures were developing normally. Fli1 is a marker for endothelial differentiation, 
which is present in both veins and arteries.  
A 
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4.5 Discussion 
4.5.1 Spatial and temporal distribution of zebrafish Ecscr 
Zebrafish has been recognised as a good genetic and developmental biology model to study 
vessel development. Many genetic mutants and transgenic lines of endothelial lineages have 
been created and are currently available. Importantly, developmental mechanisms including 
those of blood vessels are conserved between higher vertebrates and zebrafish (Davidson and 
Zon, 2004). 
A zebrafish orthologue for ECSCR has been found by Armstrong et al. (2008). In order to 
determine its endothelial specificity and therefore study its role in developmental angiogenesis, 
in situ hybridization was performed using 24 hpf wild type embryos. This revealed that Ecsr is 
expressed in the major head and trunk vessels exclusively (figure 4.1). Later others have 
independently confirmed these results. Furthermore, they have detected the message at as early 
as 10 somites in the lateral plate mesoderm, at positions where endothelial precursors are 
expressed. From 16-18 somites Ecscr message is present at midline vascular structures and at 
24 hpf it is detected on both trunk axial vessels (dorsal aorta and cardinal vein) and main head 
vessels (Verma et al., 2010). As in the present study, they have not detected Ecscr in the 
intersegmental vessels. This can be because the transcript is not there or it is expressed at such 
low levels that the technique is not powerful enough to detect it. 
Many other genes that are endothelial specific and play a role in vascular development have 
been identified in zebrafish by genome-wide analysis and in situ hybridization screening. 
GA2692 (orthologue of mammalian HspA12B, a distant member of the heat shock protein 70 
family) mRNA expression was detected in zebrafish ventral hematopoietic and vasculogenic 
mesoderm and later throughout the vasculature up to 48 hours post fertilization. Morpholino-
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mediated knockdown of this protein resulted in multiple defects in vasculature, particularly at 
sites undergoing active capillary sprouting (intersegmental vessels, sub-intestinal vessels and 
the capillary sprouts of the pectoral fin vessel). HspA12B is highly expressed in HUVECs in 
vitro and knockdown by siRNAs blocked wound healing, migration and tube formation, 
whereas overexpression enhanced migration and accelerated wound healing (Hu et al., 2006). 
Another example are the transcription factors from the ETS family members erg, fli1 and etsrp. 
Loss-of-function analyses have demonstrated that erg and fli1 are required for angiogenesis, 
acting cooperatively, possibly by regulating VE-cadherin. Etsrp, on the other hand, is essential 
for haemangioblasts and vasculogenesis (Liu and Patient, 2010; Sumanas and Lin 2006). 
Some proteins are expressed during transient distinct developmental periods to perform 
functions that are only required during development, such as GA2692, which is only expressed 
up to 48 hpf (Hu et al., 2006). Others are important during the whole lifetime of an individual. 
This seems to be the case of ECSCR. It is expressed during embryonic stages (in HUVECs) 
and in situ hybridization has detected ECSCR in human adult vessels from paraffin-embedded 
tissue arrays (appendix 2, figure A4). Temporal expression of zebrafish Ecscr was studied from 
1 cell to 72 hpf (figures 4.2 and 4.3). It is maternally expressed, as it is present already at the 
1-cell stage. Maternal gene products drive early development when the embryo is 
transcriptionally inactive. It only begins to produce its own RNA after the maternal-zygotic 
transition, which occurs at the blastula stage (Schier 2007). This suggests that Ecscr may have 
a role in very early development. However, it does not seem to be a determinant of embryonic 
survival, as Ecscr-targeting morpholino injected embryos do not present lethal phenotypes. The 
transcript starts expression remains low until 12 somites and then increases and remains high. 
This coincides with the period when vasculogenesis occurs (Baldessari and Mione, 2008), 
which implies that Ecscr may have a role during this stage. If it does, again, it does not appear 
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to be crucial, as both dorsal aorta and cardinal vein seem fairly normal when Ecscr is knocked 
down (figure 4.12). However, this in situ hybridization should be repeated and examined 
carefully, to confirm if there is a slight ventral vein expansion. Alternatively, because there is 
a temporal gap between mRNA and protein, this increase in transcript may be in preparation 
for a role in intersegmental vessel sprouting, that starts at around 22 hpf. Studies in the present 
work show that loss of Ecscr results in intersegmental vessel sprouting disruption (figure 4.7). 
Temporal expression of Ecscr was quantified using qPCR, which shows the pattern described 
above (figure 4.3). Additionally, a reverse-transcriptase PCR was also performed and the 
products were run on a gel. This allowed the identification of a second transcript that otherwise 
would have not been seen (figure 4.2). What is interesting about this transcript (lacking exon 
2, figure 4.4) is that it is only transiently expressed, between 5 somites (12 hpf) and 30 hpf. Its 
peak of expression is between 16 somites (17 hpf) and 22 hpf (figure 4.2). This coincides with 
the period during which the intersegmental vessels sprout from the axial vessels (at 22 hpf and 
then the second wave at 30 hpf) (Isogai et al., 2003). Others have also reported the existence 
of two mouse Ecscr transcripts, differing from each other in the first and second exons (Wu et 
al., 2012). The human protein is also known to present two distinct bands on an SDS-PAGE 
gel (figure 3.10; Armstrong 2005). Further investigations should be carried out to determine 
the role of this transcript in intersegmental vessel sprouting, as discussed below. 
4.5.2 Effects of zebrafish Ecscr loss of function in zebrafish embryos 
Tg[Fli:EGFP] is a zebrafish transgenic line, in which the endothelium and its precursors are 
labelled with GFP (Weinstein, 2002). These embryos were used to rapidly assess the effect of 
Ecscr loss by targeting morpholino injections. Two Ecscr-specific morpholinos were used, one 
targeting the 5’ UTR (translation-blocking morpholino) and another one targeting a region 
between exon 5 and intron 5 (splice-blocking morpholino). For each one of those, a mismatch 
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control was used, where 5 nucleotides were altered so that the sequences are very similar but 
these do not bind to the targets. When Ecscr is depleted the intersegmental vessels don’t form 
properly (figure 4.7). The injected embryos displayed a variety of intersegmental vessel 
disruption, ranging from no abnormal phenotype to mild (1-2 vessels disrupted), moderate (3-
4 disrupted vessels) and severe (more than 5 abnormal vessels). Approximately 75% of the 
observed embryos presented an altered phenotype (figure 4.8). Although mismatch controls 
that had no effect on vascular development were used, there is always concern about off-target 
effects of the Ecscr-specific morpholino. While the underlying mechanism of these effects is 
unknown, one well-described and relatively consistent phenotype is p53-dependent neural 
toxicity, which is dose-dependent and has been estimated to be apparent in 15–20% of all 
morpholinos when injected at standard efficacy doses (Bedell et al., 2011). A possible solution 
is to co-inject a p53-targeting morpholino, to eliminate this toxicity. Another common 
phenotype is known as the “monster phenotype”, where embryos display overall severe 
deformities, such as shortened and gnarled tails, massive body curvatures and small heads and 
eyes (Bedell et al., 2011). Minimum morpholino doses that would cause a vascular-only 
phenotype were carefully optimised, to avoid non-specific morphological abnormalities. Most 
of the embryos injected displayed overall normal anatomy and morphology. Therefore, any 
embryo with abnormal morphology was considered a non-specific effect and was not used 
when counting embryos and assigning them to the various intersegmental vessel defects 
categories. Furthermore, to assess the integrity of the mesoderm, where endothelial cells derive 
from (Gilbert, 2006), in situ hybridization was performed for MyoD, which shows normal 
somites in morpholino-injected embryos (figure 4.12). To additionally attest Ecscr specificity 
of the morpholinos, these were co-injected with Ecscr mRNA, which has resulted in the rescue 
of the phenotype towards milder defects or no abnormal vasculature (figure 4.9). 
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In the developing zebrafish embryo angioblasts arise from the lateral plate mesoderm at the 5-
somite stage (Gilbert, 2006).  Then, they migrate to the midline and form the dorsal aorta and 
cardinal vein by vasculogenesis. A recent study (Herbert et al., 2009), however, suggests that 
only the dorsal aorta is formed by vasculogenesis from a common precursor vessel and the 
cardinal vein is formed by venous fated endothelial cells that segregate and migrate ventrally. 
Subsequently, intersegmental vessels sprout from the dorsal aorta and cardinal vein by 
angiogenesis, forming the dorsal longitudinal anastomotic vessels. Haemangioblasts are the 
common precursors of endothelial cells, haematopoietic cells and the cells that form the heart 
tube. After trans-differentiation and migration, each of these lines expresses specific markers. 
Friend leukaemia integration (fli1) is expressed only in the endothelial lineage, and ephrin B2a 
(Efnb2a) and ephrin 4 (Eph4) are arterial and venous markers, respectively. Transcription 
factors such as stem cell leukaemia (Scl) or Gata1 are markers for the erythroid lineage. Blood 
cell development occurs in two phases, termed primitive and definitive haematopoiesis. The 
first one is transitory and occurs in the blood islands in the ventral mesoderm close to the yolk 
sac and the latter takes place in the mesodermal region surrounding the aorta (Davidson and 
Zon, 2004). Given this common origin of vascular endothelial cells and blood cells, the effect 
of Ecscr loss could be evaluated in haematopoiesis by in situ hybridization using Ecscr 
morpholino injected embryos and haematopoiesis specific RNA probes. 
The intersegmental vessels are known to sprout from both dorsal aorta and cardinal vein. Using 
specific markers for artery and vein endothelial cells, the major trunk vessels seem to be intact 
when Ecscr is depleted (figure 4.12), although these observations need to be repeated and 
confirmed carefully. Therefore, Ecscr may be more important for angiogenesis (the formation 
of new blood vessels from pre-existing ones) than it is to vasculogenesis. However, Ecscr is 
present in zebrafish at all times (as the transcript was detected from the 1-cell stage) and 
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morpholino knockdown studies by Verma et al. (2010) have shown that loss of this protein 
results in slower migration of the angioblasts to the midline, which is part of vasculogenesis, 
not angiogenesis. It is possible that there are proteins with a redundant function, or that can be 
upregulated to compensate for the loss of Ecscr at this stage, as vascular development is not 
arrested. Because it is maternally expressed, it may have other unknown roles in early 
development, as it may regulate the availability of filamin A, which is involved in a multitude 
of processes (Zhou et al., 2009). Also, other binding partners have recently been discovered, 
such as moesin (this study) and cIAP (Ikeda et al., 2009). Survivin, a member of the IAP family 
conserved in zebrafish, has been demonstrated to be an essential regulator of neurogenesis, 
vasculo-angiogenesis, haematopoiesis and cardiogenesis (Delvaeye et al., 2009; Ma et al., 
2007).  Regarding angiogenesis, it would be interesting to keep observing the morpholino-
injected Tg[Fli:EGFP] embryos over time to assess if the loss of Ecscr causes permanent 
damages in the vasculature. Also, the role of the second transcript of Ecscr that is only produced 
in the embryo from 12 to 30 hpf with a peak that coincides with intersegmental vessel sprouting 
should be investigated. For that, a translation-blocking morpholino could be used to abolish all 
Ecscr expression, in conjunction with mRNA specific for either transcript. This would evaluate 
if they have distinct roles at different stages. Additionally, a morpholino could be designed to 
specifically eliminate this transcript. Similar studies, as well as protein interaction studies could 
be performed in HUVECs using both proteins, to possibly uncover distinct binding partners 
and pathways in an isoform-dependent manner. 
In addition to visually assessing the effects of Ecscr loss via morpholino injection, the Ecscr 
transcript and protein levels were also monitored. PCR products were visualised on an agarose 
gel, which showed the absence of Ecscr in embryos injected with the 5’ UTR morpholino and 
a smaller transcript in splice morpholino injected embryos compared to controls (figure 4.11). 
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Sequencing of this band shows lack of exon 6, which was expected, as the morpholino binds 
between exon 5 and intron 5, resulting in mis-splice between exons 5 and 6. Verma et al. (2010) 
have performed the same experiment for younger embryos and have observed several bands 
smaller than the original transcript, instead of just one. This can be due to the fact that embryos 
at different developmental stages process the transcript differently or respond to the 
morpholino in a distinct manner. Another possibility is that they may have used more cDNA 
template and therefore detected low copy transcripts that were not observed in the present 
study. In order to detect the zebrafish protein, that was shown to display the same pattern as 
the transcript (figure 4.10), a rabbit polyclonal antibody was generated from a fusion protein 
containing maltose binding protein and zebrafish Ecscr intracellular domain. Before doing so, 
the polyclonal antibody against human ECSCR was tested, but failed to recognise the zebrafish 
protein (figure 4.5). Relatively few zebrafish antibodies are available, so usually the first step 
is to identify antibodies raised for other species that cross-react with the zebrafish antigen 
(Akhtar et al., 2009). Typically, a panel of different antibodies can be tested, but at the time 
our group possessed the only available anti-ECSCR antibody, which had also been custom 
made from ECSCR-GST produced in our laboratory. Having an antibody that recognises the 
zebrafish protein provides the opportunity for further zebrafish studies, such as co-
immunoprecipitation, immunofluorescence and even the possibility of it working as a blocking 
antibody. 
4.5.3 Further directions 
A recent study in zebrafish has shown that moesin 1 knockdown results in intersegmental 
vessel sprouting and lumen formation defects. Furthermore, this has led to the loss of VE-
cadherin in cell-cell junctions. During embryonic angiogenesis, the primary lumen elongates 
along cell-cell junctions and moesin 1 is enriched in intracellular vacuoles that fuse with the 
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luminal membrane during expansion of the primary lumen (Wang et al., 2010). In the future, 
Ecscr morpholino injected zebrafish embryos could be analysed in greater detail and stained 
for VE-cadherin, as Ecscr knockdown results in intersegmental vessel formation disruption and 
ECSCR has been shown to be present at cell-cell adhesions and interacts with moesin (Shi et 
al., 2011; this study). Although the initial staining (that needs repeating) for VE-cadherin in 
HUVECs where ECSCR was knocked down shows that VE-cadherin doesn’t seem to change 
(figure 3.6), this in vitro model does not contain the rich pro-angiogenic environment that the 
sprouting vessels are exposed to in vivo. This difference could be essential to uncover a role 
for Ecscr in vivo that cannot be easily reproduced in vitro. 
The tg[fli:GFP::gata1:dsRed] zebrafish transgenic line displays green vessels (GFP-tagged 
Fli1) and red erythrocytes (dsRed-tagged gata1) (Gering and Patient, 2001). Using time-lapse 
fluorescence microscopy imaging of this line, the defects in vascular development in these 
embryos can be imaged and therefore any flow disturbances or missed effects in 
haematopoiesis can be analysed. Time-lapse high magnification imaging of  tip endothelial 
cells in sprouting intersegmental vessels from controls and embryos lacking Ecscr could 
provide insights on the impact this molecule on, for example, filopodia (number, length, 
turnover), or cell-cell interactions.  
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5 PRODUCTION AND 
PRELIMINARY 
CHARACTERIZATION OF AN 
ECSCR KNOCKOUT MOUSE 
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5.1 Introduction 
In the previous chapter, RNA antisense oligonucleotides, morpholinos, were used to assess the 
role of ECSCR in angiogenesis. Morpholino-mediated knockdown of genes is a quick and 
relatively easy and cheap way of obtaining a fast answer that has been largely used in the 
zebrafish model. However, these changes are neither permanent nor complete. Homologous 
disruption has not yet been found to be efficient in zebrafish, mainly because of the difficulty 
in isolating and cultivating ES cells from this organism (Wienholds and Plasterk, 2004). To 
overcome this barrier a new gene targeting approach is starting to be used in zebrafish, 
employing synthetic zinc finger nucleases (Doyon et al., 2008; Ekker 2008; Meng et al., 2008). 
Nevertheless, the mouse is still the most widely used model to study the function of genes and 
to model human disease. As it is a mammal, it is closer to humans than the zebrafish is. 
Presently, the International Knockout Mouse Consortium (IKMC), that comprises large-scale 
efforts from the Knockout Mouse Project (KOMP), European Conditional Mouse Mutagenesis 
(EUCOMM), North American Conditional Mouse Mutagenesis Project NorCOMM and the 
International Gene Trap Consortium, aims to mutate all protein-coding genes in the mouse 
using C57BL/6 embryonic stem (ES) cells. They have employed a selection of techniques, such 
as gene traps and conditional and non-conditional gene targeting strategies. In the past, 
researchers would make their own constructs, with the desired particularities or they would be 
available from heterogeneous sources, such as BayGenomics. This consortium of research 
groups focuses mainly on genes relevant to cardiovascular and pulmonary development and 
disease (Stryke et al., 2003). At the KOMP, by creating the same types of constructs for 
different genes, the project aims to generate alleles that are as uniform as possible, to allow 
accurate comparisons. However, because of the nature of the studies to be performed or the 
severity of effects, constructs made available allow the creation of both null and conditional 
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knockouts. If nothing is known about the function of a gene or the severity of its absence is not 
thought to be lethal, a null knockout can be generated. The insertion of a reporter gene, such 
as β-galactosidase, allows the visualization of where the gene of interest would be expressed 
(Austin et al., 2004). 
In Europe, the EUCOMM is contributing to the mouse genome mutagenesis programme by 
establishing and integrating mutagenesis platforms, phenotyping units, gene expression 
resources, storage and distribution centres and bioinformatics resources. They are applying 
conditional strategies for the rapid creation of conditional alleles in ES cells (Auwerx et al., 
2004). 
In recent years many important advances have been made in improving strategies and 
efficiency of gene targeting and gene trapping. The KOMP provides constructs for these two 
strategies, transfected into ES cells. Gene targeting comprises the insertion of a drug-resistance 
selection cassette into a specific region of the genome by homologous recombination, thus 
resulting in the interruption of the target gene. Gene trapping is achieved by random integration 
of a promoterless reporter construct and is restricted to genes expressed in ES cells (Skarnes, 
2005). A clever strategy developed by Friedel et al. (2005) and named “targeted trapping” 
combines both. This was adopted by the KOMP to make their constructs to produce null 
knockouts. The null knockout produced for the present study was prepared using ES cells 
containing such a construct. There are two homologous recombination arms, 5’ and 3’, so that 
the sequences contained between them can be integrated into determined specific locations in 
the genome (figure 5.1). In the case of the Ecscr construct, the whole cassette was inserted 
between the 24 first nucleotides of exon 1 (in the untranslated (UTR) region) and the first 6 
nucleotides of exon 9, immediately before the stop codon. A promoterless β-galactosidase open 
reading frame followed by a simian virus 40 polyadenylation signal (SV40 PolyA) will both 
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interrupt the gene and indicate in which cells that has happened upon LacZ staining. This 
happens because the inserted promoterless beta- galactosidase will be expressed under the 
control of the Ecscr promoter. The SV40 polyA has the ability to terminate transcription and 
add a polyA tail to mRNA (Li et al., 2012). In order to select which ES cells were successfully 
transfected with the construct, it contains a Neomycin-resistance (Neo) cassette with an mPkg 
polyA that has the same function as the SV40 polyA. This cassette is under the control of a 
hybrid promoter between human ubiquitin C (that permits its expression in mammalian cells, 
such as ES cells) and a prokaryote promoter EM7, that allows the expression in bacteria for 
positive selection when the construct is being made and purified before going into the ES cells 
(Liu et al., 2003). The Neo cassette (promoter, open reading frame and polyA) is flanked by 
two loxP sites in the same orientation. This allows for further removal of the cassette, if 
required, using a Cre recombinase. LoxP sites (locus of X-over P1) from bacteriophage P1 are 
a 34 base pair long region consisting of two flanking 13 base pair palindromic sequences and 
an 8 base pair central sequence that is asymmetric. If the two sites are in the same orientation, 
the recombinase will produce a deletion; if the LoxP sites are in opposite orientations, then an 
inversion will be obtained (Nagy, 2000). 
Once a null knockout mouse is produced using the method mentioned above, the alteration will 
be permanent. However, if the knockout is lethal, either embryonically or during any other time 
early in life, some studies may not be possible. To overcome this problem, as well as allow 
gene function studies in mice under challenging conditions, in specific cell types or age, 
conditional knockout mice can be created instead. The KOMP provides constructs to produce 
conditional gene knockout in mice that they termed “knockout-first”. As for the previous 
construct, two homologous recombination arms are present (figure 5.2). This is a multi-purpose 
construct, that in the first instance works like the null one and a LacZ cassette will report if and 
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where the trap occurs. However, it differs in the way the LacZ cassette is inserted, as RNA 
processing signals have been added to the design. The promoterless beta-galactosidase cassette 
with its polyA tail starts with a splice acceptor from the gene engrailed homeobox 2, which 
allows it to be spliced onto the preceding mouse exon. In the case of the construct available for 
Ecscr, it would be exon 1. To prevent an accidental in frame stop codon between the mouse 
sequence for the gene of interest and the lacZ open reading frame (which would result in no 
beta-galactosidase expression), or a frameshift, or a fusion protein that might not be active, an 
encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES) has been included. 
This ensures that, regardless of the transcript, the enzyme will be fully and independently 
produced and can act as a reporter in the cells where the protein of interest is ablated. The Neo 
cassette under the control of the human beta-actin promoter and with its polyA tail has the same 
function as that mentioned for the null construct. The construct described is a modification of 
the one developed by Testa et al. (2003). 
In order to produce a conditional knockout mouse, the two cassettes (LacZ and Neo) have been 
flanked by FLP (flipase) recognition target (FRT) sites. Flipase is a recombinase that works in 
the same fashion as Cre, but recognises a different sequence. Upon removal of the cassette, the 
mice need to be subsequently crossed with a Cre-expressing deleter strain to finally remove the 
genomic information between the LoxP sites. 
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Figure 5.1 - Targeting trap construct produced by the KOMP, used to make an Ecscr 
null knockout mouse. 
In this type of construct there are two homologous recombination arms, 5’ and 3’, so that the 
sequences contained between them can be integrated into determined specific locations in the 
genome. In the case of the Ecscr construct, the whole cassette was inserted between the 24 first 
nucleotides of exon 1 (in the untranslated region) and the first 6 nucleotides of exon 9, 
immediately before the stop codon. A promoterless β-galactosidase open reading frame 
followed by a simian virus 40 polyadenylation signal will both interrupt the gene and indicate 
in which cells that has happened upon LacZ staining. The construct also contains an ES cell 
selection Neomycin-resistance (Neo) cassette. The two loxP sites flanking this cassette allow 
for further removal, if desired, using a Cre recombinase. 
βGal – beta-galactosidase; pA – polyadenylation signal; hUBC – human ubiquitin C promoter 
(the box represents a hybrid promoter, containing mostly sequence from hUBC promoter and 
67 nucleotides from the EM7 promoter); Neo – neomycin resistance cassette; red triangles – 
loxP sites; vertical black rectangles – exons. 
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Figure 5.2 - Knockout-first allele construct produced by the KOMP, used to make a 
conditional knockout mouse. 
In this type of construct two homologous recombination arms are present. When it is introduced 
into cells, it produces a null knockout and a LacZ cassette will report if and where the trap 
occurs. The promoterless beta-galactosidase cassette will be spliced onto the preceding exon 
due to the insertion of a splice acceptor. An internal ribosomal entry site was added so that the 
enzyme produced is not fused to any fraction of the trapped protein. This construct also 
comprises a Neo cassette for ES cell selection. To produce a conditional knockout mouse, the 
two cassettes are flanked by flipase recognition target (FRT) sites. Upon their removal, the 
mice will subsequently be crossed with a Cre-expressing deleter strain to finally remove the 
genomic information between the LoxP sites. 
En2 SA – engrailed homeobox 2 splice acceptor; IRES – internal ribosomal entry site; βGal – 
beta-galactosidase; pA – polyadenylation signal; βact – human beta-actin promoter; Neo – 
neomycin resistance cassette; red triangles – loxP sites; green rectangles – FRT sites; vertical 
black rectangles – exons. 
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There are currently two effective flipase deleter strains available. The first, Flpo, was produced 
in a C56BL/6 background with a codon-optimised Flpo gene, which showed higher 
recombination efficacy compared to Flpe deleter mice. A complete removal of the FRT-flanked 
Neo cassette was observed in the first generation, that was then passed on to further generations 
(Wu et al., 2009). If the construct used has the FRT sites in opposite orientations, then an 
inversion rather than a deletion is necessary to make a conditional knockout mouse. For that 
purpose, a ROSA26Flpo deleter strain has been successfully created, using the codon-
optimised Flpo at the ROSA26 locus. Like the previous one, this line is also more efficient than 
the traditional Flpe (Raymond and Soriano, 2010). As for Cre deleter strains, there are many 
available, that produce constitutive knockouts in specific tissues or inducible ones, activated 
by drugs. This offers many possibilities and applications. 
 
5.2 Ecscr expression in mouse 
In order to assess if Ecscr displayed the same endothelial specific distribution as in zebrafish 
and human tissues, an RNA in situ hybridization was performed. The mouse protein seemed to 
be expressed in the trunk, intersegmental and brain vasculature (figure 5.3). Although there 
was no staining with the sense probe (figure 5.3 A), there is much background produced with 
the antisense probe, which needs optimization. However, the observed pattern was similarly 
described by Ikeda et al. (2009). 
 
5.3 Initial attempt produce a conditional knockout mouse 
As Ecscr seemed to have a vascular distribution in the mouse, a conditional knockout was 
attempted, to characterise the role of the protein using this model. The original project 
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encompassed the in-house production of the construct and its subsequent electroporation into 
ES cells. 
A construct was designed as shown on figure 5.4. In short, a SnaBI-AgeI fragment from the 
mouse BAC clone bMQ121H10 would be cloned into the SmaI site of pBluescript by blunt-
end ligation. This fragment consists of 5.2 kb of genomic DNA upstream of the first exon, all 
9 exons and 7.3 kb of genomic DNA downstream of the last exon. Unique restriction enzyme 
sites within this fragment were selected to incorporate loxP sites as well as a neomycin 
selection cassette. 
To delete the exons 1-7, a loxP site would be inserted at Hpy99I site before exon-1 and at PmeI 
site after exon-7. A neomycin cassette flanked by FRT sites would be excised from pMyb3.0H 
vector (provided by Dr. Paloma Garcia, University of Birmingham) and cloned into the AfeI 
site after exon-9 by blunt-end ligation (Garcia et al., 2005). A thymidine kinase (TK) gene 
would be cloned into the XhoI site of pBluescript. The targeting construct would be linearized 
with NotI (which does not cut the 20.6 kb Ecscr fragment) before electroporation into the ES 
cells. 
To detect homologous recombination, two probes (one each at upstream and downstream of 
the recombination arm) could be used. To do the southern blot using the upstream probe, the 
genomic DNA would be digested with ClaI. For detection using the downstream probe the 
DNA would be digested with MfeI. 
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Figure 5.3 – Ecscr transcript distribution pattern detected by whole mount in situ 
hybridization 
The mouse Ecscr transcript was detected in E9.5 C57bl/6 wild type mouse embryos. Although 
excessive background is present in embryos treated with the Ecscr-specific (antisense) probe, 
there seems to be specific staining on the main trunk and head vessels, as well as the 
intersegmental vessels. (A) Sense probe, (B) Antisense probe. 
  
A B 
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The strategy described above was put into practise, but all the attempts to obtain the fragment 
of interest from the BAC have failed. Both restriction digestion and combined PCR 
amplification and ligation were not successful in obtaining the desired fragment. Despite 
Professor Gerard Eberl’s (Pasteur Institute, France) advice on BAC extraction, purification and 
handling, it was impossible to even amplify a small fragment (800 bp) from the original vial 
by PCR-colony. 
As an alternative, embryonic stem (ES) cells were purchased from the Sanger Institute to 
generate a conditional knock out mouse for Ecscr. These cells for the conditional knockout 
mouse were produced by the knockout mouse project – KOMP 
(http://www.knockoutmouse.org). The line JM8A1.N3 is subcloned from JM8 parental line, 
derived from C57BL/6N mice. These ES cells have been modified to correct the black mutation 
on the Agouti allele and originated an Agouti coat colour (Pettit et al., 2009). This work has 
been carried out at the University of Birmingham’s MRC centre for immune regulation by the 
centre’s animal resource manager Andrea Bacon. 
Recipient blastocysts were harvested from C57BL/6OlaHsd pregnant black mice and injected 
with the JM8A1.N3 ES cells containing a construct with potential to obtain an Ecscr 
conditional knockout (figure 5.2). In total 160 correctly injected blastocysts were implanted in 
the uteri of CD-1 pseudopregnant white mice (16 per mouse, 8 on each side). Only four 
chimeras were born in total, 3 males and one female. The coat colour chimerism was about 
50% for each mouse, but no germline transmission was observed. One of the males has never 
successfully had a female producing a plug and a second one had to be culled before germline 
testing, due to severe skeletal malformations (the necropsy revealed a protruding xyphoid 
process and a much arched spine when compared to a sex and age-matched littermate). The   
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Figure 5.4 - Diagram showing the original construct design to generate a conditional 
Ecscr knockout mouse. 
To make this construct, a fragment consisting of 5.2 kb of genomic DNA upstream of the first 
exon, all 9 exons and 7.3 kb of genomic DNA downstream of the last exon would be excised 
and inserted into pBluescript. Unique restriction enzyme sites within this fragment were 
selected to incorporate loxP sites, as well as a neomycin selection cassette. To detect 
homologous recombination by southern blot using the upstream probe, genomic DNA would 
be digested with ClaI. For detection using the downstream probe the DNA would be digested 
with MfeI. The wild type and transgenic fragments would have different sizes, depending on 
whether the cassette had been incorporated or not. 
βact – beta-actin promoter; pA – polyadenylation signal; Neo – neomycin resistance cassette; 
red triangles – loxP sites; vertical black rectangles – exons; green rectangles – FRT sites  
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remaining male and the female have only ever produced descendents with a black coat. 
In order to assess that the construct had been built according to its design, critical regions were 
amplified by PCR and sequenced (figure 5.5, table 5.1). Samples from FVB/N white mice and 
C57BL/6OlaHsd black mice were used as wild type. All the tested regions of the construct 
were successfully amplified and identified. However, since there was no germline transmission 
observed, the ES cells were compared to those used to make a full knockout mouse in our 
laboratory, which have given rise to germline transmission (for Clec14a). Overall, the 
morphology of both types of ES cells was similar, as well as the chromosome spreads (both 
contained 40 chromosomes) (Figure 5.6). 
In the KOMP website, a different type of clone was available for purchase. This is the one that 
was used to create Clec14a null knockout mice and its design is less complex. Basically, upon 
homologous recombination, the whole Ecscr gene will be replaced with a LacZ cassette (figure 
5.1). The genotyping strategy is also simpler, as depicted on table 5.4. This clone has produced 
germline transmission, as shown on the next chapter. 
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Figure 5.5 - Example of the PCR strategy used to identify the different components of 
the knockout-first construct. 
PCR 1 was performed using the pair of primers 3armF + 3armR (table 5.1). This corresponds 
to a region in the wild type genome. As the ES cells are heterozygous, all there samples were 
positive. PCR2 refers to a region within the cassette introduced by homologous recombination, 
amplified with the pair Universal5F + Common-n2R. Therefore, only the ES cells provided 
amplification of a band. 
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Table 5.1 - PCR strategy to identify critical regions in the KOMP construct to originate 
a conditional knockout mouse for Ecscr. 
The numbers correspond to the amplicon size in base pairs. 
 
 
 
 
 
 
 
 
 
 
 
Primers  FVB/N  C57BL/6OlaHsd  ES cells  Homozygous 
5armF + 5armR  330 330 330 330 
5beforeInsF + 3afterInsR 328 328 - 328 
Universal5F + Common-n2R  - - 303 303 
3IRES5F + LacZR  - - 279 279 
Common3F + BactR  - - 368 368 
RAF5F + FRTLoxR  - - 386 386 
mECSCRinSituF + WTintron3R  382 382 382 382 
CommonLoxPF + Universal3R  - - 359 359 
3armF + 3armR  303 303 303 303 
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Figure 5.6 - Comparison between ES cells purchased from the KOMP containing 
constructs for Clec14a and ECSCR knockout mice. 
ES cells containing a conditional construct for Ecscr were compared to those used to make a 
full knockout mouse in our laboratory, which have given rise to germline transmission (for 
Clec14a). Overall, the morphology of both types of ES cells was similar, as well as the 
chromosome spreads (both contained 40 chromosomes). 
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5.4 Producing a null Ecscr knockout mouse 
 
ES cells containing the conditional knockout-first construct (figure 5.2) were initially bought 
from the KOMP, as they offer the possibility of making both a null and a conditional knockout. 
However, the number of chimeras produced was very low (only 4 in total, having one suddenly 
died) and there was no germline transmission. Alternatively, ES cells containing the construct 
to produce a null Ecscr knockout mouse (figure 5.1) were purchased. 
These ES cells were expanded and injected into blastocysts by the MRC transgenic facility 
manager at the University of Birmingham, Dr. Andrea Bacon. The ES cells derived from the 
(black) C57BL/6NTac strain, so they were injected into blastocysts from an albino black 6 
strain B6(Cg)-Tyrc-2J/J (or B6-albino) and implanted into the uteri of pseudopregnant females 
also from the latter strain. As, in very simplistic terms, black is dominant over white, the degree 
of chimerism observed in the mice’s coat colour is an indicator of how well the ES cells have 
integrated into the embryos. The higher the percentage of black compared to white, the higher 
the probability of germline transmission. To test for germline transmission two male chimeras 
with over 50% black coat were chosen to be crossed with B6-albino females. One male has 
produced several litters of all-white pups and another one has produced both white and black 
pups, which confirms germline transmission for the latter male, but not the former.  
A detailed description of the litters produced by the male chimera is shown on table 5.2. Ten 
litters were produced, with 25 black pups in total. 60% of the pups were heterozygous and 40% 
were wild type. The sex ratio was 48% males and 52% females. Of the heterozygous, 66.7% 
were males and 33.3% females. Interestingly, as more litters were produced, the number of 
black pups in each increased (table 5.2).  
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Table 5.2 - Ecscr clone AB8 chimera #2 germline transmission progeny F1 (into B6-
albino background) 
 
LN – litter number; het – heterozygous; wt – wild type; the male heterozygous mice are 
highlighted in blue and the females in pink. The wild type mice of both sexes are depicted in 
black, as they are not required to proceed with the creation of a knockout mouse at this stage. 
However, in the “genotype” column, the mice are in the same order as in the previous column. 
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Once the heterozygous mice were old enough to breed (6-8 weeks), they were crossed using 
males and females from different litters, as depicted on table 5.3. Not all litters have produced 
knockout mice but, once positive males and females are mature, they will be crossed to produce 
a pure knockout colony. As this work is currently ongoing, it is yet unknown if the knockout 
mice can survive until reaching maturity and old age, if they are fertile and what phenotype the 
absence of Ecscr causes. 
  
5.5 Genotyping strategy 
The most well-known inbred mouse strain is C57BL/6. From this one, nine other substrains 
have been created, including the C57BL/6J (from the Jackson Laboratory) and C57BL/6N 
(from the National Institutes of Health). A study has found genetic differences between these 
two major substrains while genotyping for single nucleotide polymorphisms (SNP) at eleven 
loci. Even among C57BL/6J substrains there are more substantial differences. For example, 
the same group has found a deletion of exons 7-11 from the nicotinamide nucleotide 
transhydrogenase gene in C57BL/6J strains and 1,446 SNPs genotyping among seven C57BL/6 
strains (Mekada et al., 2008). For this reason, the first step before injecting the ES cells into 
B6-albino blastocysts was to check that the Ecscr gene was present in the strain of choice 
(C57BL/6JOlaHsd). A positive band obtained by PCR served both to optimise the PCR 
conditions for genotyping and to be able to proceed, as Ecscr is present in this strain. 
 
PCR of small fragments from genomic DNA (up to 400 base pairs) was chosen as the 
genotyping strategy, over the more traditional southern blot. The tissue samples used for 
genotyping were ear clippings (that serve this purpose, as well as numbering of the pups).  
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Table 5.3- Crosses between Ecscr clone AB8 chimera #2 heterozygous progeny to obtain 
knockouts 
LN – litter number; F – female; M – male; het – heterozygous; wt – wild type; ko – knockout; 
the male knockout mice are highlighted in blue and the females in pink. In the “genotype” 
column, the mice are in the same order as in the previous column. The numbers in brackets 
represent the total of pups born in a given litter and the number next to them represents the how 
many of pups were in the litter after a death. 
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Table 5.4- Genotyping strategy 
The primer combinations and respective expected amplicon sizes for wild type, heterozygous 
and knockout mice are presented. 
 
 
 
 
 
WT – wild type; Het – heterozygous; KO – knockout; bp – base pairs. 
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Figure 5.7 - Example of genotyping results for wild type, heterozygous and knockout 
mice 
In order to determine zygosity, a biopsy from each pup has to be submitted to PCR analysis for 
both wild type and cassette bands. Wild type mice are expected to have only the wild type 
band, samples from knockout mice should contain only the  cassette band and heterozygous 
will have both. The wild type band is the resulting amplicon from mECSCR-in situF and 
WTintron3R primers and the cassette band is obtained using the primers 5armF and ULacZ-
Rev. DNA from the ES cells used to produce the chimeras (heterozygous) was extracted and 
submitted to PCR analysis, as a positive control to check band sizes. 
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Primers were designed to amplify both wild type bands (present in wild type and heterozygous 
mice) and cassette bands (present in heterozygous and knockout mice) (table 
5.4). The primers to amplify the cassette bands were planned so that one of them would bind 
to the mouse genomic sequence and the other would bind to a region in the cassette. As they 
should provide the same answer, one pair for each side of the cassette was tested. The 
combination of UNeo-Fw + mECSCR-in situR provided a single, clearer band, compared to 
5armF + ULacZ-Rev, so this was chosen for further genotyping. The ES cells were used to 
optimise the primers for the cassette. 
As illustrated on figure 5.7, both bands are needed to interpret the genotyping results. The wild 
type mice should only have the wild type band (as the cassette was engineered and inserted by 
homologous recombination), the heterozygous mice should have both bands, as they have one 
wild type allele and another one that is modified. The ES cells purchased from the KOMP are 
also heterozygous. The knockout mice should have a complete replacement of the wild type 
band by the cassette. 
5.6 Monitoring and mapping the replacement of Ecscr by beta-
galactosidase 
As previously discussed, the knockout-first construct includes a gene trap that expresses beta-
galactosidase when and wherever it replaces the target gene. The location of this enzyme can 
easily be identified by LacZ staining. Litter number C (table 5.3) was suddenly left orphan and 
rejected by a possible foster mother. As the pups were too old to foster and too young to survive 
on their own (11 days post-natal), they had to be culled. This provided an opportunity to 
perform a LacZ stain. Briefly, after genotyping the pups (results shown on table 5.3) the heart 
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and lungs were removed and rapidly fixed. Then, they were incubated with X-Gal, a substrate 
for beta-galactosidase, fixed overnight and examined under the microscope. 
The degradation of X-gal produced a blue product, easily identifiable. It was possible to see a 
dose-dependent effect, and no stain was observed for the wild type organs, some staining was 
observed in the organs from heterozygous mice and strong staining was noted in organs 
belonging to knockout mice. The lungs of the knockout mice were very strong blue (figure 
5.8). After being stained for LacZ activity, the lungs were included in paraffin, sectioned and 
stained with hematoxylin and eosin to analyse tissue morphology. Lungs from knockout mice 
seemed to be denser, containing more cells and less air space than those from wild type (figure 
5.9). As for the hearts, a very interesting distribution pattern for the Ecscr has emerged (figure 
5.10). It doesn’t seem to be present in large vessels and it seems to be found only on (some but 
not all) small capillaries around the heart. Also, in the hearts from knockout and, to a lesser 
extent, heterozygous mice, there seems to be an asymmetry, where the right atria look enlarged. 
5.7 Monitoring the Ecscr protein and transcript amounts in wild 
type, heterozygous and knockout mice 
To further confirm the deletion of Ecscr, a small sample of lung, kidney, liver and blood was 
taken from a specimen of each category. The tissues were macerated using a homogeniser and 
the total protein was extracted and analysed by western blot, using the anti-human ECSCR 
polyclonal antiserum. Unfortunately, in spite of the homology between the human and mouse 
proteins, this antiserum didn’t seem to detect the murine version. Alternatively, small samples 
of lung had also been taken and snap frozen. Total RNA was extracted, converted into cDNA 
and a qPCR (real-time quantitative polymerase chain reaction) was performed. The data were 
normalised to actin and are represented as relative expression compared to the wild type (figure 
5.11). As observed for the colour gradient in the LacZ staining, Ecscr is no longer present in 
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the lungs from knockout mice and it is present in approximately half the amount of the wild 
type in heterozygous mice. As these are preliminary data, only one specimen per category was 
analysed for qPCR. Each sample was analysed in triplicates for Ecscr and actin.  
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Figure 5.8 - LacZ staining of lungs from wild type (A), heterozygous (B) and knockout 
(C) mice 
The construct used to produce an Ecscr knockout mouse contains a gene trap LacZ cassette, 
that prevents Ecscr from being transcribed and uses its promoter to produce beta-galactosidase 
instead. This way, the deletion of Ecscr and replacement by this enzyme can be monitored 
through lacZ staining, via the conversion of Xgal into a blue product. Lungs from wild type 
mice do not contain beta-galactosidase, therefore, there was no blue colour observed. Lungs 
from knockout mice displayed a bright blue coloration, due to enzymatic activity. Lungs from 
heterozygous mice exhibited a pale blue colour, resulting from less beta-galactosidase being 
present.   
A B C 
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Figure 5.9 – Hematoxylin and eosin staining of lung paraffin sections from wild type 
(A), and knockout (B) mice 
After being stained for LacZ activity, the lungs were included in paraffin, sectioned and stained 
with hematoxylin and eosin to analyse tissue morphology. Lungs from knockout mice seemed 
to be denser, containing more cells and less air space than those from wild type. 
Total magnification of the images on the left hand side is 2.5x and 7.2x on the right.   
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Figure 5.10 - LacZ 
staining of hearts from wild type (A), heterozygous (B) and knockout (C) mice 
As described on figure 5.4 for lungs, hearts from wild type, heterozygous and knockout mice were also 
stained for LacZ activity. Wild type hearts have no blue stain, hearts from knockout mice show some 
external vessels (but not all) stained in blue and heterozygous hearts display the same pattern as the 
knockouts, with a weaker signal. The right atria of knockout mice and, to a lesser extent, heterozygous, 
seem to be enlarged compared to those of wild type mice.  
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Figure 5.11 - Ecscr relative expression in lung from wild type, heterozygous and 
knockout mice 
RNA was extracted from lungs of wild type, heterozygous and knockout pups and quantitative 
PCR was performed for Ecscr and actin (3 times for each sample). Ecscr expression was 
normalised to that of actin and the relative expression compared to the wild type are 
represented. As expected, heterozygous mice have approximately half of Ecscr expression 
compared to the wild type and no Ecscr was detected in knockout mice. The error bars represent 
the standard deviation of the mean of the 3 replicates. No statistical analysis was performed to 
obtain significant differences between categories, as the aim is purely to observe that Ecscr 
expression is consistent with the genotyping results.  
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5.8 Discussion 
 
5.8.1 Ecscr transcript expression patterns in mouse E9.5 embryos 
Initial results from Ecscr in situ hybridization of E9.5 wild type embryos show that the mouse 
protein seems to be expressed in the trunk, intersegmental and brain vasculature (figure 5.3). 
Ikeda et al. (2009) found a similar distribution using the same technique and also E9.5 embryos. 
Their images for the entire embryo were even less clear than those in this thesis. They have 
then sectioned the embryos, which revealed more conclusive staining results. These authors 
described that Ecscr transcript is present in the intersegmental arteries, dorsal aorta and blood 
vessels of the yolk sac. Furthermore, they have generated an antibody against mouse Ecscr, 
which has detected the protein in bronchial epithelial cells, artery and vein in lung, as well as 
blood vessels in spleen. In blood vessels, they claimed Ecscr is expressed in both endothelial 
and smooth muscle cells. No further detail is provided regarding the age of the mice or what 
artery(ies) or vein(s) have been stained. 
The antisense probe has produced much background. This can be because the probe was too 
concentrated, in which case it should be diluted for further experiments. Probes can be re-used 
and tend to produce too much staining the first time they are used and work better in subsequent 
cycles of usage. Also, the protocol optimised by Thisse and Thisse (2008) for zebrafish was 
applied to mouse embryos. Because these are thicker and of different nature, they may not have 
been completely digested, which may have resulted in incomplete penetration of the probe. A 
protocol dedicated to mouse embryos should be applied, such as the one described by Piette et 
al. (2008). This protocol is largely similar to that described for zebrafish, but contains 
incubation times specific for the various mouse developmental stages and an additional 
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permeabilization step with RIPA buffer after the proteinase K digestion, which may contribute 
for better results. 
As Ecscr appeared to have an endothelial distribution, a knockout mouse model was generated 
to study its role in vascular development. 
 
5.8.2 Generation of an Ecscr knockout mouse model 
In order to create an Ecscr knockout mouse model, different approaches were adopted, as it 
was not a straightforward procedure. Firstly, a construct to obtain a conditional knockout 
mouse was designed (figure 5.4). Exons 1-7 would be deleted, as loxP sites would be inserted 
at Hpy99I site before exon-1 and at PmeI site after exon-7. A neomycin cassette flanked by 
FRT sites (used to screen positive ES cells once electroporated with the linearized construct) 
would be cloned into the AfeI site after exon-9 by blunt-end ligation (Garcia et al., 2005). The 
design of this construct could have been improved by the insertion of a reporter gene, such as 
β-galactosidase, which allows the visualization of where the gene of interest would be deleted 
(Austin et al., 2004). At the time Ecscr expression in mouse embryos seemed to be endothelial-
specific, but the in situ hybridization technique had to be much improved to have a more 
definitive answer (figure 5.3). Making a conditional knockout mouse meant that even if Ecscr 
expression was not restricted to the endothelium, its role in endothelial cells could still be 
studied by crossing these mice with, for example, the Tie-1-Cre delete strain. In these mice Cre 
recombinase is expressed in endothelial cells of embryoid bodies and transgenic mice driven 
by the Tie-1 promoter (Gustafsson et al., 2000). To confirm endothelial specificity, these mice 
were crossed with Rosa26R reporter mice. The Rosa26R mice have the lacZ gene inserted into 
the ubiquitously expressed Rosa locus that is preceded by a transcriptional stop cassette flanked 
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by loxP sites (Mao et al., 1999; Soriano, 1999). LacZ staining showed that the Tie-1-Cre 
transgenic strain can efficiently direct deletion of floxed genes in endothelial cells in vivo 
(Gustafsson et al., 2000). Another advantage of a floxed strain is the possibility of halting 
expression of the gene of interest at a specific point in the animal’s life. This was achieved with 
the creation of CreER inducible strains, where ligand-dependent Cre recombinases can be 
activated by administration of tamoxifen to the animal, which binds to the oestrogen receptor 
(ER) and prevents expression of the gene of interest. Cre is fused to a mutant ER that binds to 
tamoxifen but not endogenous ligands and translocates into the nucleus upon tamoxifen 
induction. CreER tissue-specific strains have also been produced (Feil et al., 2009).  
The production of this construct was, however, unsuccessful, as all components were correctly 
inserted into the backbone plasmid, but the genomic insert containing Ecscr full length and 5.2 
kb of genomic DNA upstream of the first exon, as well as 7.3 kb of genomic DNA downstream 
of exon 9 was not effectively excised or amplified to be included in the final construct. This 
was probably due to inexperience and lack of expertise in this area. As an alternative strategy, 
ES cells were purchased from the KOMP that contained a knockout-first construct, with the 
potential to also generate a conditional knockout mouse (figure 5.2). This approach is less time-
consuming and potentially yields more successful results, as the constructs and ES cell 
handling and electroporation are done by a team of experienced experts. The first step was to 
confirm that indeed the construct had all the elements as described. For that purpose, several 
PCR reactions were performed to amplify and sequence small key sequences such as LoxP 
sites, LacZ cassette or the actual Ecscr gene (figure 5.5; table 5.1). As the identity of all of them 
was confirmed, these ES cells were then injected into recipient blastocysts to generate 
chimeras. The number of chimeras created was low and no germline transmission was 
observed. In an attempt to understand why this strategy had failed, chromosome spreads were 
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done for these ES cells compared to ES cells containing a targeting trap construct used to 
successfully produce Clec14a null knockout mice, under the guidance of Dr. Laura O’Neil 
(University of Birmingham, UK). No evident abnormalities were observed (figure 5.6). 
Generating transgenic mice from genetically modified ES cells injected into blastocyst hosts 
produces chimeras that are only partially derived from the ES cells. These chimeras have to be 
tested for germline transmission of the mutant features and then the offspring need to be further 
crossed to obtain homozygosity. This is a long and expensive process and germline 
transmission is not guaranteed. An alternative strategy was proposed by Poueymirou et al. 
(2007): laser-assisted injection of transgenic ES cells into 8-cells embryos (rather than 
blastocysts). This has efficiently yielded F0 generation mice that are fully ES cell-derived and 
healthy, have 100% germline transmission and allow immediate phenotypic assessment 
(Poueymirou et al., 2007). This alternative route could be explored by the University of 
Birmingham transgenics unit, however it requires specialised equipment, training and high 
level of skill. 
Finally, ES cells containing a targeting trap construct to produce a null knockout mouse were 
purchased from the KOMP (figure 5.1). Injection of these cells into blastocysts has produced 
chimeras that yielded germline transmission of the engineered inserted cassette. The first 
generation was heterozygous and by the time of completion of this thesis heterozygous mice 
had just been crossed and produced the first homozygous pups (tables 5.2 and 5.3). To 
distinguish between homozygous, heterozygous and wild type mice, a combination of two PCR 
reactions had to be analysed (table 5.4; figure 5.7). Homozygous (knockout) mice had the 
cassette interrupting Ecscr successfully inserted in both alleles, as confirmed by the presence 
of an amplicon for the cassette and complete absence of the wild type band. This is because the 
primers designed to detect the wild type band bind to a region that was replaced by the cassette 
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by homologous recombination. Conversely, in samples from wild type mice only the wild type 
band is detected. This is because the cassette was engineered and its elements do not naturally 
occur in the mouse genome. Heterozygous mice contain one wild type allele and one allele 
where the cassette has been inserted by recombination. Therefore, both products are amplified 
by PCR. 
Apart from a less complex construct than the knockout-first, the targeting trap was also 
electroporated into different ES cells. The conditional construct was inserted into JM8A1.N3 
cells, subcloned from JM8 parental line, derived from C57BL/6N mice. These ES cells have 
been modified to correct the black mutation on the Agouti allele and originated an Agouti coat 
colour (Pettit et al., 2009). For this reason, recipient blastocysts had to be harvested from 
C57BL/6OlaHsd pregnant black mice rather than white mice. This has produced black and 
brown chimeras rather than the traditionally white and black ones. In this case, the less black 
coat coverage (and more brown), the more likely chimeras are to produce germline 
transmission. The opposite is true for the null knockout mice. Since the ES cells derived from 
the (black) C57BL/6NTac strain, they were injected into blastocysts from an albino black 6 
strain B6(Cg)-Tyrc-2J/J (white). Therefore, the more black hair patches compared to white, the 
more likely a chimera will be to yield germline transmission. It can be hypothesised that 
simpler constructs somehow have a higher rate of recombination compared to longer, more 
complex ones, resulting in faster or more successful germline transmission. So far, in our 
laboratory, two knockout strains have been successfully produced using the targeting trap 
construct. Another reason can be related to the nature of the ES cells. It is possible that line 
specific features determine the success of integration into blastocysts, producing more or less 
chimeric animals. On the other hand, assuming equal integration potential, the key may lie in 
recipient blastocysts from different strains being more or less amenable to allow foreign ES 
176 
 
cells to integrate, survive, migrate, and differentiate. To finalise, still regarding the different 
nature of the ES cells, these were cultured and manipulated in the same way, which may have 
favoured one line in detriment of the other, that may have been grown under suboptimal 
conditions, resulting in less efficiency. 
Traditionally, white mice from strains other than black 6 were used as blastocyst donors, as 
well as white mice that were crossed with chimeras to check for the presence of black pups in 
case of germline transmission (Nagy et al., 2003). This would mean that pups from these 
crossings would be discarded, as they were in a mixed background, which is not desirable. The 
use of the black 6 albino strain represents an advantage, as it allows an easy method to create 
knockout mice on the C57BL/6J genetic background and pups from the germline transmission 
confirmation crossings can be used instead of culled. This is a spontaneous mutation in the 
tyrosinase gene and when the mice are homozygous for the mutation the coat color is albino 
rather than black (this information was obtained from the Jackson Laboratory webpage at 
http://jaxmice.jax.org/strain/000058.html). 
 
5.8.3 Preliminary characterisation of the Ecscr null knockout mouse model 
As unfortunately this first litter containing some knockout pups was left orphan too old to be 
adopted by another female and too young to be weaned, they had to be culled. This has made 
it impossible to know whether they would be fertile, survive through adulthood or even develop 
a disease at old age. However, it has created the opportunity to do a preliminary analysis of 11 
days old wild type, heterozygous and homozygous knockout Ecscr littermate pups. 
Hearts and lungs from the three genotypes were chosen to perform LacZ staining to confirm 
the loss of Ecscr, as well as observe its location. The targeting trap construct contains a reporter 
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gene, β-galactosidase, which allows the visualization of a blue enzymatic product coincident 
with its location (Austin et al., 2004). Lungs from wild type pups displayed no LacZ staining, 
whereas lungs from knockout mice were intensely blue and lungs from heterozygous pups 
presented an intermediate colour (figure 5.8). This gradient is consistent with the expected 
amount of Ecscr being expressed, which was confirmed by qPCR (figure 5.11). Lung staining 
is also consistent with this organ containing 30% of endothelial cells in the body (Atochina et 
al., 1998). Furthermore, Ikeda et al. (2009) have reported Ecscr staining in lung epithelial cells, 
additionally to endothelial cells, which could explain such an intense and apparently 
homogeneous staining for lungs from knockout mice. This would also explain why the paraffin 
sections from knockouts seemed to have a pale blue-green colour throughout the whole tissue, 
compared to the white (paraffin colour) seen for the wild type. These sections were made from 
the lungs stained for LacZ. To further investigate this and compare morphology, hematoxylin 
and eosin staining was performed. Lungs from knockout mice seemed to have less air space 
and more cells, as evidenced by a much stronger dark purple hematoxylin stain of nuclei  
(Fischer et al., 2008) (figure 5.9). Lung hyperplasia has also been reported by Xian et al. (2001) 
in Dutt1/Robo1 knockout mice. This phenotype is evident since E15.5 and the newborns die 
within 24h due to breathing difficulties. Ecscr knockout mice live at least until the age of 11 
days. Ecscr heterozygous can reach breeding age and are fertile. However, the mother of the 
pups that has died was heterozygous and the same has been reported for other females by the 
technicians at the animal facility. According to animal welfare guidelines, because there may 
be a harmful phenotype that was previously unaccounted for, only heterozygous females were 
allowed to breed, which slows down the process of obtaining a knockout line. Not all 
heterozygous females died soon after giving birth, but a higher than normal number did. This 
needs to be investigated in greater detail. Giving birth to approximately 8-9 pups is a big effort, 
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that requires intense breathing. Although the LacZ staining was performed only once, as well 
as sectioning and hematoxylin and eosin, all the observations taken together seem to indicate 
that the loss of Ecscr may cause breathing problems due to changes in lung morphology and 
efficiency. 
In addition to lungs, hearts from the three genotypes were also stained for beta-galactosidase 
activity. Surprisingly, only some (but not all) superficial cardiac smaller vessels were stained 
(figure 5.10). Large vessels, such as the aorta, were not stained. Given that in both zebrafish 
and mouse embryos Ecscr transcript is found in the dorsal aorta, this was not expected. 
However, as discussed in section 4, Ecscr may have a more prominent role in the sprouting of 
smaller vessels and its role in larger vessels may be limited to a specific period during 
embryonic vascular development. To shed some light into this matter, LacZ staining could be 
performed in embryos at different stages. Koide et al. (2011) have also produced an Ecscr 
knockout mouse model, where the first three exons were deleted. Although bleeding was 
observed in embryos, mice were viable and fertile and had an overall otherwise normal 
development. Small vessel (< 10 µm) density was increased and no change was found in larger 
vessels. Accordingly, in a critical limb ischaemic model, blood flow recovery and capillary 
density was significantly increased in knockout mice compared to the wild type. 
Additionally, right atria from knockout pups seemed enlarged compared to those of wild types. 
Again, this can be linked to the phenotype observed in the lungs. Causes of right atrial 
enlargement include COPD, mitral stenosis, mitral regurgitation, or pulmonary emboli. Most 
cases of right atrial enlargement are associated with right ventricular hypertrophy (Harrigan 
and Jones, 2002). This was not as evident, but could be explored by comparing sections of 
hearts from knockout and wild type mice. In the results from pathway analysis of the 
microarray data there was a cluster called “cardiac hypertrophy”, where MEF2C is 
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downregulated. According to Zhao et al. (2002) myocyte enhancer factor-2 (MEF2) is more 
abundant in atria than ventricles and upregulated in the atria in response to hypertrophic stimuli. 
VEGF induces the expression of and MEF2 is an important mediator of VEGF in endothelial 
cells (Maiti et al., 2008). 
 
5.8.4 Further directions 
One of the aims when creating a conditional knockout mouse was to characterise the expression 
patterns and mechanism of action of Ecscr during embryonic development and tumour 
angiogenesis. In order to do that, Ecscr knockouts could be compared to the wild type. Namely, 
cryosections of different developmental stages could be done and immunostained with 
antibodies against Ecscr and general and specific vessel markers. Other markers may be found 
relevant from future results obtained with the other models (HUVECs or zebrafish). The 
embryos could be analysed anatomically and histologically to uncover any defect caused by 
the loss of Ecscr. The culture of wild type and Ecscr knock out endothelial cells could be 
attempted in order to assess the behaviour of these cells in angiogenesis assays such as the 
scratch wound and tube formation on Matrigel. In adult mice (as so far the knockout does not 
seem to be lethal) a piece of sponge could be inserted subcutaneously and the blood vessel 
growth into it could be assessed by analysing parameters such as vessel density, number, 
calibre, morphology (Andrade and Ferreira, 2009). In order to uncover any role for Ecscr in 
tumour angiogenesis, cancer cells (such as Lewis lung carcinoma) could be injected 
subcutaneously and tumour growth as well as vascularisation could be assessed (Dudek et al., 
2007). 
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Angiogenesis, although a normal process during development and wound healing, is also 
involved in pathological conditions, such as cancer. ECSCR has been identified as an 
endothelial-specific protein that binds to filamin A and is involved in tube formation and cell 
migration, possibly via modulation of the actin cytoskeleton. This makes ECSCR a potentially 
interesting marker for therapy. In the beginning of this project the mechanisms by which 
ECSCR regulates the cytoskeleton were unknown and required further investigation. 
Therefore, the aims were to 1) identify ECSCR binding partners and subsequent downstream 
signalling, 2) determine a putative role in zebrafish vascular development, 3) produce and 
characterise an Ecscr knockout mouse model and 4) assess whether ECSCR function is 
conserved across species. 
Identification of proteins interacting with ECSCR was done using two in vitro approaches, co-
immunoprecipitation combined with mass spectrometry and GST pull-down followed by 
western blotting. Two proteins were chosen for further investigations using yeast-two-hybrid: 
moesin and filamin A. Yeast-two-hybrid failed to show any association between ECSCR and 
moesin (as the yeast did not express the latter protein) and confirmed the interaction with 
filamin A. An alternative method, luciferase complementation assay, has demonstrated an 
interaction between ESCR intracellular domain and moesin. To determine the effects of 
ECSCR loss, siRNA knockdowm was performed. Several cytoskeletal proteins were visualised 
by immunofluorescent staining and lack of ECSCR resulted in disorganised stress fibres and 
uncoupling of the cytoskeleton from the plasma membrane. Overexpression of ECSCR-GFP 
in HEK 293T cells induced the formation of filopodia. This was not replicated in filamin A-
deficient M2 cells, which implies that filamin A is necessary for the formation of filopodia and 
the two proteins probably associate to form these structures. A microarray to compare 
expression of HUVECs treated with ECSCR-targeting siRNA and a negative control duplex 
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was also performed. Altered gene expression was observed for proteins involved in migration, 
apoptosis and cytoskeletal processes.  
After confirming endothelial specificity by in situ hybridization (mainly in head and major 
trunk vessels), the role of Ecscr in zebrafish developmental angiogenesis was explored using 
morpholino knockdown. Loss of Ecscr results in disrupted intersegmental vessels sprouting, 
which can be rescued by co-injection of Ecscr mRNA and morpholino. Two splice variants 
were identified, one of particular interest, which is only present during intersegmental vessel 
sprouting, possibly indicating a crucial role in this process. 
Mouse endothelial specificity of Ecscr was also confirmed by in situ hybridization, which has 
detected the transcript in trunk and head vessels, as well as intersegmental vessels. Three 
strategies were attempted to produce an Ecscr knockout mouse model. Initially, the construct 
to make a conditional knockout mouse was going to be made, electroporated into ES cells, 
selected and injected into blastocysts to produce chimeras. Most of the construct was 
successfully made, but an essential element containing the genomic DNA could not be inserted. 
Alternatively, ES cells were purchased to make the same type of knockout, but no germline 
transmission was observed. Finally, ES cells containing a construct for a null knockout have 
produced chimeras with germline transmission. Preliminary analyses show that Ecscr is 
expressed in lung and some but not all heart superficial vessels. It seems to be absent from the 
aorta. Initial observations of the lung histology indicate less air space and more cells, which 
can be indicative of respiratory problems. This seems to be supported by the presence of 
enlarged right atria and the fact that some heterozygous females have died a few days after 
giving birth. 
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ECSCR endothelial specificity seems to be conserved across species (human, zebrafish and 
mouse), as demonstrated by qPCR and in situ hybridization (this work and published literature). 
Regarding specific vessels, Ecscr seems to be present in the major trunk vessels in both 
zebrafish and mouse embryos, but absent from the murine aorta in 11 days old pups. The 
presence of Ecscr in large calibre vessels was not studied in older zebrafish or in humans. A 
role in smaller vessels seems evident. However, there seem to be differences between species, 
as loss of Ecscr results in incorrect formation of intersegmental vessels in zebrafish, but it has 
been reported to induce the growth of microvasculature in knockout mice (Koide et al., 2011). 
Nevertheless, caution must be taken when interpreting these results, as these phenomena were 
observed at different developmental stages. Additionally, Verma et al. (2010) suggest a role 
for Ecscr in angioblast migration in zebrafish, which was not studied in in mouse. 
A considerable part of this thesis involved the development and validation of techniques and 
reagents, which has proved challenging. Some of the aims were fulfilled more successfully 
than others but, when unsuccessful, techniques were replaced by logical alternatives which in 
the end proved to be more efficient to accomplish the goal. This was the case, for example, of 
the yeast-two-hybrid technique which was replaced by the luciferase complementation assay. 
The latter has confirmed the interaction between moesin and ECSCR. Three strategies were 
attempted to produce an Ecscr knockout mouse. In the end, this mouse model was successfully 
generated. 
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APPENDIX 1: LISTS OF UP AND DOWNREGULATED GENES UPON ECSCR KNOCKDOWN IN HUVECS 
Table A1 – Genes that are upregulated when ECSCR is knocked down 
FC – fold change; the numbers in brackets after the gene name are the fold change for that gene found in other probes, as the chip contains more 
than one probe for some genes 
Gene Symbol Gene name FC 
CCL20 chemokine (C-C motif) ligand 20 69,27775 
IL1B interleukin 1, beta" (50, 50, 44, 43, 41, 40, 37, 36) 55,58571 
CXCL5 chemokine (C-X-C motif) ligand 5 (5) 51,55574 
SELE selectin E 45,62285 
CXCL3 chemokine (C-X-C motif) ligand 3 (19) 43,1904 
BIRC3 baculoviral IAP repeat-containing 3 39,29428 
LINCR likely ortholog of mouse lung-inducible Neutralized-related C3HC4 RING domain protein 35,91131 
KYNU kynureninase (L-kynurenine hydrolase) (19) 35,25836 
CXCL2 chemokine (C-X-C motif) ligand 2 (12) 26,25162 
IFI44L interferon-induced protein 44-like 23,43921 
LTB lymphotoxin beta (TNF superfamily, member 3)" 22,39423 
C6orf58 chromosome 6 open reading frame 58 (15) 22,16312 
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)" 22,14715 
ATF3 activating transcription factor 3 (16) 18,71241 
IL8 interleukin 8 18,58318 
CD69 CD69 molecule (18, 18, 17, 17, 17, 15, 15, 14,12) 18,06872 
NR0B1 nuclear receptor subfamily 0, group B, member 1" 17,81812 
FAM129A family with sequence similarity 129, member A" (10) 17,73367 
NR4A3 nuclear receptor subfamily 4, group A, member 3" 17,54172 
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 17,47981 
CX3CL1 chemokine (C-X3-C motif) ligand 1 17,32104 
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UBD ubiquitin D 16,71386 
IL6 interleukin 6 (interferon, beta 2)" (14, 13, 13, 13, 13, 12, 11, 11, 11) 15,82812 
CSF3 colony stimulating factor 3 (granulocyte) 14,69577 
RRAD Ras-related associated with diabetes (11) 14,46713 
TNIP3 TNFAIP3 interacting protein 3 13,40016 
CLDN1 claudin 1 12,99483 
IL20RB interleukin 20 receptor beta 12,98884 
RSAD2 radical S-adenosyl methionine domain containing 2 (5) 12,40548 
TRAF1 TNF receptor-associated factor 1 (11) 12,26445 
C15orf48 chromosome 15 open reading frame 48 12,2139 
IL1A interleukin 1, alpha" (11, 11, 10, 10, 10, 9, 9, 9, 9) 12,11216 
MX1 myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse)" 11,93219 
ICAM1 intercellular adhesion molecule 1 (11, 10,10, 10, 9, 8) 11,49177 
TSLP thymic stromal lymphopoietin 11,48282 
TAC1 tachykinin, precursor 1 (8) 11,47063 
IL13RA2 interleukin 13 receptor, alpha 2" 11,46244 
NKD2 naked cuticle homolog 2 (Drosophila) 11,24896 
ETV7 ets variant 7 11,24188 
IFI6 interferon, alpha-inducible protein 6" 11,17219 
LOC344887 similar to hCG2041270 (9) 10,93561 
RASGRF2 Ras protein-specific guanine nucleotide-releasing factor 2 10,12908 
EBI3 Epstein-Barr virus induced 3 (3) 10,12063 
KCNA7 potassium voltage-gated channel, shaker-related subfamily, member 7 9,942975 
GAL galanin prepropeptide 9,67776 
FOXF1 forkhead box F1 9,476391 
FOXF2 forkhead box F2 9,372928 
DDIT4L DNA-damage-inducible transcript 4-like 9,327639 
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (9, 9, 8, 8, 8, 8, 7, 7, 7, 4) 9,198848 
TUBB2B tubulin, beta 2B" 9,191147 
FGF13 fibroblast growth factor 13 (6) 8,862905 
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CLDN14 claudin 14 8,828304 
CCL2 chemokine (C-C motif) ligand 2 (9, 9, 9, 8, 8, 8, 6) 8,810368 
HOXB9 homeobox B9 8,671537 
TRIB3 tribbles homolog 3 (Drosophila) (4) 8,443915 
IL23A interleukin 23, alpha subunit p19" 8,419675 
NEFM neurofilament, medium polypeptide" 8,411503 
EPSTI1 epithelial stromal interaction 1 (breast) (4) 8,375842 
CSF2 colony stimulating factor 2 (granulocyte-macrophage) 8,360494 
SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11" (4, 4) 8,256422 
CD70 CD70 molecule 8,229235 
TNFRSF9 tumor necrosis factor receptor superfamily, member 9" 8,17885 
DDIT3 DNA-damage-inducible transcript 3 8,141426 
C8orf4 chromosome 8 open reading frame 4 (5) 7,844324 
TNC tenascin C 7,838327 
IRS1 insulin receptor substrate 1 7,838222 
LAMP3 lysosomal-associated membrane protein 3 7,703025 
RCSD1 RCSD domain containing 1 7,612539 
NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 7,609051 
OLAH oleoyl-ACP hydrolase 7,510173 
IGFBP3 insulin-like growth factor binding protein 3 (7, 7, 6, 6, 6, 6, 5, 5) 7,506168 
XAF1 XIAP associated factor 1 (6) 7,504867 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 7,332894 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 7,329811 
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha" (6) 7,300273 
RGS16 regulator of G-protein signaling 16 7,266498 
LSM14B LSM14B, SCD6 homolog B (S. cerevisiae)" 7,246722 
RASD1 RAS, dexamethasone-induced 1" (5) 7,178346 
CXCL6 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 7,102826 
MX2 myxovirus (influenza virus) resistance 2 (mouse) 7,085482 
PLA2G4C phospholipase A2, group IVC (cytosolic, calcium-independent)" (4) 7,081566 
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IL7R interleukin 7 receptor 7,035184 
OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa" 6,923822 
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b" (6, 5, 5, 4, 4, 4,  4, 4, 4, 4, 3) 6,869461 
FAM150B family with sequence similarity 150, member B" 6,783794 
RELB v-rel reticuloendotheliosis viral oncogene homolog B 6,686273 
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) (6, 6, 6, 6, 5, 5, 5, 5, 4) 6,63401 
PAPLN papilin, proteoglycan-like sulfated glycoprotein" 6,546394 
LPL lipoprotein lipase 6,513617 
TNFAIP6 tumor necrosis factor, alpha-induced protein 6" 6,463195 
CEBPB CCAAT/enhancer binding protein (C/EBP), beta" (6, 6, 6, 6, 6, 5, 5, 5) 6,44158 
PRRX2 paired related homeobox 2 6,388108 
SLC15A3 solute carrier family 15, member 3 6,239996 
CXCL10 chemokine (C-X-C motif) ligand 10 6,202999 
SLC12A7 solute carrier family 12 (potassium/chloride transporters), member 7" (3) 6,169221 
TLR2 toll-like receptor 2 (4, 3, 3) 6,165808 
FLJ45422 FLJ45422 protein 6,096475 
KCTD16 potassium channel tetramerisation domain containing 16 6,084301 
PITX2 paired-like homeodomain 2 6,051326 
LOC645638 similar to WDNM1-like protein 5,975268 
ITGA9 integrin, alpha 9 (4) 5,931367 
SLC10A4 solute carrier family 10 (sodium/bile acid cotransporter family), member 4 5,916113 
HLA-B major histocompatibility complex, class I, B" 5,911434 
SH2D5 SH2 domain containing 5 5,896935 
OASL 2'-5'-oligoadenylate synthetase-like 5,862833 
CITED4 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 (4) 5,815169 
HMOX1 heme oxygenase (decycling) 1 (5, 5, 5, 5, 5, 5, 5, 5, 5, 5) 5,76187 
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa (4) 5,754087 
HERC6 hect domain and RLD 6 5,740996 
SQSTM1 sequestosome 1 5,73985 
SOD2 superoxide dismutase 2, mitochondrial" 5,735423 
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ISG20 interferon stimulated exonuclease gene 20kDa 5,687222 
PTCHD1 patched domain containing 1 5,684286 
UNC5B unc-5 homolog B (C. elegans) 5,601578 
COL8A2 collagen, type VIII, alpha 2" 5,560278 
MC5R melanocortin 5 receptor 5,555165 
MMP1 matrix metallopeptidase 1 (interstitial collagenase) (5, 5, 5, 5, 4, 4, 4, 4) 5,527686 
LOC100126784 hypothetical LOC100126784 5,510926 
CLIP4 CAP-GLY domain containing linker protein family, member 4" 5,503133 
NUAK2 NUAK family, SNF1-like kinase, 2" 5,486645 
SPINK1 serine peptidase inhibitor, Kazal type 1" 5,394292 
AREG Amphiregulin 5,373462 
NOG Noggin 5,250764 
HES4 hairy and enhancer of split 4 (Drosophila) 5,148451 
IFIT3 interferon-induced protein with tetratricopeptide repeats 3 5,105371 
KCNN2 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2" 5,069032 
IFI27 interferon, alpha-inducible protein 27" (4, 4, 4, 4, 4, 3, 3, 3, 3, 3, 3) 5,067551 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide" (4) 5,004399 
MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) 4,972289 
HIST1H3D histone cluster 1, H3d" 4,962294 
SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2" 4,883991 
CD83 CD83 molecule 4,870915 
DUSP5P dual specificity phosphatase 5 pseudogene (4) 4,861522 
TNFRSF4 tumor necrosis factor receptor superfamily, member 4" 4,851218 
RAB3IL1 RAB3A interacting protein (rabin3)-like 1 4,788185 
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) (3) 4,775168 
CBS cystathionine-beta-synthase 4,752131 
LOC728855 hypothetical LOC728855 4,659575 
BDKRB2 bradykinin receptor B2 4,656202 
BATF3 basic leucine zipper transcription factor, ATF-like 3 4,645409 
DNER delta/notch-like EGF repeat containing 4,63993 
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GPC6 glypican 6 4,598506 
HLA-F major histocompatibility complex, class I, F" 4,588335 
ICAM4 intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) 4,587044 
AKAP12 A kinase (PRKA) anchor protein 12 4,581684 
CEBPE CCAAT/enhancer binding protein (C/EBP), epsilon" 4,578664 
ICOSLG inducible T-cell co-stimulator ligand 4,560733 
POU2F2 POU class 2 homeobox 2 4,555146 
FAM148B family with sequence similarity 148, member B" 4,55495 
CAMTA1 calmodulin binding transcription activator 1 (3) 4,544532 
FOXA3 forkhead box A3 4,532092 
BMP8B bone morphogenetic protein 8b 4,528976 
SLC7A5 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5" 4,501349 
MAMDC2 MAM domain containing 2 4,490658 
ADRA2C adrenergic, alpha-2C-, receptor" 4,46032 
MMP10 matrix metallopeptidase 10 (stromelysin 2) 4,445137 
LOC345630 similar to hCG1641252 4,377962 
MT1M metallothionein 1M 4,374825 
ZC3H12A zinc finger CCCH-type containing 12A 4,362434 
DDIT4 DNA-damage-inducible transcript 4 4,353625 
BMPR1B bone morphogenetic protein receptor, type IB" 4,336013 
IFITM1 interferon induced transmembrane protein 1 (9-27) 4,335091 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 (4, 4, 4, 3, 3, 3, 3, 3) 4,238996 
PPARG peroxisome proliferator-activated receptor gamma (3, 2) 4,237915 
ATP13A3 ATPase type 13A3 (4) 4,177427 
VEGFA vascular endothelial growth factor A (3) 4,167951 
MT1JP metallothionein 1J (pseudogene) 4,12442 
SPATA13 spermatogenesis associated 13 4,106179 
CTHRC1 collagen triple helix repeat containing 1 4,103684 
IRX2 iroquois homeobox 2 4,090886 
TNF tumor necrosis factor (TNF superfamily, member 2)" 4,087982 
191 
 
TRA@ T cell receptor alpha locus 4,086858 
RGAG4 retrotransposon gag domain containing 4 4,074331 
LOR Loricrin 4,071845 
E2F7 E2F transcription factor 7 4,04478 
YPEL2 yippee-like 2 (Drosophila) 4,040712 
ISG15 ISG15 ubiquitin-like modifier 4,012287 
FLJ10490 hypothetical protein FLJ10490 3,993195 
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein" (3) 3,991321 
LL22NC03-75B3.6 KIAA1644 protein 3,965081 
MSX1 msh homeobox 1 (3) 3,963032 
ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 3,95733 
IER5 immediate early response 5 3,951198 
SLC2A6 solute carrier family 2 (facilitated glucose transporter), member 6" 3,926804 
ALOX5AP arachidonate 5-lipoxygenase-activating protein 3,923313 
SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporters), member 2" 3,870077 
SOX11 SRY (sex determining region Y)-box 11 3,835315 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa (3) 3,810113 
SPPL2B signal peptide peptidase-like 2B 3,793562 
PTPRH protein tyrosine phosphatase, receptor type, H" 3,786373 
CDV3 CDV3 homolog (mouse) 3,726423 
IL32 interleukin 32 3,714886 
NAT8L N-acetyltransferase 8-like (GCN5-related, putative)" 3,708802 
NF-E4 transcription factor NF-E4 3,702473 
F2RL3 coagulation factor II (thrombin) receptor-like 3 3,700633 
CBLN2 cerebellin 2 precursor 3,692642 
CXCL11 chemokine (C-X-C motif) ligand 11 3,679541 
ZNF644 zinc finger protein 644 (3) 3,661652 
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 3,655188 
GADD45G growth arrest and DNA-damage-inducible, gamma" 3,644449 
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) (4) 3,641341 
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HRK harakiri, BCL2 interacting protein (contains only BH3 domain) 3,596273 
CTH cystathionase (cystathionine gamma-lyase) 3,582555 
ITPR1 inositol 1,4,5-triphosphate receptor, type 1" 3,572426 
HIST1H2AC histone cluster 1, H2ac" 3,548782 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3" 3,544287 
LOC644135 hypothetical LOC644135 3,537164 
FBXO6 F-box protein 6 3,53669 
KCNIP3 Kv channel interacting protein 3, calsenilin" 3,531159 
IFI35 interferon-induced protein 35 3,526616 
F2RL1 coagulation factor II (thrombin) receptor-like 1 3,521476 
PPAP2C phosphatidic acid phosphatase type 2C 3,512899 
S100A3 S100 calcium binding protein A3 3,496241 
PHLDA1  pleckstrin homology-like domain, family A, member 1 (3) 3,48519 
EIF5 eukaryotic translation initiation factor 5 3,466144 
GPR150 G protein-coupled receptor 150 3,462558 
VCAM1 vascular cell adhesion molecule 1 3,451567 
TIFA TRAF-interacting protein with forkhead-associated domain 3,446937 
SLC3A2 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2" 3,444901 
DCBLD2 discoidin, CUB and LCCL domain containing 2" (2) 3,425845 
C10orf63 chromosome 10 open reading frame 63 3,416924 
NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) (3, 3, 3) 3,408586 
GBA3 glucosidase, beta, acid 3 (cytosolic)" 3,398055 
GEM GTP binding protein overexpressed in skeletal muscle 3,396345 
STC2 stanniocalcin 2 3,394851 
LOC401317 hypothetical LOC401317 3,387634 
TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)" 3,370895 
TXNL4B thioredoxin-like 4B 3,355144 
GATA5 GATA binding protein 5 3,353586 
TMEM217 transmembrane protein 217 (3) 3,348653 
NFIL3 nuclear factor, interleukin 3 regulated 3,334935 
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STX6 syntaxin 6 3,323307 
LOC646626 hypothetical LOC646626 3,302352 
WWC1 WW and C2 domain containing 1 3,284061 
RAB12 RAB12, member RAS oncogene family 3,273459 
ZNF365 zinc finger protein 365 3,270699 
SNX26 sorting nexin 26 3,266806 
FBXL13 F-box and leucine-rich repeat protein 13 3,263564 
HIST1H2BG histone cluster 1, H2bg 3,259872 
IFIT5 interferon-induced protein with tetratricopeptide repeats 5 (3) 3,250025 
PARD6G par-6 partitioning defective 6 homolog gamma (C. elegans) 3,246163 
EMILIN2 elastin microfibril interfacer 2 3,24535 
PKN2 protein kinase N2 3,240875 
LARS leucyl-tRNA synthetase 3,232565 
OR11G2 olfactory receptor, family 11, subfamily G, member 2" 3,218494 
RSL1D1 ribosomal L1 domain containing 1 3,204735 
S100P S100 calcium binding protein P 3,202209 
ESM1 endothelial cell-specific molecule 1 3,19416 
ZBED1 zinc finger, BED-type containing 1 3,184566 
PTPRK protein tyrosine phosphatase, receptor type, K" 3,179771 
DUX4 double homeobox, 4" 3,179511 
USHBP1 Usher syndrome 1C binding protein 1 3,170622 
SYNGR3 synaptogyrin 3 3,140811 
ZFP91 zinc finger protein 91 homolog (mouse) 3,131078 
GVIN1 GTPase, very large interferon inducible 1" (3) 3,110038 
C5orf41 chromosome 5 open reading frame 41 3,106751 
IFI30 interferon, gamma-inducible protein 30" 3,103898 
TPM1 tropomyosin 1 (alpha) 3,094334 
ADAM12 ADAM metallopeptidase domain 12 3,092041 
JUNB jun B proto-oncogene 3,081591 
SIK1 salt-inducible kinase 1 3,079149 
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ZDHHC11 zinc finger, DHHC-type containing 11" 3,064191 
CTSS cathepsin S 3,063559 
SP5 Sp5 transcription factor 3,062138 
CD274 CD274 molecule 3,050084 
SGK1 serum/glucocorticoid regulated kinase 1 3,042282 
LOC100127983 hypothetical protein LOC100127983 3,038411 
CDH24 cadherin-like 24 3,03514 
MT2A metallothionein 2A 3,032209 
HES2 hairy and enhancer of split 2 (Drosophila) 3,030875 
OBFC2A oligonucleotide/oligosaccharide-binding fold containing 2A 3,018 
EVC2 Ellis van Creveld syndrome 2 3,015805 
CRCP CGRP receptor component 3,007095 
FTH1 ferritin, heavy polypeptide 1" 2,963964 
OSGIN1 oxidative stress induced growth inhibitor 1 2,957198 
KITLG KIT ligand 2,9491 
IRF7 interferon regulatory factor 7 2,933232 
RCOR2 REST corepressor 2 2,922273 
TNFSF15 tumor necrosis factor (ligand) superfamily, member 15" 2,90531 
DHX58 DEXH (Asp-Glu-X-His) box polypeptide 58 2,899787 
N4BP3 Nedd4 binding protein 3 2,89582 
HDAC9 histone deacetylase 9 2,892829 
LOC644189 similar to peroxisomal long-chain acyl-coA thioesterase 2,88748 
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha" 2,867977 
KCNJ14 potassium inwardly-rectifying channel, subfamily J, member 14 2,867113 
MAFA v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian) 2,860308 
CFTR cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)" 2,851662 
PDGFA platelet-derived growth factor alpha polypeptide 2,842574 
RHBDF2 rhomboid 5 homolog 2 (Drosophila) 2,84253 
FCRLB Fc receptor-like B 2,833371 
NUPL1 nucleoporin like 1 2,832407 
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KBTBD11 kelch repeat and BTB (POZ) domain containing 11 2,821291 
DTX3L deltex 3-like (Drosophila) 2,799295 
PLXNA1 plexin A1 2,793375 
OCIAD2 OCIA domain containing 2 2,789949 
UBE2E1 ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast)" 2,776083 
WNT5A wingless-type MMTV integration site family, member 5A" 2,772922 
KITLG KIT ligand 2,76321 
PARP9 poly (ADP-ribose) polymerase family, member 9 2,757096 
SPON2 spondin 2, extracellular matrix protein" 2,755371 
GPR68 G protein-coupled receptor 68 2,749564 
SIX1 SIX homeobox 1 2,732723 
PAG1 phosphoprotein associated with glycosphingolipid microdomains 1 2,728033 
GRPEL2 GrpE-like 2, mitochondrial (E. coli)" 2,728015 
ZNF697 zinc finger protein 697 2,716183 
AIFM2 apoptosis-inducing factor, mitochondrion-associated, 2" 2,716176 
FOSL2 FOS-like antigen 2 2,711685 
AADAC arylacetamide deacetylase (esterase) 2,710489 
MYLK myosin light chain kinase 2,707101 
TCF7 transcription factor 7 (T-cell specific, HMG-box)" 2,704893 
FAM132A family with sequence similarity 132, member A 2,68782 
ADFP adipose differentiation-related protein 2,662066 
MT2A metallothionein 2A 2,660903 
IL4I1 interleukin 4 induced 1 2,658979 
UTS2R urotensin 2 receptor 2,645053 
HIST1H2AE histone cluster 1, H2ae 2,631659 
PRDM10 PR domain containing 10 2,627767 
CIDECP cell death-inducing DFFA-like effector c pseudogene 2,62727 
ZNF322B zinc finger protein 322B 2,624297 
TLR7 toll-like receptor 7 2,620025 
ERRFI1 ERBB receptor feedback inhibitor 1 2,613644 
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VAV3 vav 3 guanine nucleotide exchange factor 2,612158 
NPBWR1 neuropeptides B/W receptor 1 2,578884 
SOX7 SRY (sex determining region Y)-box 7 2,576394 
CKB creatine kinase, brain" 2,49131 
EIF1 eukaryotic translation initiation factor 1 2,487807 
GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 2,478448 
G0S2 G0/G1switch 2 2,464977 
AKIRIN1 akirin 1 2,454619 
DEAF1 deformed epidermal autoregulatory factor 1 (Drosophila) 2,446047 
C9orf150 chromosome 9 open reading frame 150 2,423348 
HIST2H2AA4 histone cluster 2, H2aa4 2,417622 
BCAN Brevican 2,402919 
SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein" 2,385486 
MT1G metallothionein 1G 2,382322 
C3orf52 chromosome 3 open reading frame 52 2,378354 
CTSK cathepsin K 2,369672 
LIPG lipase, endothelial 2,368038 
SRGN Serglycin 2,367863 
KLF11 Kruppel-like factor 11 2,360476 
PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7)" 2,354499 
CLDN23 claudin 23 2,313628 
CUEDC1 CUE domain containing 1 2,288127 
MAFK v-maf musculoaponeurotic fibrosarcoma oncogene homolog K (avian) 2,278666 
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Table A2 – Genes that are downregulated when ECSCR is knocked down 
FC – fold change; the numbers in brackets after the gene name are the fold change for that gene found in other probes, as the chip contains more 
than one probe for some genes 
 
Gene Symbol Gene name FC 
CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1" 24,59053 
LYVE1 lymphatic vessel endothelial hyaluronan receptor 1 13,12212 
SEPP1 selenoprotein P, plasma, 1" 12,15971 
METTL7A methyltransferase like 7A 10,99246 
SELP selectin P (granule membrane protein 140kDa, antigen CD62)" 9,65395 
MATN2 matrilin 2 9,515602 
CCL15 chemokine (C-C motif) ligand 15 9,117793 
AK5 adenylate kinase 5 8,991111 
IL33 interleukin 33 8,245166 
MYCN v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)" 8,125842 
CD36 CD36 molecule (thrombospondin receptor) 7,961454 
SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein)" 7,878169 
COL3A1 collagen, type III, alpha 1" 7,645113 
AGTPBP1 ATP/GTP binding protein 1 7,417495 
PKNOX2 PBX/knotted 1 homeobox 2 7,40154 
MEST mesoderm specific transcript homolog (mouse) 7,063699 
AQP1 aquaporin 1 (Colton blood group) (6) 7,014114 
ECSM2 endothelial cell-specific molecule 2 6,358596 
ALDH1A1 aldehyde dehydrogenase 1 family, member A1" 6,182551 
NKAIN2 Na+/K+ transporting ATPase interacting 2 6,160984 
LIMCH1 LIM and calponin homology domains 1 5,903961 
CCRL1 chemokine (C-C motif) receptor-like 1 5,860797 
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MAN1C1 mannosidase, alpha, class 1C, member 1" 5,814218 
ACP5 acid phosphatase 5, tartrate resistant" 5,77145 
CCL3L3 chemokine (C-C motif) ligand 3-like 3 5,76664 
CCNE2 cyclin E2 5,625399 
LEPR leptin receptor 5,61404 
E2F8 E2F transcription factor 8 5,571739 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 5,535094 
PCDH10 protocadherin 10 5,530232 
SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1" 5,287551 
PLAT plasminogen activator, tissue" (5, 5,5, 5, 5, 5,4, 4) 5,287475 
KIAA0644 KIAA0644 gene product 5,275179 
MRAP2 melanocortin 2 receptor accessory protein 2 5,238853 
METTL7A methyltransferase like 7A 5,222575 
ST6GALNAC1 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 5,183783 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine)" 5,165852 
GUCY1A3 guanylate cyclase 1, soluble, alpha 3" 5,073154 
FRY furry homolog (Drosophila) 5,057096 
MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) 5,052179 
PCDH7 protocadherin 7 5,047044 
ACSM2B acyl-CoA synthetase medium-chain family member 2B 5,043029 
ACSM2A acyl-CoA synthetase medium-chain family member 2A 4,975459 
KCNMB2 potassium large conductance calcium-activated channel, subfamily M, beta member 2" 4,939225 
GPR126 G protein-coupled receptor 126 4,853051 
SULF1 sulfatase 1 4,766119 
PROS1 protein S (alpha) 4,764287 
C5orf4 chromosome 5 open reading frame 4 4,721733 
ITGA11 integrin, alpha 11 4,673621 
MGP matrix Gla protein 4,665341 
SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group)" 4,550198 
SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein)" 4,550033 
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THBD Thrombomodulin 4,512136 
RNF125 ring finger protein 125 4,503208 
GLT8D2 glycosyltransferase 8 domain containing 2 4,501765 
CMAH cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-N-acetylneuraminate monooxygenase) pseudogene 4,487061 
KLRG1 killer cell lectin-like receptor subfamily G, member 1" 4,442692 
ELMOD1 ELMO/CED-12 domain containing 1 4,406717 
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B 4,400674 
COL3A1 collagen, type III, alpha 1" 4,305804 
GIMAP1 GTPase, IMAP family member 1 4,302009 
KIAA1524 KIAA1524 4,301181 
CROT carnitine O-octanoyltransferase 4,280991 
ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 4,261901 
PLXDC2 plexin domain containing 2 4,224135 
MST150 MSTP150 4,213687 
TP53TG1 TP53 target 1 (non-protein coding) 4,212748 
THSD7A thrombospondin, type I, domain containing 7A" 4,175809 
NTN4 netrin 4 4,139463 
ANGPT1 angiopoietin 1 4,131439 
TSPAN7 tetraspanin 7 4,127978 
C17orf58 chromosome 17 open reading frame 58 4,093107 
ACSM3 acyl-CoA synthetase medium-chain family member 3 4,078574 
GUCY1A3 guanylate cyclase 1, soluble, alpha 3" 4,073248 
SETBP1 SET binding protein 1 4,068339 
CD36 CD36 molecule (thrombospondin receptor) 4,056686 
OLFML2A olfactomedin-like 2A 4,05054 
ADAM22 ADAM metallopeptidase domain 22 4,043939 
FAM63A family with sequence similarity 63, member A" 4,019929 
MAN1C1 mannosidase, alpha, class 1C, member 1 4,00291 
AMIGO2 adhesion molecule with Ig-like domain 2 3,994552 
ITLN1 intelectin 1 (galactofuranose binding) 3,976707 
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PCDH17 protocadherin 17 3,971997 
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4" 3,970255 
CYP4X1 cytochrome P450, family 4, subfamily X, polypeptide 1" 3,933246 
KLHL13 kelch-like 13 (Drosophila) 3,926297 
LIMCH1 LIM and calponin homology domains 1 3,901281 
CASP12 caspase 12 (gene/pseudogene) 3,859531 
NPHS2 nephrosis 2, idiopathic, steroid-resistant (podocin) 3,839631 
ZNF608 zinc finger protein 608 3,831042 
COL1A2 collagen, type I, alpha 2" 3,81778 
KIAA1377 KIAA1377 3,801961 
GDF6 growth differentiation factor 6 3,789169 
SP8 Sp8 transcription factor 3,789124 
C10orf10 chromosome 10 open reading frame 10 3,785241 
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4" 3,776615 
KCNMB4 potassium large conductance calcium-activated channel, subfamily M, beta member 4 3,756521 
PIK3C2B phosphoinositide-3-kinase, class 2, beta polypeptide" 3,746364 
COL1A2 collagen, type I, alpha 2" 3,737154 
PXMP2 peroxisomal membrane protein 2, 22kDa 3,706716 
RAD51AP1 RAD51 associated protein 1 3,697544 
ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 3,696764 
STON1 stonin 1 3,687482 
CYP4X1 cytochrome P450, family 4, subfamily X, polypeptide 1" 3,681587 
TTC13 tetratricopeptide repeat domain 13 3,667282 
LOC339483 hypothetical LOC339483 3,659573 
FAM107A family with sequence similarity 107, member A 3,65268 
C4orf49 chromosome 4 open reading frame 49 3,642848 
COL1A2 collagen, type I, alpha 2" 3,634113 
SDPR serum deprivation response (phosphatidylserine binding protein) 3,628161 
DSCC1 defective in sister chromatid cohesion 1 homolog (S. cerevisiae) 3,617317 
GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase) 3,613131 
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MMRN1 multimerin 1 3,597911 
CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)" 3,581516 
ATAD2 ATPase family, AAA domain containing 2" 3,576729 
MYO5C myosin VC 3,567839 
FABP4 fatty acid binding protein 4, adipocyte" 3,548161 
ALDH6A1 aldehyde dehydrogenase 6 family, member A1" 3,525673 
RACGAP1 Rac GTPase activating protein 1 3,517794 
FAM107A family with sequence similarity 107, member A 3,514274 
KLHL3 kelch-like 3 (Drosophila) 3,513667 
GIPC2 GIPC PDZ domain containing family, member 2 3,512596 
SCN9A sodium channel, voltage-gated, type IX, alpha subunit" 3,502842 
FCRL3 Fc receptor-like 3 3,492753 
NAP1L3 nucleosome assembly protein 1-like 3 3,491722 
CCDC80 coiled-coil domain containing 80 3,484302 
COL1A2 collagen, type I, alpha 2" 3,458554 
NDC80 NDC80 homolog, kinetochore complex component (S. cerevisiae)" 3,449489 
C6orf142 chromosome 6 open reading frame 142 3,449136 
GIPC2 GIPC PDZ domain containing family, member 2 3,42513 
CDO1 cysteine dioxygenase, type I" 3,414906 
KIF20B kinesin family member 20B 3,414889 
TRERF1 transcriptional regulating factor 1 3,399105 
COL1A2 collagen, type I, alpha 2" 3,390621 
COL1A2 collagen, type I, alpha 2" 3,381495 
GJA4 gap junction protein, alpha 4, 37kDa" 3,377162 
CLDN22 claudin 22 3,364727 
VWA5A von Willebrand factor A domain containing 5A 3,346545 
CLEC14A C-type lectin domain family 14, member A 3,331307 
DSCC1 defective in sister chromatid cohesion 1 homolog (S. cerevisiae) 3,328079 
LOC643733 hypothetical LOC643733 3,325942 
HAPLN1 hyaluronan and proteoglycan link protein 1 3,320056 
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SORT1 sortilin 1 3,31407 
SPTLC3 serine palmitoyltransferase, long chain base subunit 3 3,309382 
KAL1 Kallmann syndrome 1 sequence 3,302677 
SELENBP1 selenium binding protein 1 3,287307 
PTGIS prostaglandin I2 (prostacyclin) synthase 3,286498 
CFH complement factor H 3,272152 
TMEM71 transmembrane protein 71 3,262596 
CCL3L3 chemokine (C-C motif) ligand 3-like 3 3,26022 
GPR126 G protein-coupled receptor 126 3,258217 
C18orf34 chromosome 18 open reading frame 34 3,250303 
KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15" 3,238777 
ABLIM1 actin binding LIM protein 1 3,235758 
CGNL1 cingulin-like 1 3,234857 
KCND2 potassium voltage-gated channel, Shal-related subfamily, member 2" 3,234167 
LUM Lumican 3,231183 
TMSB15A thymosin beta 15a 3,231081 
TRERF1 transcriptional regulating factor 1 3,230042 
GRB14 growth factor receptor-bound protein 14 3,220014 
CALCRL calcitonin receptor-like 3,219786 
SESN3 sestrin 3 3,209932 
SLC22A5 solute carrier family 22 (organic cation/carnitine transporter), member 5" 3,207387 
KBTBD6 kelch repeat and BTB (POZ) domain containing 6 3,207162 
FILIP1 filamin A interacting protein 1 3,19257 
GALNTL2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 2 3,188781 
HMCN1 hemicentin 1 3,186536 
STAB2 stabilin 2 3,166811 
B3GNT1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1" 3,165542 
ACOX2 acyl-Coenzyme A oxidase 2, branched chain" 3,163547 
ALS2CR4 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 4" 3,147664 
SLC9A9 solute carrier family 9 (sodium/hydrogen exchanger), member 9" 3,132598 
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COL1A2 collagen, type I, alpha 2" 3,128723 
FAT4 FAT tumor suppressor homolog 4 (Drosophila) 3,120981 
SORT1 sortilin 1 3,118484 
KIAA0101 KIAA0101 3,118215 
HEPH Hephaestin 3,117348 
MAP2K6 mitogen-activated protein kinase kinase 6 3,1117 
TTK TTK protein kinase 3,111003 
AMPH Amphiphysin 3,105592 
KLRG1 killer cell lectin-like receptor subfamily G, member 1" 3,101475 
TMEM106C transmembrane protein 106C 3,096738 
UBA5 ubiquitin-like modifier activating enzyme 5 3,095758 
FUCA1 fucosidase, alpha-L- 1, tissue" 3,093508 
GGTA1 glycoprotein, alpha-galactosyltransferase 1" 3,090182 
TBC1D8B TBC1 domain family, member 8B (with GRAM domain)" 3,086032 
ATAD2 ATPase family, AAA domain containing 2" 3,083222 
TBC1D8B TBC1 domain family, member 8B (with GRAM domain)" 3,069616 
NCAPG non-SMC condensin I complex, subunit G 3,064876 
SPEG SPEG complex locus 3,036352 
RNFT2 ring finger protein, transmembrane 2 3,034193 
EDNRB endothelin receptor type B 3,033874 
SAMD13 sterile alpha motif domain containing 13 3,032893 
SATB1 SATB homeobox 1 3,029964 
RRM2 ribonucleotide reductase M2 polypeptide 3,029954 
ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4" 3,027554 
LMO7 LIM domain 7 3,023999 
SLC1A1 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1" 3,013368 
TRO Trophinin 3,007376 
NHLRC3 NHL repeat containing 3 3,003075 
MYH10 myosin, heavy chain 10, non-muscle 3,000197 
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 2,996805 
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KLHL4 kelch-like 4 (Drosophila) 2,987169 
ANGPT1 angiopoietin 1 2,98547 
ETV1 ets variant 1 2,983133 
RBP1 retinol binding protein 1, cellular" 2,98245 
TCF19 transcription factor 19 (SC1) 2,980965 
GIMAP8 GTPase, IMAP family member 8" 2,977004 
RNASE1 ribonuclease, RNase A family, 1 (pancreatic)" 2,975943 
ATAD2 ATPase family, AAA domain containing 2" 2,962574 
MELK maternal embryonic leucine zipper kinase 2,961678 
DCLK1 doublecortin-like kinase 1 2,960902 
DEPDC1B DEP domain containing 1B 2,959885 
E2F2 E2F transcription factor 2 2,959335 
BEND5 BEN domain containing 5 2,944889 
HFE Hemochromatosis 2,942213 
C1orf21 chromosome 1 open reading frame 21 2,939498 
MGC16121 hypothetical protein MGC16121 2,938651 
C17orf76 chromosome 17 open reading frame 76 2,929663 
RICH2 Rho-type GTPase-activating protein RICH2 2,925252 
FAM64A family with sequence similarity 64, member A" 2,925092 
TXNDC16 thioredoxin domain containing 16 2,922002 
CD46 CD46 molecule, complement regulatory protein" 2,921294 
GNA14 guanine nucleotide binding protein (G protein), alpha 14 2,919711 
PCDH17 protocadherin 17 2,916579 
NUDT7 nudix (nucleoside diphosphate linked moiety X)-type motif 7 2,916499 
LOC54492 neuralized-2 2,910138 
ATAD2 ATPase family, AAA domain containing 2" 2,907876 
COL1A2 collagen, type I, alpha 2" 2,905537 
C6orf114 chromosome 6 open reading frame 114 2,904462 
METTL2A methyltransferase like 2A 2,897252 
ATAD2 ATPase family, AAA domain containing 2" 2,894996 
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COL1A2 collagen, type I, alpha 2" 2,893378 
GPR124 G protein-coupled receptor 124 2,889106 
GIMAP1 GTPase, IMAP family member 1" 2,888239 
ATAD2 ATPase family, AAA domain containing 2" 2,881836 
ANGPTL5 angiopoietin-like 5 2,881786 
KIF18A kinesin family member 18A 2,875793 
MAGEH1 melanoma antigen family H, 1 2,873733 
THRA thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian)" 2,861482 
PLS1 plastin 1 (I isoform) 2,854548 
EPHA4 EPH receptor A4 2,853894 
SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2" 2,851817 
FGGY FGGY carbohydrate kinase domain containing 2,849485 
ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)" 2,847288 
KBTBD7 kelch repeat and BTB (POZ) domain containing 7 2,815308 
ATAD2 ATPase family, AAA domain containing 2" 2,812275 
FAM74A3 family with sequence similarity 74, member A3" 2,807836 
MRAP2 melanocortin 2 receptor accessory protein 2 2,806959 
FADS2 fatty acid desaturase 2 2,804734 
FAM64A family with sequence similarity 64, member A" 2,803523 
EPHX2 epoxide hydrolase 2, cytoplasmic 2,802932 
FAM64A family with sequence similarity 64, member A" 2,802722 
FAM113B family with sequence similarity 113, member B 2,795731 
NR1H3 nuclear receptor subfamily 1, group H, member 3" 2,786837 
FAM83D family with sequence similarity 83, member D 2,771843 
CEP192 centrosomal protein 192kDa 2,769905 
KCNMA1 potassium large conductance calcium-activated channel, subfamily M, alpha member 1" 2,747961 
GUCY1B3 guanylate cyclase 1, soluble, beta 3 2,739744 
DZIP1 DAZ interacting protein 1 2,735478 
NPAL3 NIPA-like domain containing 3 2,719882 
SEMA3D sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D 2,719666 
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TLR4 toll-like receptor 4 2,719458 
GLRXL glutaredoxin (thioltransferase)-like 2,718919 
ATAD2 ATPase family, AAA domain containing 2" 2,717136 
NEIL3 nei endonuclease VIII-like 3 (E. coli) 2,712439 
PIR pirin (iron-binding nuclear protein) 2,701644 
TXNDC12 thioredoxin domain containing 12 (endoplasmic reticulum) 2,701128 
FAM74A3 family with sequence similarity 74, member A3" 2,699797 
LOC151878 hypothetical protein LOC151878 2,697855 
TYMS thymidylate synthetase 2,696464 
KAT2B K(lysine) acetyltransferase 2B 2,690971 
PCNA proliferating cell nuclear antigen 2,690725 
RRM1 ribonucleotide reductase M1 2,68714 
RCAN2 regulator of calcineurin 2 2,686817 
ATAD2 ATPase family, AAA domain containing 2" 2,684398 
HMMR hyaluronan-mediated motility receptor (RHAMM) 2,683695 
ZDHHC13 zinc finger, DHHC-type containing 13 2,682936 
DMTF1 cyclin D binding myb-like transcription factor 1 2,678654 
GPSM2 G-protein signaling modulator 2 (AGS3-like, C. elegans) 2,677193 
CPE carboxypeptidase E 2,675854 
KIF20A kinesin family member 20A 2,670471 
ERCC6L excision repair cross-complementing rodent repair deficiency, complementation group 6-like" 2,669791 
RIBC2 RIB43A domain with coiled-coils 2 2,648765 
POLQ polymerase (DNA directed), theta" 2,643268 
RP5-1022P6.2 hypothetical protein KIAA1434 2,630018 
SPINK5 serine peptidase inhibitor, Kazal type 5" 2,629796 
KIAA0485 hypothetical LOC57235 2,629308 
E2F1 E2F transcription factor 1 2,618136 
LOX lysyl oxidase 2,617217 
ATAD2 ATPase family, AAA domain containing 2" 2,612732 
C12orf48 chromosome 12 open reading frame 48 2,608701 
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LMO7 LIM domain 7 2,60593 
TLR4 toll-like receptor 4 2,594917 
PLEKHA6 pleckstrin homology domain containing, family A member 6" 2,591856 
LGR4 leucine-rich repeat-containing G protein-coupled receptor 4 2,589069 
CCDC3 coiled-coil domain containing 3 2,579823 
C4orf12 chromosome 4 open reading frame 12 2,578949 
RACGAP1 Rac GTPase activating protein 1 2,571524 
FLJ30901 hypothetical protein FLJ30901 2,570284 
LOX lysyl oxidase 2,569416 
RNASEL ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) 2,56885 
ERLIN2 ER lipid raft associated 2 2,566741 
MTSS1 metastasis suppressor 1 2,565103 
NCAM2 neural cell adhesion molecule 2 2,56095 
CFH complement factor H 2,558314 
SGIP1 SH3-domain GRB2-like (endophilin) interacting protein 1 2,557269 
KIAA1522 KIAA1522 2,554842 
ALDH5A1 aldehyde dehydrogenase 5 family, member A1" 2,550732 
FAM64A family with sequence similarity 64, member A" 2,547409 
INHBB inhibin, beta B" 2,540446 
C16orf75 chromosome 16 open reading frame 75 2,537688 
KIF20A kinesin family member 20A 2,534352 
MYH10 myosin, heavy chain 10, non-muscle 2,527407 
LTA4H leukotriene A4 hydrolase 2,525544 
ADSS adenylosuccinate synthase 2,519818 
PLK4 polo-like kinase 4 (Drosophila) 2,518215 
CCL23 chemokine (C-C motif) ligand 23 2,512078 
C10orf58 chromosome 10 open reading frame 58 2,507434 
KIF20A kinesin family member 20A 2,495433 
PBX1 pre-B-cell leukemia homeobox 1 2,487947 
C3orf64 chromosome 3 open reading frame 64 2,479864 
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PAM peptidylglycine alpha-amidating monooxygenase 2,475382 
LOX lysyl oxidase 2,467707 
PTGER4 prostaglandin E receptor 4 (subtype EP4) 2,464955 
DIAPH3 diaphanous homolog 3 (Drosophila) 2,460108 
LOC100129406 hypothetical protein LOC100129406 2,448051 
RAB38 RAB38, member RAS oncogene family" 2,446264 
RUNX1T1 runt-related transcription factor 1; translocated to, 1 (cyclin D-related)" 2,442814 
ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) 2,440793 
KIAA0586 KIAA0586 2,434786 
CASC5 cancer susceptibility candidate 5 2,424181 
C1R complement component 1, r subcomponent" 2,420773 
LOC100134119 similar to hCG2018924 2,420194 
CD302 CD302 molecule 2,413478 
SGOL2 shugoshin-like 2 (S. pombe) 2,410969 
DYNC1I1 dynein, cytoplasmic 1, intermediate chain 1" 2,410772 
FAM64A family with sequence similarity 64, member A" 2,409291 
TM7SF3 transmembrane 7 superfamily member 3 2,40264 
EXO1 exonuclease 1 2,378808 
NAIP NLR family, apoptosis inhibitory protein" 2,374909 
C18orf56 chromosome 18 open reading frame 56 2,374383 
FLJ14213 protor-2 2,37244 
GIMAP8 GTPase, IMAP family member 8" 2,368156 
ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)" 2,366366 
BRCA1 breast cancer 1, early onset" 2,35691 
MALL mal, T-cell differentiation protein-like" 2,353596 
SAMD12 sterile alpha motif domain containing 12 2,336493 
LIPA lipase A, lysosomal acid, cholesterol esterase" 2,33034 
MEF2C myocyte enhancer factor 2C 2,325836 
P2RY5 purinergic receptor P2Y, G-protein coupled, 5" 2,32418 
HNRNPA0 heterogeneous nuclear ribonucleoprotein A0 2,323535 
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NUDT15 nudix (nucleoside diphosphate linked moiety X)-type motif 15 2,308787 
EXO1 exonuclease 1 2,306251 
DPY19L4 dpy-19-like 4 (C. elegans) 2,28757 
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APPENDIX 2: TESTING THE EFFECTS OF AN ANGIOGENESIS-
BLOCKING ANTIBODY 
A1.1 Angiogenesis assays 
Wound healing usually depends on a combination of both cell migration and proliferation 
(Boamah, 2007). Mitomycin C is an antibiotic that is activated in vivo into an alkylating agent 
that binds to DNA, blocking DNA synthesis and inhibiting cell growth (Yarrow et al., 2004). 
Therefore, mitomycin C was added to the scratch wound assay to ensure that closure of the 
wound was not due to cell division but to migration solely. Some care needs to be taken in 
order to have a uniform width of the scratch. An alternative may be to grow the cells in special 
inserts that contain a separation and remove the insert by the time of the assay. In this way, all 
the scratches would be directly comparable. 
Matrigel is a mixture of extracellular and basement membrane proteins derived from the mouse 
Engelbreth–Holm–Swarm sarcoma on which endothelial cells attach and rapidly form tubes 
(Lawley, 1898). Matrigel stimulates attachment, migration and differentiation of endothelial 
cells into tubes mimicking in vivo angiogenesis (Auerbach et al., 2003). Electron microscopy 
showed that tight junctions are formed between the endothelial cells during these assays. 
Therefore, in vitro 2-dimensional tube formation assays are considered a model of capillary 
development and represent the differentiation stage of angiogenesis (Auerbach et al., 2003; 
Staton et al., 2006). 
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The ECSCR siRNA-mediated knockdown with duplex 1 (D1) was used as a control for further 
experiments. An antibody company based in Belfast (Northern Ireland), Fusion Antibodies, 
has produced a monoclonal antibody in mouse against the extracellular domain of ECSCR 
(13G11). The naked protein, produced in bacteria, was used as an immunogen. This antibody 
was employed in two angiogenesis assays: the scratch wound assay and the tube formation on 
MatrigelTM. 
 
A1.1.1 Scratch wound assay 
Cell migration was observed over a period of 24h after making a scratch on siRNA knocked 
down HUVECs (and controls, mock and negative control duplex) or HUVECs treated with 4.5, 
23 and 45 nM of 13G11 antibody (and IgG controls). siRNA knocked down cells, after a period 
of 24h seemed to be able to close the wound, but slower compared to the controls. In the 
controls it was impossible to trace the scratch and the treated cells still showed a migration 
phenotype. However, it is not quantitatively significant (figure A1). On the other hand, as little 
as 4.5 nM of 13G11 antibody seemed to inhibit cell migration, since the wound is still not 
closed after 24h (figure A1). All the used concentrations of blocking antibody have had an 
effect on cell migration, which seems to be dose dependent.  
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Figure A 1 Wound closure capacity of HUVECs on MatrigelTM measured over a period 
of 24h 
A – representative pictures of normal and abnormal wound closing after 24h. B – quantification 
of wound closure for the different treatments after 24h. All the images analysed contained a 
scratch width not significantly different within and between treatments (-p < 0.05). UT – 
untransfected; KD – knockdown; Ab – 13G11 antibody. * significantly different from the 
respective controls (-p < 0.05). 
A B 
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A1.1.2 Matrigel tube formation assay 
For the same treatments as on section A1.1.1, the ability of forming tubular structures on 
MatrigelTM was assessed (Arnaoutova et al., 2009). Both siRNA knock down and 13G11 
antibody at all concentrations had a negative effect on tube formation in contrast to the controls 
(figure A2 B). The quantification of this effect was done by counting the number of nodes per 
image, which was not significantly different (figure A2 B, blue bars). However, the images of 
the phenotypes caused by either the 13G11 blocking antibody or siRNA looked quite different 
from the respective controls. Therefore, the number of branches radiating from each node was 
not only quantified but also qualified. Strong branches are those which are thick and connect 
two nodes; weak branches still connect two nodes, but are very thin; broken branches were also 
counted because they budded from one particular node, but did not connect it to any other. 
Compared to the respective controls both siRNA and increasing concentrations of 13G11 
antibody caused a decreased number of strong branches and an increased number of weak and 
broken branches sprouting from the nodes (figure A2 B). 
 
Previous work (Bicknell and Nagy, unpublished) had suggested that ECSCR might be 
upregulated at the transcript level in some types of human cancer, compared to matched normal 
tissue (figure A3). The 13G11 antibody was used to stain tissue sections of normal versus 
cancer, using a variety of tissues. No significant differences were found between the two types 
of samples. The antibody seemed to recognise vessels and could be used for both 
immunohistochemistry and immunofluorescence. Figure A4 illustrates an example of these 
two techniques using 13G11. Interestingly, the staining seems to co-localise with ULEX (a 
vascular marker) only on the lumen of the vessels.  
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Figure A 2 - Tube formation capacity of HUVECs on Matrigel measured over a period 
of 24h. 
A – representative pictures of normal and abnormal tube formation on MatrigelTM after 24h. B 
– quantification of tube formation through the count of the number of nodes and branches per 
image. UT – untransfected; KD – knock down; Ab – 13G11 antibody. * significantly different 
from the respective controls (-p < 0.05, unpaired two-tailed t-test). 
 
  
A B 
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Figure A 3 - Qualitative analysis of ECSCR transcript by in situ hybridization in 
normal and cancer human tissues. 
An ECSCR RNA probe was produced to detect and quantify the ECSCR transcript in human 
normal and cancer tissues (tissue arrays, SuperBioChips Laboratoties). The results were 
divided into three categories: strong staining, some staining and no or very little staining 
detected. Due to the fact that not all tissues/types of cancer were represented by the same 
number of paraffin-embedded spots, the total counts for each category were divided by the total 
number of spots analysed. For each vertical bar, the different colours represent each category 
and the sum is 100%.  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Si
gm
o
id
 c
o
lo
n
P
ro
st
at
e
B
la
d
d
er
Li
ve
r
St
o
m
ac
h
Th
yr
o
id
O
va
ry
K
id
n
ey
O
e
so
p
h
ag
u
s
B
re
as
t
Lu
n
g
R
e
ct
u
m
C
o
lo
n
C
e
cu
m
P
an
cr
e
as
St
ai
n
in
g 
in
te
n
si
ty
 r
at
io
 f
o
r 
e
ac
h
 c
at
e
go
ry
Strong
Some
No/very little
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
St
ai
n
in
g 
in
te
n
si
ty
 f
o
r 
e
ac
h
 c
at
e
go
ry
ECSCR transcript in normal samples 
ECSCR transcript in cancer samples 
216 
 
 
 
Figure A 4 - Breast cancer paraffin sections stained with 13G11. 
Since ECSCR transcript seemed to be upregulated in some cancer types (figure A3), an 
antibody against ECSCR (13G11) produced by our collaborators at Phusion Antibodies 
(Belfast) was used to assess the protein levels in human paraffin samples (SuperBioChips 
Laboratories) by immunofluorescence and immunohistochemistry. The qualitative results of 
staining are shown on tables A3-A9. This figure shows an example of 13G11 endothelial-
specific staining in samples from human breast cancer. Panels on the left – 
immunofluorescence; panel on the right immunohistochemistry. Endothelial cell markers were 
used (Ulex, CD31) to confirm endothelial specificity of the 13G11 staining. All staining and 
image analysis were performed with Dr. Stephanie Maloney, who has acquired these images 
and kindly allowed their inclusion in this thesis.  
217 
 
Table A3 – Analysis of ECSCR antibody staining on whole (human) tissue sections by 
immunohistochemistry (IHC) and immunofluorescence (IF). + strong staining; +/- some 
staining; - no staining detected. 
 Tissue IHC IF  Tissue IHC 
IF 
N
o
rm
a
ls
 
Placenta + + 
T
u
m
o
u
rs
 
Colon - 
- 
Adrenal 
gland 
- - Ovary - 
- 
Breast skin - - Rectal +/- 
- 
Colon - - Sq Cervix - 
- 
Foreskin - - Ad Cervix + 
+ 
Heart +/- +/- Bladder + 
- 
Kidney - +/- Endometrial + 
+ 
Liver - - Breast + 
+ 
Lung - -    
 
Lymph 
gland 
- -    
 
Pancreas - -    
 
Spleen - -    
 
Stomach - +/-    
 
Tonsil - -    
 
Scalp +/- +/-    
 
Prostate + -    
 
Brain + +    
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Table A4 – Analysis of ECSCR antibody staining on human cancer tissue array MA2 
(SuperBioChips Laboratories) by immunohistochemistry. + strong staining; +/- some 
staining; - no staining detected. The numbers on the first column represent each spot for each 
sample type. The cells with no annotation mean that either that specific spot got lost or damaged 
during processing or there were less spots present in the chip for that specific tissue. 
 
Tissue microarray MA2 common cancers 
# stomach esophagus lung colon thyroid 
Kidney 
1 - - - - +/- 
- 
2 - +/- - - - 
+/- 
3 + - + - + 
- 
4 + - - + +/- 
- 
5 +/- + + - +/- 
+/- 
6 - - - - - 
- 
7 - +/-  +/- - - 
- 
8 - + - - + 
+/- 
9 - - - - - 
  
10 - +/-  +/- - - 
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Table A5 – Analysis of ECSCR antibody staining on human normal tissue array MAN2 
(SuperBioChips Laboratories) by immunohistochemistry. + strong staining; +/- some 
staining; - no staining detected. The numbers on the first column represent each spot for each 
sample type. The cells with no annotation mean that either that specific spot got lost or damaged 
during processing or there were less spots present in the chip for that specific tissue. 
 
Tissue microarray MAN2 matching normals  
# stomach esophagus lung colon thyroid 
kidney 
1 - +/-  +  +  +  
+  
2 +  +/-  +/-  -  -  
+/-  
3 -  +  -  +  +/-  
+  
4 -  +  +/-  +  -  
+/-  
5 +  +  +  -  +/-  
-  
6 -  +  +  -  +  
-  
7 +/-  +/-  +  -  -  
+/-  
8 -  -  +  +  +/-  
-  
9 -  +  +  -  -  
- 
10 -  -  +/-  +  -  
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Table A6 – Analysis of ECSCR antibody staining on human cancer tissue array MB3 
(SuperBioChips Laboratories) by immunohistochemistry. + strong staining; +/- some 
staining; - no staining detected. The numbers on the first column represent each spot for each 
sample type. The cells with no annotation mean that either that specific spot got lost or damaged 
during processing or there were less spots present in the chip for that specific tissue. 
 
Tissue microarray MB3 common cancers 
# breast  liver  bladder  ovary  pancreas  
prostate  
1 +  +/-  -  -  +/-  
-  
2 -  -  +/-  +  -  
-  
3 +/-  -  -  +  -  
+/-  
4 +/-  -  -  +  -  
-  
5 - +/-  +  -  -  
-  
6 -  -  -  -  -  
+/-  
7 +  +/-  -  -  -  
+/-  
8 -  -  -  +  -  
-  
9 -  -  +/-  +  -  
-  
10 -  -  -  -  -  
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Table A7 – Analysis of ECSCR antibody staining on human normal tissue array MBN3 
(SuperBioChips Laboratories) by immunohistochemistry. + strong staining; +/- some 
staining; - no staining detected. The numbers on the first column represent each spot for each 
sample type. The cells with no annotation mean that either that specific spot got lost or damaged 
during processing or there were less spots present in the chip for that specific tissue. 
 
Tissue microarray MBN3 matching normals  
# breast  liver  bladder  ovary  pancreas  
prostate  
1 +/-  -   -  +/-  
+/-  
2 +  +/-  -  +  +  
+/-  
3 -  +  -  +/-  -  
+  
4 +  -  +/-  +  +  
-  
5 -  -  +/-  +/-  -  
+  
6 +  -  -  +  +  
-  
7 +/-  -  +  -  -  
-  
8 +/-  -  +  -  -  
+  
9 +  +/-  -  +  -  
+  
10 +/-  - -  +  +/-  
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Table A8 – Analysis of ECSCR antibody staining on human cancer tissue array MC4 
(SuperBioChips Laboratories) by immunohistochemistry. + strong staining; +/- some 
staining; - no staining detected. The numbers on the first column represent each spot for each 
sample type. The cells with no annotation mean that either that specific spot got lost or damaged 
during processing or there were less spots present in the chip for that specific tissue. 
 
Tissue microarray MC4 common cancers 
# Endometrium  
Gall- 
bladder  
Larynx  Cervix  Lymphoma  Melanoma  
1 +/-  -  -  -  -  
-  
2 +/-  +/-  -  -  +/-  
-  
3 -  -   +/-  -  
-  
4 -  -  -  -  +  
-  
5 - -  -  +/-  -  
-  
6 -  +/-  -  -  -  
+/-  
7 -  -  -  -  +/-  
+  
8 -  -  -  -  -  
-  
9 -  -  +/-  +/-  +/-  
-  
10 +/-   -  +/-  -  
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Table A9 – Analysis of ECSCR antibody staining on human normal tissue array MCN4 
(SuperBioChips Laboratories) by immunohistochemistry. + strong staining; +/- some 
staining; - no staining detected. The numbers on the first column represent each spot for each 
sample type. The cells with no annotation mean that either that specific spot got lost or damaged 
during processing or there were less spots present in the chip for that specific tissue. 
 
Tissue microarray MCN4 matching normals  
# Endometrium  
Gall- 
bladder  
Larynx  Cervix  Lymphoma  Melanoma  
1 -  +  -  +  +/-  
-  
2 -  -  +  +/-  +/-  
+  
3 -  -  +  +  +  
-  
4 -  -  +/-  +  +  
+/-  
5 - +   +  +/-  
+/-  
6 +  +  +  +/-  -  
+/-  
7 -  +/-   +  -  
 
8 -  +/-  +/-  +/-  -  
 
9 +  +  +   +  
 
10 +/-  +/-  +/-  -  +/-  
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While the functional assays and tissue staining were being done in Birmingham, the isotype 
(IgG1) and epitope of 13G11 were being determined in Belfast. In order to map the epitope, 
several constructs were made, lacking segments of the protein (figure A5) and subsequent 
western blots were performed to assess where the antibody would bind or not. The epitope 
recognised by 13G11, QTVPPNSTTM, is located between amino acids 91 and 100. 
To test the specificity of 13G11 for ECSCR, in Belfast, HEK 293T cells were transfected with 
ECSCR-GFP (and untransfected HEK 293T cells were used as a control). The antibody has 
recognised a protein at about 55 kDa in the transfected lysate. This corresponds to the size of 
a fusion protein between GFP and unglycosylated or very little glycosylated ECSCR. 
Several attempts were made to use 13G11 to detect ECSCR in HUVEC lysate, but they were 
unsuccessful. In order to further test for specificity, HUVECs were transfected with ECSCR 
siRNA (and respective controls) and analysed by FACS. This analysis has shown that the 
antibody binds to HUVECs, but does not recognise ECSCR (figure A 7), as there is a shift from 
the population not treated with 13G11 to the populations exposed to the antibody, but there are 
no differences between mock, negative control duplex and ECSCR siRNA. 
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Figure A 5 – Epitope mapping strategy of 13G11 
In order to map the epitope recognised by 13G11, several constructs were made, lacking 
segments of the protein and subsequent western blots were performed to assess where the 
antibody would bind or not. The epitope recognised by 13G11 is QTVPPNSTTM. 
 
 
 
 
 
 
Figure A 6 – 13G11 recognises an ECSCR-GFP fusion.protein produced in HEK 293T 
cells 
To test the specificity of 13G11 for ECSCR, HEK 293T cells were transfected with ECSCR-
GFP (and untransfected HEK 293T cells were used as a control). The antibody has recognised 
a protein at about 55 kDa in the transfected lysate.  
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Figure A 7 – FACS analysis of 13G11 in HUVECs. 
HUVECs were transfected with ECSCR siRNA (and respective controls) and analysed by 
FACS. This analysis has shown that the antibody produced in Belfast by Phusion Antibodies 
binds to HUVECs, but doesn’t recognise ECSCR (figure A 7), as there is a shift from the 
population not treated with 13G11 (dark blue) to the populations exposed to the antibody, but 
there are no differences between mock (green), negative control duplex (pink) and ECSCR 
siRNA (light blue). 
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APPENDIX 3: RE-PRINT OF THE THESIS-RELATED PUBLICATION 
Verissimo AR, Herbert JMJ, Heath VL, Legg JA, Sheldon H, Andre M, Swain RK and 
Bicknell R. (2009). Functionally defining the endothelial transcriptome, from Robo4 to 
ECSCR. Biochem Soc Trans. 37: 1214-1217 
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APPENDIX 4: LIST OF PRESENTED ABSTRACTS 
1. Poster presentations 
2011 – The role of ECSCR in endothelial cell biology. Gordon Research Conference on 
Vascular Cell Biology, Ventura, CA, USA. 
 
2010 – Regulation of zebrafish developmental angiogenesis by endothelial cell specific 
chemotaxis regulator (ECSCR). 9th International Zebrafish Development and Genetics 
Conference, Madison, WI, USA. 
 
2009 – Endothelial cell specific molecule 2 is involved in actin cytoskeleton modulation. 
Molecular and Cellular Mechanisms of Angiogenesis (Biochemical Society meeting), Chester, 
UK. 
 
2009 – Endothelial cell specific molecule 2 is involved in actin cytoskeleton modulation. 
Angionet Meeting, Dundee, UK. 
 
2. Oral presentations 
2010 – Functional characterisation of ECSCR.  EMBO mouse anatomy and embryology 
practical course, Split, Croatia – award for best oral presentation. 
 
2009 – The role of endothelial cell specific molecule 2 in angiogenesis. VITA seminars, 
University of Birmingham, UK. 
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